

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

AMENDMENT NO. 2
TO
FORM S-1

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

MANNATECH, INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)

TEXAS
(State or other Jurisdiction of
Incorporation or Organization)

2833
(Primary Standard Industrial
Classification Code Number)

75-2508900
(I.R.S. Employer
Identification No.)

600 S. ROYAL LANE, SUITE 200
COPPELL, TEXAS 75019
(972) 471-7400
(Address, including zip code, and telephone number, including
area code, of registrant's principal executive offices)

CHARLES E. FIORETTI
CHAIRMAN OF THE BOARD AND CHIEF EXECUTIVE OFFICER
MANNATECH, INCORPORATED
600 S. ROYAL LANE, SUITE 200
COPPELL, TEXAS 75019
(972) 471-7400

(Name, and address, including zip code, and telephone number,
including area code, of agent for service)

COPY TO:
J. KENNETH MENGES, JR., P.C.
Akin, Gump, Strauss, Hauer & Feld, L.L.P.
1700 Pacific, Suite 4100
Dallas, Texas 75201
(214) 969-2800

APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:
AS SOON AS PRACTICABLE AFTER THE EFFECTIVE DATE OF THIS REGISTRATION STATEMENT.

If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, check the following box. /X/

If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. / /

If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. / /

If this Form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. / /

If delivery of the prospectus is expected to be made pursuant to Rule 434,
check the following box. / /

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a),
MAY DETERMINE.

A MINIMUM OF 2,500,000 SHARES
AND
A MAXIMUM OF 5,295,015 SHARES

[LOGO]

COMMON STOCK

A minimum of 2,500,000 shares and a maximum of 5,295,015 shares at the price of \$8 per share are being offered by Mannatech, Incorporated ("the Company") and certain selling shareholders (the "Selling Shareholders"). Of the minimum of 2,500,000 shares, 1,500,000 are being offered by the Company and 1,000,000 are being offered by the Selling Shareholders. The next 1,055,000 shares to be sold are being offered by certain of the Selling Shareholders. Sales of an amount of shares in excess of 3,555,000 up to 4,955,000 will be divided equally between the Company and the Selling Shareholders and sales in excess of 4,955,000 up to the maximum of 5,295,015 will be made by the Selling Shareholders. All sales by the Selling Shareholders will be divided ratably among the Selling Shareholders. During the period the offering is open, each subscriber may subscribe for a minimum of 100 shares.

The offering will continue until January 15, 1999, unless terminated by the Company prior thereto, and at the option of the Company, may be extended through February 12, 1999 (as extended, the "Termination Date"), at the election of the Company. All subscription proceeds for the minimum amount to be sold will be deposited in an escrow account at Bank One, Kentucky, NA (the "Escrow Agent"), subject to a closing (the "Initial Closing") on such escrowed funds once the Company has accepted subscriptions for at least 2,500,000 shares. After the Initial Closing, if all shares offered hereby are not sold at such time, the Company may accept subscriptions at any time or from time to time during the offering and subscription proceeds shall be deposited by J.J.B. Hilliard, W.L. Lyons, Inc. (the "Placement Agent") in a segregated account, subject to subsequent closings from time to time as determined by the Company. Escrowed funds will be promptly returned to subscribers, without interest or deduction, if the minimum subscriptions are not received by the Termination Date. No shares of Common Stock will be issued until subscription proceeds are released to the Company or the Selling Shareholders. See "Plan of Distribution."

Prior to this offering, there has been no public market for the Common Stock of the Company. See "Plan of Distribution" for a discussion of the factors considered in determining the initial public offering price. The Common Stock has been approved, subject to the fulfillment of certain conditions, for quotation and trading on the Nasdaq National Market under the symbol "MTEX."

SEE "RISK FACTORS" COMMENCING ON PAGE 7 FOR A DISCUSSION OF CERTAIN FACTORS THAT SHOULD BE CONSIDERED BY PROSPECTIVE PURCHASERS OF THE COMMON STOCK OFFERED HEREBY.

THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

	PRICE TO PUBLIC	FEES TO PLACEMENT AGENT (1)	NUMBER OF SHARES OFFERED	PROCEEDS TO COMPANY (2)	PROCEEDS TO SELLING SHAREHOLDERS(2)
Per Share.....	\$8.00	\$0.32	1	\$7.68	\$7.68
Total Minimum.....	\$20,000,000	\$800,000	2,500,000	\$11,520,000	\$7,680,000
Total Maximum.....	\$42,360,120	\$1,694,405	5,295,015	\$16,896,000	\$23,769,715

(1) The Company and the Selling Shareholders have agreed to pay the Placement Agent a 4% fee for each share sold. This fee will be deducted from the proceeds due to the Company or the Selling Shareholders, as appropriate.

(2) Before deducting expenses payable by the Company estimated at \$460,000.

The date of this Prospectus is November 25, 1998.

PROSPECTUS SUMMARY

THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION AND THE FINANCIAL STATEMENTS AND NOTES THERETO APPEARING ELSEWHERE IN THIS PROSPECTUS. INVESTORS SHOULD CAREFULLY CONSIDER THE RISK FACTORS RELATED TO THE PURCHASE OF COMMON STOCK OF THE COMPANY. UNLESS OTHERWISE INDICATED, ALL INFORMATION IN THIS PROSPECTUS REFLECTS A 1,000-FOR-1 SPLIT OF THE COMPANY'S OUTSTANDING COMMON STOCK EFFECTED IN 1997 (THE "STOCK SPLIT"). SEE "RISK FACTORS."

THE COMPANY

Mannatech develops and sells proprietary nutritional supplements and topical products through a network marketing system. The Company sells its products in the United States and Canada through a network consisting of approximately 226,000 active Associates (an "active" Associate has purchased products from the Company within the last 12 months) as of September 30, 1998, and has begun to expand into Australia, while continuing to assess the potential of other foreign markets. Since commencing operations in November 1993, the Company's sales have grown from approximately \$8.4 million in 1994 to approximately \$150.6 million in 1997.

The Company pursues a two-fold business strategy: (i) to develop a proprietary line of nutritional supplements having both health benefits and mass appeal to a general population demanding non-toxic healthcare alternatives and (ii) to provide an appealing framework for persons interested in the products to establish a direct sales business. To date, the Company has focused its development efforts primarily in the area of carbohydrate technology, creating a proprietary ingredient, Ambrotose-Registered Trademark- Complex, which combines the naturally occurring sugars required to support optimal cell-to-cell communication. Additional Company efforts have been focused on developing products based on scientific advances in the emerging field of phytochemistry, which has identified certain naturally occurring components of various plants, known as "phytochemicals," which, while not essential to sustain life, are fundamental to optimal health.

Ambrotose-Registered Trademark- Complex is the cornerstone of the Company's product lines. These products are designed to support various systems and functions of the human body, including (i) the cell-to-cell communication system, (ii) the immune system, (iii) the endocrine system, (iv) the intestinal system and (v) the dermal system. The Company also markets products designed to aid in sports performance and nutritional support. The Company's products, Man-Aloe-Registered Trademark-, Ambrotose-Registered Trademark- and Bulk Ambrotose-Registered Trademark-, are designed to support cell-to-cell communication. For immune system support, the Company offers Phyt-Aloe-Registered Trademark-, for adults, and Phyto-Bears-Registered Trademark-, a chewable gummi-bear nutritional supplement product marketed to children but popular with adults. Other products include MVP-TM- and Plus for endocrine system support, MannaCleanse-TM- for intestinal system support and Emprizone-Registered Trademark-, Firm and Naturalizer for dermal care. The Company offers several products designed to aid sports performance by enhancing the body's natural recovery process and supporting lean tissue development, including Em-Pact-TM-, Bulk Em-Pact-TM- and Sport with Ambrotose-Registered Trademark-. The Company also markets Profile 1, Profile 2 and Profile 3, which support the body's nutritional needs.

In March 1998, the Company introduced MannaBAR-TM-, a nutritional supplement bar in two versions that contain the equivalent of the Company's recommended minimum daily supply of Ambrotose-Registered Trademark-Complex, Phyt-Aloe-Registered Trademark- and Plus. In September 1998 the Company introduced Manna-C-TM-, a nutritional support for nasal and sinus health containing Ambrotose-Registered Trademark- Complex, monosaccharides necessary to the manufacture of glycoproteins and an herbal blend of Vitamin C and other nutrients which support cell functions and, in October 1998, introduced Ambrostart-TM-, a nutritional support fiberdrink containing Ambrotose-Registered Trademark- Complex, and Bulk Phyt-Aloe-TM-. In addition to MannaBAR-TM- and Manna-C-TM-, the Company plans to release additional products as new nutritional compounds or areas of consumer demand are identified by the Company. All new products are expected to contain proprietary components.

The Company's products are marketed exclusively through a network marketing system. The Company believes that its network marketing system is well-suited to its products, which emphasize health and nutrition, because network marketing allows in-person product education not available through traditional marketing techniques. The Company's network marketing system appeals to a broad cross-section of people, particularly those seeking to supplement family income, start a home-based business or pursue employment opportunities other than conventional, full-time employment.

In 1997, the Company made a substantial investment in infrastructure, including investments in its new headquarters building, new distribution center, information technology systems and new research and development laboratory. The Company believes it will be able to continue its sustained and profitable growth by capitalizing on its operating strengths, including its (i) proprietary product offerings, (ii) superior research and development capability, (iii) strong Associate support philosophy, (iv) flexible operating strategy and (v) experienced management team.

Prior to June 1, 1997, certain of the Company's intellectual property rights and marketing rights were held by limited partnerships controlled by certain of the Company's shareholders. On June 1, 1997, in order to simplify the Company's ownership structure and consolidate all operating activities, the Company entered into agreements to effect a reorganization through merging with the corporate general partners of the limited partnerships in which the Company was the surviving corporation and exchanging shares of Common Stock for the entire ownership interests of the limited partnerships (the "Reorganization"). Pursuant to the Reorganization, the Company issued an aggregate of 10,000,000 shares of Common Stock to the holders of the general partnership and the limited partnership interests. In addition, during May and June 1997 the Company issued 2,027,571 shares of Common Stock in consideration for the cancellation of incentive compensation agreements with two shareholder-employees and four other employees of the Company, including 626,971 shares issued to cancel incentive compensation agreements that had been provided in lieu of ownership interests in the limited partnerships. See Note 9 to the Financial Statements. The net effect of the foregoing transactions was to increase the number of shares of Common Stock outstanding by 12,027,571, while retaining substantially the same relative ownership of the Company among the Company's original shareholders. See "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Certain Transactions-Partnership Transactions" and "-Incentive Compensation Agreements."

The Company was incorporated in Texas in 1993 under the name Emprise International, Inc. and changed its name to Mannatech, Incorporated in 1995. The principal executive offices of the Company are located at 600 S. Royal Lane, Suite 200, Coppell, Texas 75019, and the Company's telephone number is (972) 471-7400.

THE OFFERING

Common Stock offered:	
Minimum.....	2,500,000 shares
Maximum.....	5,295,015 shares
Common Stock to be outstanding after this offering:	
Minimum.....	23,618,769(1)
Maximum.....	24,776,753(2)
Use of proceeds.....	For international expansion, capital investments, working capital and other general corporate purposes. See "Use of Proceeds."
Nasdaq National Market Symbol.....	MTEX

(1) Includes 17,031 shares of Common Stock which may be sold in this offering upon exercise of an outstanding warrant (the "Exercised Warrant Shares"), assuming the sale of the minimum number of shares offered hereby. Does not include 3,000,000 shares of Common Stock reserved for issuance under the Company's 1997 Stock Option Plan and 1998 Incentive Stock Option Plan, of which 2,243,000 shares were subject to outstanding options as of September 30, 1998 at a weighted average exercise price of \$3.32 per share, (ii) 100,000 shares of Common Stock reserved for issuance subject to another option outstanding as of September 30, 1998 at an exercise price of \$2.00 per share and (iii) 457,984 shares of Common Stock reserved for issuance subject to a warrant outstanding as of September 30, 1998 at an exercise price of \$1.35 per share.

(2) Includes 475,015 Exercised Warrant Shares which may be sold in this offering assuming the sale of the maximum number of shares offered hereby. Does not include (i) 3,000,000 shares of Common Stock reserved for issuance under the Company's 1997 Stock Option Plan and 1998 Incentive Stock Option Plan, of which 2,243,000 shares were subject to outstanding options as of September 30, 1998 at a weighted average exercise price of \$3.32 per share and (ii) 100,000 shares of Common Stock reserved for issuance subject to another option outstanding as of September 30, 1998 at an exercise price of \$2.00 per share.

HOW TO PURCHASE SHARES

Included as the final page of this prospectus is a subscription agreement which must be completed by potential investors in order to purchase the Common Stock offered hereby. The page containing the subscription agreement is perforated to enable it to be detached. In order to subscribe to purchase Common Stock, please detach, complete and execute the subscription agreement, include a cashier's check made payable to "Mannatech Subscription Account" and return the executed subscription agreement and payment to the Placement Agent at P.O. Box 70210, Louisville, Kentucky 40270-0210 as soon as possible, but in no event later than January 15, 1999. The minimum amount that may be subscribed for is 100 shares. There is no maximum. Subscriptions will be given priority based upon their date of receipt by the Placement Agent. In the event that the minimum number of 2,500,000 shares is not subscribed, all amounts received by the Escrow Agent will be returned without interest or deduction. In the event that the Company terminates this offering after the Initial Closing, all amounts received by the Placement Agent shall be returned without interest or deduction.

SUMMARY FINANCIAL INFORMATION

	YEAR ENDED DECEMBER 31,				UNAUDITED NINE MONTHS ENDED SEPTEMBER 30,	
	1994(1)	1995	1996	1997	1997	1998
	(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)					
STATEMENT OF INCOME DATA:						
Net sales.....	\$ 8,445	\$32,071	\$86,311	\$150,570	\$111,102	\$122,853
Cost of sales.....	1,499	4,880	13,406	24,735	17,866	20,581
Commissions.....	3,256	12,339	35,155	61,677	45,460	48,975
Gross profit.....	3,690	14,852	37,750	64,158	47,776	53,297
Operating expenses:						
Selling and administrative expenses.....	2,063	7,012	17,764	27,846	19,940	22,622
Other operating costs.....	2,115	5,253	11,746	19,402	13,401	15,679
Cancellation of incentive compensation agreements.....	-	-	-	2,192(2)	1,821	-
Writeoff of deferred offering costs.....	-	-	-	-	-	941
Total operating expenses.....	4,178	12,265	29,510	49,440	35,162	39,242
Income (loss) from operations.....	(488)	2,587	8,240	14,718	12,614	14,055
Other (income) expense, net.....	22	181	(116)	(43)	174	(4)
Income (loss) before income taxes.....	(510)	2,406	8,356	14,761	12,440	14,059
Income tax (benefit) expense.....	(168)	67	1,194	4,139	3,507	5,413
Net income (loss).....	\$ (342)	\$ 2,339	\$ 7,162	\$ 10,622	\$ 8,933	\$ 8,646
Earnings (loss) per common share:(3)						
Basic.....	\$ (0.02)	\$ 0.11	\$ 0.35	\$ 0.50	\$ 0.42	\$ 0.39
Diluted.....	\$ (0.02)	\$ 0.11	\$ 0.35	\$ 0.47	\$ 0.41	\$ 0.37
Weighted average common and common equivalent shares outstanding:(3)						
Basic.....	20,627	20,627	20,627	21,449	21,253	22,102
Diluted.....	20,627	20,627	20,627	22,400	21,989	23,674
PRO FORMA INFORMATION:(4)						
Income (loss) before income taxes, as reported.....	\$ (510)	\$ 2,406	\$ 8,356	\$ 14,761	\$ 12,440	
Pro forma provision for income tax (benefit) expense.....	(191)	902	3,134	5,683	4,790	
Pro forma net income (loss).....	\$ (319)	\$ 1,504	\$ 5,222	\$ 9,078	\$ 7,650	
PRO FORMA EARNINGS (LOSS) PER COMMON SHARE:(3)						
Basic.....	\$ (0.02)	\$ 0.07	\$ 0.25	\$ 0.42	\$ 0.36	
Diluted.....	\$ (0.02)	\$ 0.07	\$ 0.25	\$ 0.41	\$ 0.34	
OTHER FINANCIAL DATA:						
Depreciation and amortization.....	\$ 4	\$ 75	\$ 414	\$ 1,189	\$ 486	\$ 1,584
Capital expenditures(5).....	\$ 72	\$ 769	\$ 2,660	\$ 9,135	\$ 5,501	\$ 4,877
Dividends declared per common share.....	\$ 1.00(6)	\$ 1.00(6)	\$ 10.00(6)	\$ 0.37	\$ 0.19	\$ 0.36

SEPTEMBER 30, 1998

	ACTUAL	AS ADJUSTED(7)	AS ADJUSTED(8)
(IN THOUSANDS)			
BALANCE SHEET DATA:			
Cash and cash equivalents.....	\$ 1,373	\$ 12,456	\$ 16,851
Working capital.....	(11,329)	(247)	5,412
Total assets.....	26,611	36,194	41,225
Total liabilities.....	24,373	24,373	22,773
Redeemable warrants.....	300	289	-
Total shareholders' equity.....	1,938	11,532	18,452

- (1) Statement of Income Data for the year ended December 31, 1994 includes the period from November 4, 1993 (inception) through December 31, 1994. For the two months of operations ended December 31, 1993, the Company's financial data consisted of net sales of \$0, selling and administrative expenses of \$43,049, other operating costs of \$68,683 and a net loss of (\$112,733). The balance sheet reflects a total shareholders' deficit of (\$111,733).
- (2) In June 1997 and December 1997, the Company recorded one-time charges to operations for the issuance of stock in exchange for the cancellation of certain incentive compensation agreements. See "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Certain Transactions."
- (3) Computed on the basis described in Note 1 in the Notes to Financial Statements.
- (4) The pro forma information shows the Company's net income and earnings per share as if all income earned by the Company and the limited partnerships was taxable at federal and state statutory rates.
- (5) Capital expenditures include assets acquired through capital lease obligations of \$397,402 in 1997 and \$1,471,985 for the nine months ended September 30, 1998.
- (6) Dividends were recalculated based upon shares outstanding prior to the Stock Split and the Reorganization (10,000 shares), each of which took place in 1997. Aggregate dividends declared amounted to \$10,000, \$10,000 and \$100,000 in 1994, 1995 and 1996, respectively.
- (7) As adjusted to give effect to the sale of 1,500,000 shares of Common Stock offered by the Company hereby at an assumed initial public offering price of \$8.00 per share and the application of the estimated net proceeds therefrom. See "Use of Proceeds" and "Capitalization." In addition, as of September 30, 1998, the Company had recorded \$1,500,000 of deferred offering costs relating to this offering. Total assets and shareholders' equity have been reduced by this amount as well.
- (8) As adjusted to give effect to the sale of 2,200,00 shares of Common Stock offered by the Company hereby at an assumed initial public offering price of \$8.00 per share and the application of the estimated net proceeds therefrom. See "Use of Proceeds" and "Capitalization." Also reduced for the \$1,500,000 in deferred offering costs noted in (7) above.

TRADEMARKS

The tradename Mannatech-TM- and the Company's logo is a Texas trademark of the Company. Product names used in this Prospectus are, in certain cases, trademarks and are also the property of the Company, including; Ambrostart-TM-; Ambrotose-Registered Trademark-; Bulk Ambrotose-Registered Trademark-; Bulk Phyt-Aloe-TM-; Man-Aloe-Registered Trademark-; Manna-C-TM-; MannaBAR-TM- (carbohydrate formula); MannaBAR-TM- (protein formula); MVP-TM- Phyt-Aloe-Registered Trademark-; Phyto-Bears-Registered Trademark-; MannaCleanse-TM-; and Emprizone-Registered Trademark-. Manapol-Registered Trademark- is a registered trademark of Carrington Laboratories, Inc. All other tradenames and trademarks appearing in this Prospectus are the property of their respective owners.

RISK FACTORS

THE FOLLOWING RISK FACTORS SHOULD BE CONSIDERED CAREFULLY IN ADDITION TO THE OTHER INFORMATION IN THIS PROSPECTUS BEFORE PURCHASING THE COMMON STOCK OFFERED BY THIS PROSPECTUS. EXCEPT FOR THE HISTORICAL INFORMATION CONTAINED HEREIN, THE DISCUSSION IN THIS PROSPECTUS CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. WHEN USED IN THIS PROSPECTUS, THE WORDS "BELIEVES," "EXPECTS," "ANTICIPATES," "INTENDS," "ESTIMATES," "SHOULD," "WILL LIKELY," "PLANS TO" AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY SUCH FORWARD-LOOKING STATEMENTS. THE CAUTIONARY STATEMENTS MADE IN THIS PROSPECTUS SHOULD BE READ AS BEING APPLICABLE TO ALL RELATED FORWARD-LOOKING STATEMENTS WHEREVER THEY APPEAR IN THIS PROSPECTUS. THE COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE DISCUSSED HEREIN. IMPORTANT FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE THOSE DISCUSSED BELOW, AS WELL AS THOSE DISCUSSED ELSEWHERE HEREIN.

BEST EFFORTS OFFERING; MINIMUM NUMBER OF SHARES TO BE SOLD. The Company is offering its Common Stock on a "best efforts" basis. There can be no assurance that all of the 2,200,000 shares of Common Stock offered by the Company hereby will be sold and that the estimated net proceeds generated from such a sale of all such Common Stock will actually be received by the Company. If the Company and the Selling Shareholders are unable to sell at least 2,500,000 shares of the Common Stock offered hereby, this offering will be cancelled and all monies collected from subscribers and held in escrow shall be returned to such subscribers without interest or deduction. Furthermore, if all of the 2,200,000 shares of Common Stock offered by the Company hereby are not sold, the Company may be unable to fund all the intended uses described herein for the net proceeds anticipated from this offering without obtaining funds from alternative sources or using working capital generated by the Company. Alternative sources of funds may not be available to the Company at a reasonable cost, and the working capital generated by the Company may not be sufficient to fund any uses not financed by offering proceeds. See "Use of Proceeds," "Management's Discussion and Analysis of Financial Condition and Results of Operations-Liquidity and Capital Resources" and "Plan of Distribution."

RELATIONSHIP OF OFFERING PRICE TO MARKET PRICE. The initial public offering price of the Common Stock has been arbitrarily determined by the Company and may not be indicative of the price at which shares of Common Stock will sell after this offering or its value, in general. In determining the offering price, the Board of Directors of the Company (the "Board of Directors") considered, among other things, the Company's earnings, its view of the Company's prospects, the earnings of comparable publicly traded nutritional supplement companies and the trading price of the stock of those companies. See "Plan of Distribution-Determination of Offering Price." The Company makes no representations as to any objectively reasonable value of the Common Stock. Since the Company has not retained an underwriter for purposes of this offering, the offering price has not been subject to evaluation by any third party as would be the case in an underwritten offering. Prices for the shares of Common Stock after this offering will be determined in the available market and may be influenced by many factors, including the depth and liquidity of the market for the Common Stock, the perception of the Company by other investors, the nutritional supplement industry as a whole, and general economic and market conditions.

NO PRIOR MARKET FOR COMMON STOCK; PRICE VOLATILITY. Prior to this offering, there has been no public market for the Common Stock, and there can be no assurance that an active trading market will develop subsequent to this offering or, if developed, that it will be sustained. Upon completion of this offering, it is expected that the Common Stock will be quoted on the Nasdaq National Market, which has experienced and is likely to experience in the future significant price and volume fluctuations which could adversely affect the market price of the Common Stock without regard to the operating performance of the Company. Broad market fluctuations, as well as general economic conditions, in the United States or internationally, may adversely affect the market price of the Common Stock. In addition, the Company believes that factors such as quarterly fluctuations in the financial results of the Company, the Company's earnings, changes in earnings estimates by analysts, financial and business announcements by the Company or its competitors, the overall economy and the condition of the financial markets could cause the market price of the Common Stock to fluctuate substantially. There can be no assurance that the market price of the Common Stock will not decline below the initial public offering price. See "Plan of

Distribution" and "Management's Discussion and Analysis of Results of Operations and Financial Condition."

RISKS ASSOCIATED WITH INTERNATIONAL EXPANSION. An element of the Company's growth strategy is to initiate the distribution and sale of the Company's products in international markets. The Company may experience difficulty entering new international markets due to greater regulatory barriers, the necessity of adapting to new regulatory systems and problems related to entering new markets with different cultural bases and political systems. The Company's planned international operations will be subject to political and economic uncertainties, including, among others, inflation, risk of renegotiation or modification of existing agreements or arrangements with governmental authorities, transportation, tariffs, export control, government regulation, trademark availability and registration issues, currency exchange rate fluctuations, foreign exchange restrictions which limit the repatriation of investments and earnings therefrom, changes in taxation, hostilities or confiscation of property. Changes related to these matters could have a material adverse effect on the Company's business, results of operations and financial condition. No assurance can be given that the Company will be able to successfully reformulate its product lines in any of the Company's potential new markets to attract local consumers or to meet regulatory requirements. The failure to do so would have a material adverse effect on the Company's business, results of operations and financial condition. See "Business-Growth Strategy."

SHARES ELIGIBLE FOR FUTURE SALE. Sales of a substantial number of shares of Common Stock in the public market following this offering could adversely affect the market price for the Common Stock. Upon completion of this offering, there is expected to be a minimum of 23,618,769 shares and a maximum of 24,776,753 shares of Common Stock outstanding. All of the shares offered hereby will be freely tradeable without restriction or further registration under the Securities Act of 1933, as amended (the "Securities Act"), unless purchased by "affiliates" of the Company, as that term is defined in Rule 144 under the Securities Act ("Rule 144") described below. The remaining 21,118,769 shares or 19,481,738 shares, respectively, of Common Stock outstanding upon completion of this offering are "restricted securities," as that term is defined in Rule 144 (the "Restricted Shares"). Of the Restricted Shares, 20,999,602 shares or 19,362,571 shares, respectively, will be eligible for sale in the open market after the effective date of the Registration Statement, all under and subject to the restrictions contained in Rule 144 and Rule 701.

Prior to the completion of this offering, the Company intends to enter into lock-up agreements (the "Lock-up Agreements") with each of the Company's shareholders and holders of options to purchase Common Stock, with the exception of the holder of the Exercised Warrant Shares. Pursuant to the Lock-up Agreements, each such shareholder will agree, subject to certain exceptions, not to sell or otherwise dispose of any of its shares of Common Stock until 180 days after the completion of this offering (the "Lock-up Expiration Date").

Under the Company's 1997 Stock Option Plan (the "1997 Stock Option Plan"), as of September 30, 1998 options to purchase 2,000,000 shares of Common Stock were outstanding, 1,600,000 of which will become exercisable 90 days after the completion of this offering and 400,000 of which will be exercisable on July 31, 1999, assuming completion of this offering. No shares remained available for future grants to employees and consultants of the Company under the 1997 Stock Option Plan. Under the Company's 1998 Incentive Stock Option Plan (the "1998 Stock Option Plan"), as of September 30, 1998 options to purchase 243,000 shares of Common Stock were outstanding, of which 228,000 will become exercisable on July 31, 1999, assuming completion of this offering and 15,000 of which will become exercisable ratably over a three year period. An additional 757,000 remained available for future option grants. The Company intends to register on Form S-8 under the Securities Act the offering and sale of Common Stock issuable under the 1997 Stock Option Plan and the 1998 Stock Option Plan as soon as practicable after the date of this Prospectus.

As of September 30, 1998, an additional 100,000 shares of Common Stock were issuable upon the exercise of an outstanding option (the "Non-Plan Option") at an exercise price of \$2.00 per share, which will become exercisable 90 days after the effective date of this Prospectus. In addition, as of September 30, 1998, a warrant (the "Warrant") to purchase 475,015 shares of Common Stock was outstanding,

which is currently exercisable and of which a maximum of 475,015 shares may be sold in this offering. The holder of the Warrant possesses registration rights with respect to the shares of Common Stock underlying the Warrant. Sales of shares of Common Stock under either Rule 144 or pursuant to a registration statement could have a material adverse effect on the price of the Common Stock. See "Management-Stock Option Plans," "Description of Capital Stock-Warrant Shares" and "Shares Eligible for Future Sale."

RELIANCE UPON ASSOCIATES. The Company distributes its products exclusively through its Associates, and the Company's success depends in significant part upon its ability to attract, maintain and motivate a large base of Associates, who, in turn, recruit additional Associates to purchase and sell the Company's products. Significant turnover among Associates from year to year, which the Company believes is typical of direct selling, requires the sponsoring of new Associates by existing Associates in order to maintain or increase the overall Associate force. Efforts by Associates to obtain new Associates are affected by the level of Associate motivation, which in turn can be positively or negatively affected by certain factors, including general economic conditions, modifications in the amount of commissions paid, and public perception of the quality of the Company's products. For 1997, the Company's commission expense comprised approximately 56% of its total expenses exclusive of cost of sales and income taxes. The Company's ability to attract and retain new Associates could be negatively affected by adverse publicity relating to the Company or its services or its operations, including its network marketing system. Because of the number of factors that impact the recruiting of Associates, the Company cannot predict when or to what extent increases or decreases in the level of Associate retention will occur. In addition, the number of Associates as a percentage of the population may reach levels that become difficult to exceed due to the finite number of persons inclined to pursue direct selling as a business. There can be no assurance that the number or productivity of Associates will be sustained at current levels or will increase in the future. The failure of the Company to attract and retain Associates in sufficient numbers would have a material adverse effect on the Company's business, results of operations and financial condition. Furthermore, the Company's business, results of operations and financial condition could be materially adversely affected if the Company finds it necessary to terminate a significant number of Associates or certain Associates who play a key role in the Company's distribution system. See "Business-Growth Strategy" and "-Product Distribution System."

REGULATION AND MANAGEMENT OF ASSOCIATES. Associates are independent contractors, not employees of the Company, and are not subject to the same level of direction and oversight as Company employees. While the Company has policies and rules in place governing the conduct of Associates, as well as a systematic method of monitoring, compliance enforcement and discipline, it is difficult to detect and correct all instances of Associate misconduct. The Company's efforts to manage its Associates can result in litigation from time to time between the Company and its Associates and an adverse outcome in such litigation could adversely affect the Company's business, results of operations and financial condition. See "Business-Legal Proceedings." Violations of these policies and rules reflect negatively on the Company and could also lead to formal or informal complaints by various federal, state or foreign regulatory authorities. In addition, formal and informal complaints regarding Associate conduct issues are occasionally filed with state attorneys general offices. These offices have, from time-to-time, contacted the Company and, in two instances, have met with representatives of the Company to review the activities of the Company and its Associates in their respective jurisdictions. Complaints or enforcement actions by federal, state or foreign regulatory authorities may occur in the future and could have a material adverse effect on the Company's business, results of operations and financial condition. If the Company enters new international markets, the challenge of coordinating existing Associate requirements, policies and procedures with the overlay of international legal requirements will provide the potential for increased risk to the Company. See "Business-Product Distribution System-Management of Associates."

The Company's network marketing system is or may be subject to or affected by extensive government regulation, including, without limitation, federal and state regulation regarding network marketing plans, and the offer and sale of business franchises, business opportunities and securities. Various governmental agencies monitor direct selling activities, and the Company has occasionally been

requested to supply information regarding its marketing plan to certain of such agencies. There can be no assurance that legislation and regulations adopted in particular jurisdictions in the future will not adversely affect the Company's business, results of operations and financial condition. The Company also could be found to be in non-compliance with existing statutes or regulations as a result of, among other things, vicarious liability arising from allegations of misconduct and misconduct by Associates, who are independent contractors over whom the Company has limited control, the ambiguous nature of certain of such statutes, regulations and related court decisions, and the considerable interpretive and enforcement discretion statutorily granted to regulatory authorities and the courts. Any assertion or determination that the Company or the Associates are not in compliance with existing statutes or regulations could have a material adverse effect on the Company's business, results of operations and financial condition. Furthermore, an adverse determination by any one state could influence the decisions of regulatory authorities in other jurisdictions. See "Business-Product Distribution System-Management of Associates."

ABILITY TO MANAGE GROWTH. The Company's officers have had limited experience in managing companies as large as the Company. Further growth and expansion of the Company's business would place additional demands upon the Company's current management and other resources and would require additional production capacity, working capital, information systems, management, operational and other financial resources. Further growth of the Company will depend on various factors, including, among others, its ability to attract and retain new Associates, the development of new products, competition and federal and state regulation of the nutritional supplements industry. Not all of the foregoing factors are within the control of the Company. No assurance can be given that the Company's business will grow in the future and that the Company will be able to effectively manage such growth. If the Company is unable to manage growth effectively, the Company's business, results of operations and financial condition would be materially adversely affected. See "Business-Growth Strategy," "-Product Distribution System-Associate Development," "-Product Distribution System-Management of Associates," "-Information Technology and Systems," "-Production and Distribution" and "Management."

COMPETITION. The nutritional supplements market is large and intensely competitive. The Company competes directly with companies that manufacture and market nutritional products in each of the Company's product lines, including General Nutrition Companies, Inc., Solgar Vitamin and Herb Company, Inc., Twinlab Corporation and Weider Nutrition International, Inc. Many of the Company's competitors in the nutritional supplements market have longer operating histories and greater name recognition and financial resources than the Company. In addition, nutritional supplements can be purchased in a wide variety of channels of distribution. While the Company believes that consumers appreciate the convenience of ordering products from home through a sales person, the buying habits of many consumers accustomed to purchasing products through traditional retail channels are difficult to change. The Company's product offerings in each product category are also relatively small compared to the wide variety of products offered by many other nutritional supplement companies. There can be no assurance that the Company's business, results of operations and financial condition will not be adversely affected by market conditions and competition in the future.

The Company also competes in the nutritional supplements market and for new Associates with other direct selling organizations, many of which have longer operating histories and greater name recognition and financial resources than the Company, including Amway Corporation, Nu Skin Enterprises, Inc., Body Wise International, Inc., ENVION International, Herbalife International, Inc., Enrich International, Rexall Showcase International, Forever Living Products, Inc. and Melaleuca, Inc. The Company competes for new Associates on the basis of its compensation plan and its proprietary and quality products. The Company believes that many more direct selling organizations will enter the marketplace as this channel of distribution expands over the next several years. The Company also competes for the commitment of its Associates. Given that the pool of individuals interested in direct selling tends to be limited in each market, the potential pool of Associates for the Company's products is reduced to the extent other network marketing companies successfully recruit these individuals into their businesses. There can be no assurance that other network marketing companies will not be able to

recruit the Company's existing Associates or deplete the pool of potential Associates in a given market. The competition for Associates from such other companies could have a material adverse effect on the Company's business, results of operations and financial condition. See "Business-Competition."

POTENTIAL EFFECTS OF ADVERSE PUBLICITY. The Company's products contain vitamins, minerals, herbs and other ingredients that the Company regards as safe when taken as directed by the Company and that various scientific studies have suggested may offer health benefits. The Company conducts quality control testing on its products and, from time to time, conducts or sponsors scientific studies relating to the benefits of its products. The Company is highly dependent upon Associate perception of the overall integrity of its business, as well as the safety and quality of its products and similar products distributed by other companies which may not adhere to the same quality standards as the Company. The size of the Company's distribution force and results of operations can be particularly affected by adverse publicity regarding the Company, or its competitors, including publicity regarding the legality of network marketing or the Company's network marketing system, the quality of the Company's products and product ingredients or those of its competitors, regulatory investigations of the Company or the Company's competitors and their products, Associate actions, the Company's management of its Associates and the public's perception of the Company's Associates and direct selling businesses generally. See "-Limited Availability of Conclusive Clinical Studies," "Business-Products" and "-Product Distribution System."

RELIANCE ON CERTAIN ASSOCIATES. The Company's compensation plan allows Associates to sponsor new Associates. The sponsoring of new Associates creates multiple Associate levels in the network marketing structure. Sponsored Associates are referred to as "downline" Associates within the sponsoring Associates' "downline network." If downline Associates also sponsor new Associates, additional levels of downline Associates are created, with the new downline Associates also becoming part of the original sponsor's "downline network." As a result of this network marketing distribution system, Associates develop relationships with other Associates. The Company believes that its revenue is generated from thousands of Associate networks. The loss of a high-level sponsoring Associate or another key Associate together with a group of leading Associates in such Associate's downline network, or the loss of a significant number of Associates for any reason, could adversely affect sales of the Company's products and impair the Company's ability to attract new Associates, which would have a material adverse effect on the Company's business, results of operations and financial condition. As of September 30, 1998, only one of the Company's Associates had executed a non-competition agreement with the Company. See "Business-Product Distribution System-Associate Development."

RELIANCE ON AND CONCENTRATION OF OUTSIDE MANUFACTURERS. All of the Company's products are manufactured by outside manufacturers. The Company's profit margins and its ability to deliver its existing products on a timely basis are dependent upon the ability of the outside manufacturers to continue to supply products that meet the Company's quality standards in a timely and cost-efficient manner. In response to the Company's growth, relationships were developed with three large manufacturers in 1997. Currently, substantially all of the Company's products are produced by these manufacturers. The Company's ability to enter new markets and sustain satisfactory levels of sales in each market will be dependent in part upon the ability of these or other suitable outside manufacturers to reformulate existing products, if necessary to comply with local regulations or market environments, for introduction into such markets. Finally, the development of additional new products in the future will likewise be dependent in part on the services of suitable outside manufacturers. The failure of any manufacturer to supply products as required by the Company could have a material adverse effect on the Company's business, results of operations and financial condition.

The Company currently acquires ingredients solely from suppliers that are considered by the Company to be the superior suppliers of such ingredients. The Company believes it has developed dependable alternative sources for all of its ingredients except Manapol-Registered Trademark- and arabinogalactan, which are components of the Company's proprietary raw material. The Company believes that, in the event it is unable to source any ingredients from its current suppliers, such ingredients could be produced by the Company or replaced with substitute ingredients. However, any delay in replacing or substituting such

ingredients would have a material adverse effect on the Company's business, results of operations and financial condition. See "Business-Production and Distribution."

DEPENDENCE ON PROPRIETARY INGREDIENT. Two ingredients are proprietary to the Company: (i) Ambrotose-Registered Trademark- Complex, a glyconutritional dietary supplement consisting of a blend of plant polysaccharides, which is a component of each of the Company's products; and (ii) Dioscorea Complex, a blend of herbal extracts. The Company's success will depend in large part on its ability to protect and promote its proprietary rights to these products, in particular Ambrotose-Registered Trademark- Complex. The Company has filed a composition and use of matter patent application for this compound, and has entered into confidentiality agreements with its manufacturers and suppliers to protect its proprietary rights. However, there can be no assurance that the Company will be granted a patent for its Ambrotose-Registered Trademark- Complex compound or that any such patent granted to the Company will not be substantially narrower in scope than that sought in the Company's application or that other means employed by the Company to protect its proprietary rights will be adequate. Any failure of the Company to protect its proprietary rights would have a material adverse effect on the Company's business, results of operations and financial condition.

GOVERNMENT REGULATION OF PRODUCTS AND MARKETING; IMPORT RESTRICTIONS. In addition to regulation of its direct selling activities, the Company, in both its United States and foreign markets, is or will be subject to and affected by extensive laws, governmental regulations, administrative determinations, court decisions and similar constraints (as applicable, at the federal, state and local levels) including, among other things, regulations pertaining to (i) the formulation, manufacturing, packaging, labeling, distribution, importation, sale and storage of the Company's products, (ii) product claims and advertising (including direct claims and advertising by the Company as well as claims and advertising by Associates, for which the Company may be held responsible), (iii) the Company's network marketing system, (iv) transfer pricing and similar regulations that affect the level of foreign taxable income and customs duties and (v) taxation of Associates, which in some instances may impose an obligation on the Company to collect the taxes and maintain appropriate records. See "Business-Government Regulation."

The Company may experience complications regarding health and safety and food and drug regulations for nutritional products. Many products could require reformulation to comply with local requirements. In some foreign countries, certain nutritional products may be considered foods, while other countries may consider them drugs. New regulations could be adopted or any of the existing regulations could be changed at any time in a manner that could have a material adverse effect on the Company's business, results of operations and financial condition. Duties on imports are a component of national trade and economic policy and could be changed in a manner that would be materially adverse to the Company's sales and its competitive position compared to locally produced goods, in particular in countries where the Company's products would be subject to high customs duties. In addition, import restrictions in certain countries and jurisdictions will limit the Company's ability to import products from the United States. Present or future health and safety or food and drug regulations could delay or prevent the introduction of new products into a given country or marketplace or suspend or prohibit the sale of existing products in such country or marketplace. The occurrence of any of these complications could have a material adverse effect on the Company's business, results of operations and financial condition.

If the Company expands into foreign markets, the Company will be affected by the general stability of foreign governments and the regulatory environment relating to the degree of acceptance attendant to network marketing generally, and nutritional supplements and other products of the Company's line, specifically.

DEPENDENCE ON KEY PERSONNEL. The Company's success will depend largely on the efforts and abilities of senior management, particularly Charles E. Fioretti, Chairman of the Board and Chief Executive Officer, and Samuel L. Caster, President, each a founder of the Company. There can be no assurance that the Company's existing management team will be able to manage the Company or its growth or that the Company will be able to attract and retain additional qualified personnel as needed in the future. Mr. Fioretti has executed an employment agreement with an initial term of five years, but there can be no assurance that he will remain with the Company for the full term of such agreement. The loss of the services of Messrs. Fioretti or Caster or the services of other members of senior management, or the

failure of the Company to attract and retain additional qualified personnel, could have a material adverse effect on the Company's business, results of operations and financial condition. See "Management."

GOVERNMENT REGULATION OF DIRECT SELLING ACTIVITIES. Direct selling activities are regulated by various governmental agencies. These laws and regulations are generally intended to prevent fraudulent or deceptive schemes, often referred to as "pyramid" or "chain sales" schemes, that promise quick rewards for little or no effort or risk, require high entry costs, use high pressure recruiting methods and/or do not involve legitimate products. The Company could be found not to be in material compliance with existing regulations as a result of, among other things, the considerable interpretative and enforcement discretion given to regulators or misconduct by Associates. Any assertion or determination that the Company is not currently, or was not in the past, in compliance with laws or regulations governing the Company's direct selling activities could have a material adverse effect on the Company's business, results of operations and financial condition. In addition, in any country or jurisdiction, the adoption of new laws or regulations or changes in the interpretation of existing laws or regulations could generate negative publicity and/or have a material adverse effect on the Company's business, results of operations and financial condition. The Company cannot determine the effect, if any, that future governmental regulations or administrative orders may have on the Company's business, results of operations and financial condition. Moreover, governmental regulations in countries where the Company may in the future commence operations may prevent, delay or limit market entry of certain products or require the reformulation of such products. Regulatory action, whether or not it results in a final determination adverse to the Company, has the potential to create negative publicity, with detrimental effects on the motivation and recruitment of Associates and, consequently, on the Company's business, results of operations and financial condition. See "-Potential Effects of Adverse Publicity," "-Risks Associated with International Expansion" and "Business-Government Regulation."

As is the case with most network marketing companies, the Company has from time-to-time received inquiries from various government regulatory authorities regarding the nature of its business and other issues such as compliance with local business opportunity laws and Associate sales practices. Although to date none of these inquiries has resulted in a finding materially adverse to the Company, adverse publicity resulting from inquiries into the Company's operations by government agencies could materially adversely affect the Company's business, results of operations and financial condition. See "-Potential Effects of Adverse Publicity."

PRODUCT LIABILITY. Under applicable laws and regulations, the Company, like any other retailer, distributor or manufacturer of products that are designed to be ingested by consumers or applied to their bodies, faces an inherent risk of exposure to product liability claims in the event that the use of its products results in an allegation of loss or injury. Although the Company has not been the subject of material product liability claims, no assurance can be given that the Company may not be exposed to future product liability claims, including, among other things, that its products contain contaminants or include inadequate instructions as to use or inadequate warnings concerning side effects and interactions with other substances. The Company maintains product liability insurance, however, the successful assertion or settlement of any uninsured claim, a significant number of insured claims, a claim exceeding the Company's insurance coverage or adverse publicity associated with any product liability allegation could have a material adverse effect on the Company's business, results of operations and financial condition.

One of the Company's products, MVP-TM-, contains country mallow, a plant which contains an ephedra. Products containing ephedrine have been the subject of adverse publicity in the United States and other countries relating to alleged harmful effects, including the deaths of several individuals. The United States Food and Drug Administration (the "FDA") has received numerous reports of adverse reactions to the ingestion of a naturally-occurring form of ephedrine from the Chinese herb, Ma Huang. The FDA has issued a warning to consumers regarding the possible effects of ephedrine ingestion and has also issued a proposed regulation for dietary supplements containing ephedrine. The proposed regulation would prohibit dietary supplements containing eight milligrams or more of ephedrine alkaloids per serving, and would not permit such products to contain any other stimulant ingredients. The FDA is also

considering whether to also prohibit diuretic or laxative ingredients in such products. In addition, the labeling of supplements would be prohibited from suggesting or recommending conditions of use that would result in an intake of eight milligrams or more of ephedrine alkaloids within a six-hour period, or a total daily intake of 24 milligrams or more. The FDA proposal would also require a warning not to take the product for more than seven days, and would prohibit the supplements from being represented, either expressly or implicitly, as being suitable for long-term uses, such as for weight loss or body building. Similarly, claims for increased energy, increased mental concentration or enhanced well-being that might encourage the consumer to take more of the product to achieve more of the purported effect would be required to be accompanied by a warning stating that taking more than the recommended serving may cause a heart attack, stroke, seizure or death. If the proposed regulation were to be implemented, MVP would be subject to its labeling requirements and possibly to reformulation. Company sales of MVP were \$3.8 million, \$5.5 million and \$5.9 million in 1995, 1996 and 1997, respectively. Moreover, depending on claims made for the product, the FDA could regulate it as a drug, thus requiring product approval prior to marketing. The negative publicity or product liability claims that could stem from such actions could have a material adverse effect on the Company's business, results of operation and financial condition.

LIMITED AVAILABILITY OF CONCLUSIVE CLINICAL STUDIES. In general, the Company's products consist of food, nutritional supplements and topical products, one of which, Emprizone-Registered Trademark-, is classified in the United States as an "over-the-counter" ("OTC") drug which the Company believes does not require approval from the FDA or other regulatory agencies prior to sale. Although many of the ingredients in the Company's products are vitamins, minerals, herbs and other substances for which there is a long history of human consumption, some of the Company's products contain innovative ingredients or combinations of ingredients. Although the Company believes all of its products to be safe when taken as directed by the Company, there is little long-term experience with human consumption of certain of these innovative product ingredients or combinations thereof in concentrated form. Accordingly, there can be no assurance that the Company's products, even when used as directed, will have the effects intended or will not have harmful side effects. The Company performs research and/or tests in connection with the formulation and production of its products, and from time to time conducts or sponsors clinical studies. See "-Product Liability."

VARIATIONS IN OPERATING RESULTS. The Company may experience variations on a quarterly basis in its results of operations, in response to, among other things, the timing of Company-sponsored Associate events; new product introductions; the opening of new markets; the timing of holidays, especially in the fourth quarter, which may reduce the amount of time Associates spend selling the Company's products or recruiting new Associates; the adverse effect of Associates' or the Company's failure, and allegations of their failure, to comply with applicable government regulations; the negative impact of changes in or interpretations of regulations that may limit or restrict the sale of certain of the Company's products; the operation of its network marketing system; the introduction of its products into each market; the recruitment and retention of Associates; the inability of the Company to introduce new products or the introduction of new products by the Company's competitors; general conditions in the nutritional supplement and personal care industries or the network marketing industry; and consumer perceptions of the Company's products and operations. In particular, because the Company's products are ingested by consumers or applied to their bodies, the Company is highly dependent upon consumers' perception of the safety, quality and effectiveness of its products. As a result, substantial negative publicity, whether founded or unfounded, concerning one or more of the Company's products or other products similar to the Company's products could adversely affect the Company's business, results of operations and financial condition.

As a result of these and other factors the Company's quarterly revenues, expenses and results of operations could vary significantly in the future, and period-to-period comparisons should not be relied upon as indications of future performance. There can be no assurance that the Company will be able to increase its revenues in future periods or be able to sustain its level of revenue or its rate of revenue growth on a quarterly or annual basis. The Company's rate of growth compared to previous periods has

been decreasing in recent periods and this trend is expected to continue as the Company matures. Furthermore, no assurances can be given that the Company's revenue growth rate in new markets where operations have not commenced will follow this pattern. Due to the foregoing factors, the Company's future results of operations could be below the expectations of public market analysts and investors. In such event, the market price of the Common Stock would likely be materially adversely affected. See "Management's Discussion and Analysis of Financial Condition and Results of Operations."

CONTROL BY INSIDERS. Assuming the sale of 2,500,000 shares and 5,295,015 shares of Common Stock in this offering, Charles E. Fioretti, Samuel L. Caster and the Company's other directors and officers, together with members of their families and entities that may be deemed affiliates of or related to such persons or entities, will, upon completion of this offering beneficially own approximately 52.6% and 42.9%, respectively, of the Common Stock outstanding. These individuals are likely to be able to maintain effective control of the Company, including the ability to elect a majority of the Board of Directors. In addition, such a high level of ownership by such persons may have a significant effect in delaying, deferring or preventing a change in control of the Company or other events which could be of benefit to the Company's other shareholders including mergers, acquisitions, tender offers and proxy contests. Accordingly, holders of Common Stock may be deprived of an opportunity to sell their shares at a premium to the price paid for such shares. See "Principal and Selling Shareholders."

UNSPECIFIED USE OF PROCEEDS. The principal purposes of this offering are to provide the capital for international expansion, to increase the Company's working capital and financial flexibility, to facilitate future access by the Company to public equity markets and to provide increased visibility, credibility and name recognition for the Company in the marketplace where several of its competitors are publicly held companies. In addition, the Company intends to repay its existing capital lease debt of approximately \$1.6 million if the maximum offering level is achieved. Prior to completion of this offering, the Company intends to continue to pay approximately \$1.3 million in monthly dividends to its existing shareholders. This dividend will be limited by the pre-offering earnings of the Company. To the extent the Company sells less than all of the shares offered by it in this offering, fewer net proceeds will be available to fund these intended uses. The Company has not yet identified specific uses for a majority of the net proceeds, and, pending such uses, the Company expects that it will invest such net proceeds in short-term, interest-bearing investment-grade securities. Accordingly, the Company's management will have broad discretion as to the use of such net proceeds without any action or approval of the Company's shareholders. See "Use of Proceeds."

PREFERRED STOCK. The Board of Directors may from time to time authorize the issuance of one or more classes or series of Preferred Stock without shareholder approval and may change the number of shares constituting any series and fix and determine the designation and preferences, limitations and relative rights, including voting rights, of the shares of any series of Preferred Stock so established, in each case without any action or vote by the shareholders.

One of the effects of undesignated Preferred Stock may be to enable the Board of Directors to discourage an attempt to obtain control of the Company by means of a tender offer, proxy contest, merger or otherwise, and thereby protect the Company's management, which may adversely affect the rights of the holders of Common Stock. Preferred Stock issued by the Company may rank senior to the Common Stock as to dividend rights, liquidation preference or both, may have full or limited voting rights and may be convertible into shares of Common Stock. Accordingly, the issuance of shares of Preferred Stock may discourage bids for the Common Stock or may otherwise adversely affect the trading price of the Common Stock.

RISKS ASSOCIATED WITH INFORMATION TECHNOLOGY. The Company is fundamentally dependent upon information technology and its related systems to manage and operate its key business functions: order processing, customer service, distribution, commission processing, and paying and receiving. The Company recently implemented an internally developed computer software system, creating certain risks to its operations. The most immediate risk to the business operations of the Company is during the implementation phase, in which the new computer software is substituted for the prior software. During

this period, certain variances between business requirements and the actual software functionality have been and will continue to be identified and ameliorated in a real-time environment. Additionally, there will have been and will continue to be deviations in user job performance and efficiency of an unknown duration, resulting from lack of proficiency with respect to the requirements of the new software, diminished access to significant business information, and inherent resistance to change. There have been, and it is anticipated that there will continue to be, periods during which the software system will not be optimally functional or periods during which it will be rendered temporarily inoperative while it is adjusted to achieve required performance. Moreover, varied computational results may ensue during the period of adjustment of the software system to allow for all of the requisites of the Company's specific business environment. During this period, it can be anticipated that related adverse effects could result in other areas dependent upon information systems for functionality. Also, it is likely that during such period, reversion to manual methods, such as written order-taking and computation may be required during times of adjustment, thereby substantially decreasing the efficiency of the Company's operations, and possibly adding, temporarily, to overall costs attendant to such operations. Standard accounting and inventory functions are currently supported by an off-the-shelf software package known as CS/3, provided by Tetra International, Inc. The reliability of inventory information contained within this system is entirely dependent on the accuracy of data retained in the core custom system. However, regular manual reconciliation of inventory diminishes this risk over the long term.

In the event that the software system should fail, the Company would experience an inability to conduct its day-to-day business for a period of time dependent upon the severity of the failure and the ability of the Company to remedy the cause. Should such a failure occur, it could have a material adverse effect on the Company's business results of operations and financial condition.

ANTI-TAKEOVER MATTERS. Certain provisions of the Company's Amended and Restated Articles of Incorporation (the "Articles"), the Company's Amended and Restated Bylaws (the "Bylaws") and the Texas Business Corporation Act (the "TBCA") may have the effect of discouraging unsolicited proposals for acquisition of the Company. The Bylaws provide for a classified Board of Directors serving staggered terms of three years. Additionally, the Board of Directors has the authority to issue up to 1,000,000 shares of preferred stock having such rights, preferences and privileges as are designated by the Board of Directors without shareholder approval. Effective September 1, 1997, the TBCA restricts certain business combinations with any "affiliated shareholder," as defined therein. These provisions may have the effect of delaying, deterring or preventing a takeover of the Company and could limit the price that certain investors might be willing to pay in the future for the Common Stock. See "Description of Capital Stock-Preferred Stock" and "-Anti-Takeover Considerations."

DILUTION TO NEW INVESTORS. Purchasers of Common Stock in this offering will incur immediate and substantial dilution in net tangible book value per share. See "Dilution."

USE OF PROCEEDS

The net proceeds to the Company from the sale of the 1,500,000 shares and 2,200,000 shares of Common Stock offered by the Company hereby at an assumed initial public offering price of \$8.00 per share, after deducting sales commissions and offering expenses payable by the Company, estimated to total approximately \$940,000 and \$1,164,000, respectively, are \$11,060,000 and \$16,436,000, respectively. The Company will not receive any proceeds from the sale of shares by the Selling Shareholders. See "Principal and Selling Shareholders."

The following table sets forth the Company's anticipated use of the net offering proceeds, assuming the sale, respectively, of the minimum of 1,500,000 shares and the maximum of 2,200,000 shares of Common Stock offered by the Company hereby. Pending application of the net proceeds, the Company will invest such proceeds in short term, interest-bearing instruments and investment grade securities.

	MINIMUM 1,500,000 SHARES SOLD	MAXIMUM 2,200,000 SHARES SOLD
	-----	-----
Sources of Funds:		
Offering proceeds.....	\$ 12,000,000	\$ 17,600,000
Offering expenses.....	(460,000)	(460,000)
Commissions(1).....	(480,000)	(704,000)
	-----	-----
TOTAL FUNDS.....	\$ 11,060,000	\$ 16,436,000
	-----	-----
Use of Funds:		
International expansion.....	\$ 6,060,000	\$ 9,836,000
Repayment of debt.....	0	1,600,000
Working capital.....	5,000,000	5,000,000
	-----	-----
TOTAL USES.....	\$ 11,060,000	\$ 16,436,000
	-----	-----

(1) Assumes a 4.0% fee is paid to the Placement Agent on sales of Common Stock in this offering. See "Plan of Distribution."

The Company intends to use proceeds from this offering to complete its expansion into Australia and to begin its expansion into the United Kingdom. The Company also intends to use proceeds from this offering to finance its working capital needs and to repay certain indebtedness, including expenses related to a previous stock offering terminated in July 1998. See "Management's Discussion and Analysis of Financial Condition and Results of Operations."

DIVIDEND POLICY

The Company has in the past paid dividends to its shareholders, including dividends in 1997 in the aggregate amount of \$6,928,547. In the first nine months of 1998, the Company paid an aggregate of \$9,273,830 in dividends to its shareholders. The Company currently intends to declare monthly dividends of up to \$0.06 per share until consummation of this offering. Such dividends are expected to be paid entirely out of pre-offering earnings, and therefore are not expected to have a dilutive effect on equity. Following this offering, the Company currently does not anticipate that any dividends will be paid on its Common Stock in the foreseeable future. The Company intends from time to time to re-evaluate this policy based on its net income and its alternative uses for retained earnings, if any. Any future payments of dividends will be subject to the discretion of the Board of Directors and subject to certain limitations under the TBCA. The timing, amount and form of dividends, if any, will depend, among other things, on the Company's results of operations, financial condition, cash requirements and other factors deemed relevant by the Board of Directors.

CAPITALIZATION

The following table sets forth the short-term debt and capitalization of the Company as of September 30, 1998 and as adjusted to reflect the application of the estimated net proceeds from the sale by the Company of a minimum of 1,500,000 shares and a maximum of 2,200,000 shares, respectively, of Common Stock offered by the Company hereby at an assumed initial public offering price of \$8.00 per share. The capitalization information set forth in the table below is qualified by the more detailed Financial Statements and Notes thereto included elsewhere in this Prospectus and should be read in conjunction with such Financial Statements and Notes. See "Management's Discussion and Analysis of Financial Condition and Results of Operations."

	SEPTEMBER 30, 1998		
	ACTUAL	AS ADJUSTED(1)	AS ADJUSTED(2)
	(IN THOUSANDS)		
Short-term debt, including current maturities of long-term debt.....	\$ 770	\$ 770	\$ 173
Total long-term debt, less current portion.....	\$ 1,205	\$ 1,205	\$ 202
Redeemable warrants.....	300	289	-
Shareholders' equity:			
Preferred Stock, \$0.01 par value, 1,000,000 shares authorized; no shares issued and outstanding.....	-	-	-
Common stock, \$0.0001 par value, 99,000,000 shares authorized (actual and as adjusted); 22,101,738 shares issued and outstanding (actual); 23,618,769 issued and outstanding as adjusted (minimum)(3); and 24,776,753 shares issued and outstanding, as adjusted (maximum)(4).....	2	2	2
Additional paid-in capital.....	2,632	12,226	18,510
Notes receivable from shareholders.....	(636)	(636)	-
Retained earnings (deficit).....	(60)	(60)	(60)
Total shareholders' equity.....	1,938	11,532	18,452
Total capitalization.....	\$ 3,443	\$ 13,026	\$ 18,654

(1) As adjusted to give effect to the sale of 1,500,000 shares of Common Stock offered by the Company hereby at an assumed offering price of \$8.00 per share and the application of the estimated net proceeds therefrom.

(2) As adjusted to give effect to the sale of 2,200,000 shares of Common Stock offered by the Company hereby at an assumed offering price of \$8.00 per share and the application of the estimated net proceeds therefrom.

(3) Includes 17,031 Exercised Warrant Shares. Excludes (i) 3,000,000 shares reserved for issuance under the 1997 Stock Option Plan and 1998 Stock Option Plan, of which 2,243,000 shares will be issuable upon the exercise of outstanding options, (ii) 100,000 shares issuable upon the exercise of the Non-Plan Option and (iii) 457,984 shares issuable upon the exercise of the Warrant.

(4) Includes 475,015 Exercised Warrant Shares. Excludes (i) 3,000,000 shares reserved for issuance under the 1997 Stock Option Plan, of which 2,243,000 shares will be issuable upon the exercise of outstanding options and (ii) 100,000 shares issuable upon the exercise of the Non-Plan Option.

DILUTION

The net tangible book value of the Common Stock as of September 30, 1998 was approximately \$493,000 or \$0.02 per share. Net tangible book value per share represents the Company's total tangible assets less total liabilities, divided by the total number of shares of Common Stock outstanding.

After giving effect to the sale of the minimum of 1,500,000 shares of Common Stock offered by the Company hereby and the receipt of the net proceeds therefrom (at an assumed initial public offering price of \$8.00 per share), the net tangible book value of the Common Stock as of September 30, 1998 would have been approximately \$11,532,000 or \$0.49 per share. This represents an immediate increase in net tangible book value of \$0.47 per share to existing shareholders and an immediate dilution in net tangible book value of \$7.51 per share to purchasers of Common Stock in this offering. The following table illustrates the per share dilution as of September 30, 1998:

Assumed initial public offering price per share.....		\$	8.00
Net tangible book value per share as of September 30, 1998....	\$0.02		
Increase per share attributable to new shareholders.....	0.47		

Net tangible book value per share as of September 30, 1998 after this offering.....			0.49

Dilution per share to new shareholders.....		\$	7.51

After giving effect to the sale of the maximum of 2,200,000 shares of Common Stock offered by the Company hereby and the receipt of the net proceeds therefrom (at an assumed initial public offering price of \$8.00 per share) the net tangible book value of the Common Stock as of September 30, 1998 would have been approximately \$18,452,000 or \$0.74 per share. This represents an immediate increase in net tangible book value of \$0.72 per share to existing shareholders and an immediate dilution in net tangible book value of \$7.26 per share to purchasers of Common Stock in this offering. The following table illustrates the per share dilution as of September 30, 1998:

Assumed initial public offering price per share.....		\$	8.00
Net tangible book value per share as of September 30, 1998....	\$0.02		
Increase per share attributable to new shareholders.....	0.72		

Net tangible book value per share as of September 30, 1998 after this offering.....			0.74

Dilution per share to new shareholders.....		\$	7.26

The following table sets forth as of September 30, 1998, after giving effect to the sale of the minimum number of shares of Common Stock by the Company in this offering, the number of shares of Common Stock purchased from the Company, the total consideration paid and the average price per share paid by existing shareholders and by new shareholders:

	SHARES PURCHASED		TOTAL CONSIDERATION		AVERAGE PRICE PAID PER SHARE
	NUMBER	PERCENT	AMOUNT	PERCENT	
Existing shareholders.....	22,118,769	93.6%	\$ 2,020,992	14.4%	\$ 0.09
New shareholders (minimum).....	1,500,000	6.4	12,000,000	85.6	8.00
	-----	-----	-----	-----	-----
Total.....	23,618,769	100.0%	\$ 14,020,992	100.0%	
	-----	-----	-----	-----	-----

The following table sets forth as of September 30, 1998, after giving effect to the sale of the maximum number of shares of Common Stock by the Company in this offering, the number of shares of Common Stock purchased from the Company, the total consideration paid and the average price per share paid by existing shareholders and by new shareholders:

	SHARES PURCHASED		TOTAL CONSIDERATION		AVERAGE PRICE PAID PER SHARE
	NUMBER	PERCENT	AMOUNT	PERCENT	
Existing shareholders.....	22,576,753	91.1%	\$ 2,639,270	11.0%	\$ 0.12
New shareholders (maximum).....	2,200,000	8.9	17,600,000	89.0	8.00
Total.....	24,776,753	100.0%	\$ 20,239,270	100.0%	

Sales by the Selling Shareholders in this offering of the maximum number of shares offered by such selling shareholders will reduce the number of shares held by existing shareholders as of September 30, 1998 to 19,481,738 or 82% or 79.6% of the total number of shares of Common Stock outstanding immediately after the sale, respectively, of the minimum number of shares of Common Stock offered hereby or the maximum number of shares of Common Stock offered hereby, and will increase the number of shares being purchased by new investors to 5,295,015, or approximately 18.3% of the total number of shares of Common Stock outstanding immediately after this offering. See "Principal and Selling Shareholders."

There have been no exercises of outstanding stock options as of the date of this Prospectus. As of September 30, 1998, there were (i) options outstanding under the 1997 Stock Option Plan to purchase 2,000,000 shares of Common Stock at a weighted average exercise price of \$2.75 per share, none of which were vested or exercisable as of such date, (ii) options outstanding under the 1998 Stock Option Plan to purchase 243,000 shares at an exercise price of \$8.00, none of which were vested or exercisable as of such date, (iii) the Non-Plan Option to purchase 100,000 shares of Common Stock at an exercise price of \$2.00 per share, which was not vested or exercisable as of such date, (iv) the Warrant to purchase 475,015 shares of Common Stock at an exercise price of \$1.35 per share, which is currently fully exercisable and (v) 757,000 shares of Common Stock available for grant under the 1998 Stock Option Plan. To the extent that any shares of Common Stock are issued upon exercise of (i) any of these options or the Warrant or (ii) any additional options that are granted under the 1998 Stock Option Plan or otherwise, there will be further dilution to new investors. See "Management-Stock Option Plans," and "Principal and Selling Shareholders."

SELECTED FINANCIAL DATA

The Selected Financial Data set forth below for each of the four years ended December 31, 1997 have been derived from, and should be read in conjunction with, the financial statements of the Company audited by PricewaterhouseCoopers LLP, with respect to 1997, and Belew Averitt LLP, with respect to earlier periods, independent public accountants, whose reports appear elsewhere in this Prospectus. The Selected Financial Data set forth below for the nine months ended September 30, 1997 and 1998 have been derived from the Company's unaudited financial statements but have been prepared on the same basis as the audited financial statements of the Company included herein and, in the opinion of management, include all adjustments, consisting of normally recurring adjustments considered necessary for a fair presentation of the Company's financial position and results of operations for such period. The information contained in this table should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Financial Statements and accompanying Notes thereto included elsewhere in this Prospectus.

	YEAR ENDED DECEMBER 31,				UNAUDITED NINE MONTHS ENDED SEPTEMBER 30,	
	1994(1)	1995	1996	1997	1997	1998
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)						
STATEMENT OF INCOME DATA:						
Net sales.....	\$ 8,445	\$32,071	\$86,311	\$150,570	\$111,102	\$122,853
Cost of sales.....	1,499	4,880	13,406	24,735	17,866	20,581
Commissions.....	3,256	12,339	35,155	61,677	45,460	48,975
Gross profit.....	3,690	14,852	37,750	64,158	47,776	53,297
Operating expenses:						
Selling and administrative expenses.....	2,063	7,012	17,764	27,846	19,940	22,622
Other operating costs.....	2,115	5,253	11,746	19,402	13,401	15,679
Cancellation of incentive compensation agreements.....	-	-	-	2,192(2)	1,821	-
Writeoff of deferred offering costs.....	-	-	-	-	-	941
Total operating expenses.....	4,178	12,265	29,510	49,440	35,162	39,242
Income (loss) from operations.....	(488)	2,587	8,240	14,718	12,614	14,055
Other (income) expense, net.....	22	181	(116)	(43)	174	(4)
Income (loss) before income taxes.....	(510)	2,406	8,356	14,761	12,440	14,059
Income tax (benefit) expense.....	(168)	67	1,194	4,139	3,507	5,413
Net income (loss).....	\$ (342)	\$ 2,339	\$ 7,162	\$ 10,622	\$ 8,933	\$ 8,646
Earnings (loss) per common share:(3)						
Basic.....	\$ (0.02)	\$ 0.11	\$ 0.35	\$ 0.50	\$ 0.42	\$ 0.39
Diluted.....	\$ (0.02)	\$ 0.11	\$ 0.35	\$ 0.47	\$ 0.41	\$ 0.37
Weighted average common and common equivalent shares outstanding:(3)						
Basic.....	20,627	20,627	20,627	21,449	21,253	22,102
Diluted.....	20,627	20,627	20,627	22,400	21,989	23,674
PRO FORMA INFORMATION:(4)						
Income (loss) before income taxes, as reported.....	\$ (510)	\$ 2,406	\$ 8,356	\$ 14,761	\$ 12,440	
Pro forma provision for income tax (benefit) expense.....	(191)	902	3,134	5,683	4,790	
Pro forma net income (loss).....	\$ (319)	\$ 1,504	\$ 5,222	\$ 9,078	\$ 7,650	
PRO FORMA EARNINGS (LOSS) PER COMMON SHARE:(3)						
Basic.....	\$ (0.02)	\$ 0.07	\$ 0.25	\$ 0.42	\$ 0.36	
Diluted.....	\$ (0.02)	\$ 0.07	\$ 0.25	\$ 0.41	\$ 0.34	
OTHER FINANCIAL DATA:						
Depreciation and amortization.....	\$ 4	\$ 75	\$ 414	\$ 1,189	\$ 486	\$ 1,584
Capital expenditures(5).....	\$ 72	\$ 769	\$ 2,660	\$ 9,135	\$ 5,501	\$ 4,877
Dividends declared per common share.....	\$ 1.00(6)	\$ 1.00(6)	\$ 10.00(6)	\$ 0.37	\$ 0.19	\$ 0.36

	DECEMBER 31,				UNAUDITED
	1994	1995	1996	1997	SEPTEMBER 30, 1998
(IN THOUSANDS)					
BALANCE SHEET DATA:					
Cash and cash equivalents.....	\$ 283	\$ 953	\$ 1,160	\$ 61	\$ 1,373
Working capital.....	(423)	(1,228)	(2,580)	(9,239)	(11,329)
Total assets.....	1,577	5,712	11,410	19,558	26,611
Total liabilities.....	1,928	6,103	10,579	18,015	24,373
Redeemable warrants.....	-	-	-	300	300
Total shareholders' equity (deficit).....	(351)	(391)	831	1,244	1,938

(1) Statement of Income Data for the year ended December 31, 1994 includes the period from November 4, 1993 (inception) through December 31, 1994. For the two months of operations ended December 31, 1993, the Company's financial data consisted of net sales of \$0, selling and administrative expenses of \$43,049, other operating costs of \$68,683 and a net loss of (\$112,733). The balance sheet reflects a total shareholders' deficit of (\$111,733).

(2) In June 1997 and December 1997, the Company recorded one-time charges to operations for the issuance of stock in exchange for the cancellation of certain incentive compensation agreements. See "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Certain Transactions."

(3) Computed on the basis described in Note 1 in the Notes to Financial Statements.

(4) The pro forma information shows the Company's net income and earnings per share as if all income earned by the Company and the Partnerships was taxable at federal and state statutory rates.

(5) Capital expenditures include assets acquired through capital lease obligations of \$397,402 in 1997 and \$1,471,985 for the nine months ended September 30, 1998.

(6) Dividends were calculated based upon shares outstanding prior to the Stock Split and the Reorganization (10,000 shares), each of which took place in 1997. Aggregate dividends declared amounted to \$10,000, \$10,000 and \$100,000 in 1994, 1995 and 1996, respectively.

MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of the Company's financial condition and results of operations should be read in conjunction with the Financial Statements and Notes thereto included elsewhere in this Prospectus.

OVERVIEW

Mannatech develops and sells proprietary nutritional supplements and topical products through a network marketing system. The Company sells its products in the United States and Canada, through a network of approximately 226,000 active Associates as of September 30, 1998, and has begun to expand into Australia, while continuing to assess the potential of other foreign markets.

Since commencement of operations in November 1993, the Company has achieved year-to-year growth in net sales. This growth is primarily attributable to the increase in both existing and new product sales, growth in the number of Associates and expansion into new geographic markets in the United States and Canada.

The Company's revenues are derived primarily from sales of its products, sales of Associate starter and renewal packs, which include products, promotional materials, and free admission to the Company events and promotional materials. To become an Associate of the Company, a person may enroll as a Preferred Customer and subsequently execute an Associate Application, sponsor new Associates or purchase a starter pack. Alternatively, one can become an Associate by purchasing one of the Associate starter packs. Each starter pack includes some combination of nutritional products, promotional materials, and free admission to events. Each pack also allows the Associate to purchase product at the Company's wholesale price. The components, purchase price of the pack, and wholesale value of the included items for the periods for which financial data is presented are detailed in the table below.

PACKS SOLD PRIOR TO JUNE 1998

	ALL STAR BUSINESS PACK	MASTER ASSOCIATE AND ALL STAR TRAINING PACK	ALL STAR TRAINING PACK	MASTER STARTER PACK	NEW ASSOCIATE PROMO PACK	PREFERRED CUSTOMER PACK
Associate Cost.....	\$1,000.00	\$ 568.00	\$ 339.00	\$ 229.00	\$ 49.00	\$ 29.00
Number of Nutritional Products Included.....	27	15	9	6	1	-
Wholesale Value of Nutritional Products.....	\$ 736.00	\$ 412.50	\$ 253.00	\$ 166.00	\$ 28.50	-
Number of Promotional Materials Included.....	108	26	3	23	15	15
Wholesale Value of Promotional Materials.....	\$ 345.99	\$ 298.04	\$ 186.90	\$ 111.14	\$ 12.59	\$ 14.50
Event Admission Included....	Yes	Yes	Yes	No	No	No
Implied Admission Value.....	\$ 50.00	\$ 50.00	\$ 50.00	\$ -	\$ -	\$ -
Total Wholesale and Implied Value.....	\$1,131.99	\$ 760.54	\$ 489.90	\$ 277.14	\$ 41.09	\$ 14.50

PACKS SOLD BEGINNING IN JUNE 1998

	ALL STAR BUSINESS PACK	MASTER ASSOCIATE AND ALL STAR TRAINING PACK	MASTER STARTER PACK	NEW ASSOCIATE PROMO PACK	PREFERRED CUSTOMER PACK
Associate Cost.....	\$1,000.00	\$ 664.00	\$ 289.00	\$ 49.00	\$ 29.00
Number of Nutritional Products Included...	26	17	9	1	-
Wholesale Value of Nutritional Products...	\$ 750.50	\$ 491.00	\$ 216.74	\$ 28.50	-
Number of Promotional Materials Included.....	131	26	23	14	14
Whole Value of Promotional Materials.....	\$ 357.52	\$ 276.32	\$ 115.37	\$ 16.12	\$ 16.12
Events Admission Included.....	Yes	Yes	No	No	No
Implied Admission Value.....	\$ 50.00	\$ 50.00	\$ -	\$ -	\$ -
Total Wholesale and Implied Value.....	\$1,158.02	\$ 817.32	\$ 332.11	\$ 44.62	\$ 16.12

The Company views the nutritional product sale included in the "New Associate Promo Pack" as a retail sale. Viewed as a retail sale the value of the product would be \$39.00 and the total value of the pack would be \$51.59. The Company adopted this view as purchasers of the "New Associate Promo Pack" were often previously retail customers of other Associates before seeking Associate status themselves.

The Company also requires an Associate to renew status each year by renewing as a Preferred Customer and continuing to sponsor New Associates or by purchasing a renewal pack. Prior to June 1998 the Associates renewed at the \$49.00, \$229.00, and \$568.00 levels. Currently, the Associate can renew at the \$29.00, \$200.00 or \$350.00 levels. The renewal packs were identical to the starter packs in the table above sold at the same price. If an Associate chose not to renew his Associate status he could continue to purchase the Company's products at the wholesale price and resell the products if he desired; however, he would not be qualified to earn commissions or bonuses under the Company's compensation plan. In May 1998 the Company instituted its \$29.00 Preferred Customer Pack, which also provides a method of renewal of Associate status.

Associates are also eligible to purchase upgrade packs. Historically, upgrade packs were purchased at the \$229.00, \$339.00, \$568.00 and \$1,000.00 levels. Beginning June 1998 upgrade packs are priced at \$289.00, \$375.00, \$664.00 and \$1,000.00. Upgrade packs are accounted for as renewal packs as they renew an Associate's membership for one year from the time of upgrade.

In May 1998, the Company introduced a new starter and renewal pack priced at \$29.00 which consists of 15 promotional materials which would cost \$14.50 if purchased separately at their wholesale value.

Revenues are generally recognized when products or sales aids are shipped. The Company's revenues are based primarily on the wholesale prices of the products sold. The Company defers revenue received from the sale of promotional packs which is in excess of the wholesale value of the individual items included in such packs. Revenues from promotional packs are allocated between products and events admission based on the proportionate fair value of these items. Allocated event revenues are also deferred. All deferred revenue is amortized over a twelve-month period. Total deferred revenue was approximately \$521,000 and \$809,000 at December 31, 1996 and 1997, respectively and was \$641,000 for the nine-month period ended September 30, 1998. The Company currently outsources all of its product manufacturing needs and all of its ingredients are supplied by outside vendors.

As a result of the Company's expansion into Canada, and its change, in the fourth quarter of 1997, to higher quality manufacturers, the Company has experienced an increase in cost of sales as a percentage of net sales. Sales of products in Canada have also resulted in increased shipping costs and additional costs to reformulate certain products.

Associates are compensated by commissions, which are directly correlated to the placement and position of the Associate within the Company's compensation plan, volume of direct sales and number of

new enrolled Associates. Commissions as a percentage of net sales were 38.5%, 40.7%, 41.0% and 39.8% for 1995, 1996, 1997 and the nine months ended September 30, 1998, respectively. The Company believes that, under the Company's existing compensation plan, commissions will not exceed 42% of net sales. See "Business-Product Distribution System-Associate Compensation."

The Company's selling and administrative expenses consist of human resource expense, including wages, bonuses and marketing expenses, and are a mixture of both fixed and variable expenses. Company-sponsored Associate events held throughout the year also have an effect on its selling and administrative expenses, as does the Company's continuing commitment to investment in information technology systems. In 1997, the Company recorded sales and administrative expenses at 18.5% of net sales, a lower rate than prior years, as a result of increased net sales, a reduction in executive salaries beginning in June 1997 and the management of expenses.

The increased demand for the Company's products has necessitated significant investment in infrastructure to support the growth of the Company. In 1997, the Company invested in its new headquarters building, new distribution center and new research and development laboratory. As a result of its investment in infrastructure, the Company's other operating costs have increased significantly.

The Company is subject to taxation in the United States at the federal statutory tax rates of 34% for 1995 and 1996 and 35% for 1997 and 1998. The Company is also subject to taxation in various state jurisdictions with an average statutory tax rate of approximately 5%. With the expected international expansion, a portion of the Company's income will be subject to taxation in the country in which it operates and the Company may be eligible for foreign tax credits for the amount of foreign taxes paid in a given period to offset taxes otherwise payable. The Company may not be able to fully utilize such foreign tax credits in the United States. The use of the foreign tax credits would be based upon the proportionate amount of net sales in each country. This could result in the Company paying a higher overall effective tax rate on its worldwide operations. Many of the countries in which the Company is considering for expansion during 1998 and beyond have maximum statutory tax rates in excess of the United States rate.

REORGANIZATION

In December 1994, to achieve certain tax efficiencies and to protect certain of the Company's proprietary rights, the Company transferred certain rights and interest in intellectual property, its right to use a supplier's trademark and its marketing rights to two affiliated partnerships (the "Royalty Partnership" and the "Marketing Partnership," respectively). The Marketing Partnership was owned by two affiliated partnerships that also shared common ownership with the Company (collectively with the Royalty Partnership and the Marketing Partnership, the "Partnerships"). The respective ownership interests in the Partnerships were structured with the intention of retaining the same economic interests among the partners as that of the shareholders of the Company. In the case of the intellectual property and trademark transferred to the Royalty Partnership, the Company entered into a 17-year agreement with the Royalty Partnership to pay a royalty based on sales volume. In the case of the Marketing Partnership, the Company paid a commission based on a specified percentage of sales volume. At the time of transfer, the rights and interest in intellectual property, supplier's trademark and marketing rights had a minimal basis. During 1994, the Company also entered into separate incentive compensation agreements with two of its shareholders pursuant to which the Company agreed to pay commissions based on specified monthly sales volumes and increases in number of new enrolled Associates. These agreements were designed to compensate for the differences in ownership in the Partnerships for one of the principal shareholders and to provide compensation to a shareholder in lieu of receiving a Partnership interest.

On June 1, 1997, in order to simplify the Company's ownership structure and consolidate all operating activities, the Company entered into agreements to effect the Reorganization through merging with the corporate general partners of the Partnerships in which the Company was the surviving corporation and exchanging shares of Common Stock for the entire ownership interests of the Partnerships. Pursuant to the Reorganization, the Company issued an aggregate of 10,000,000 shares of Common Stock to holders of the general partnership and limited partnership interests. In addition, during May and June 1997 the Company issued 2,027,571 shares of Common Stock in consideration for the cancellation of incentive compensation agreements with two shareholder-employees and four other employees of the Company, including 626,971 shares issued to cancel incentive compensation agreements that had been provided in lieu of ownership interests in the Partnerships. See Note 9 to the Financial Statements. The net effect of the foregoing transactions was to increase the number of shares of Common Stock outstanding by 12,027,571 while retaining substantially the same relative ownership of the Company. The only ownership percentage change among the original shareholders related to 208,024 shares granted to one shareholder in recognition of significant contributions to the Company, which resulted in minor dilution to the other original seven shareholders at the time of the exchange. No monetary consideration changed hands and the changes were designed to reestablish the original economic characteristics of the Company. Other than the new shares issued to the four employees to cancel their incentive compensation agreements, relative ownership interests, as evidenced by retention of economic risks and benefits, remained virtually the same. After the exchange, the Company terminated and liquidated the Partnerships at no gain or loss.

RESULTS OF OPERATIONS

The following table summarizes the Company's operating results as a percentage of net sales for each of the periods indicated:

	YEAR ENDED DECEMBER 31,			NINE MONTHS ENDED SEPTEMBER 30,	
	1995	1996	1997	1997	1998
Net sales.....	100.0%	100.0%	100.0%	100.0%	100.0%
Cost of sales.....	15.2	15.5	16.4	16.1	16.8
Commissions.....	38.5	40.7	41.0	40.9	39.8
Gross profit.....	46.3	43.8	42.6	43.0	43.4
Operating expenses:					
Selling and administrative expenses.....	21.9	20.6	18.5	17.9	18.4
Other operating costs.....	16.4	13.6	12.9	12.1	12.8
Cancellation of incentive compensation agreements.....	-	-	1.5	1.6	-
Write-off of deferred offering costs.....	-	-	-	-	0.8
Income from operations.....	8.0	9.6	9.7	11.4	11.4
Other (income) expense, net.....	0.5	(0.1)	(0.0)	0.2	0.0
Income before income taxes.....	7.5	9.7	9.7	11.2	11.4
Income tax expense.....	0.2	1.4	2.7	3.1	4.4
Net income.....	7.3%	8.3%	7.0%	8.1%	7.0%
Number of starter packs sold.....	66,623	97,813	133,461	103,562	76,620
Number of renewal packs sold.....	907	19,875	41,219	29,597	44,157
Total number of packs sold.....	67,530	117,688	174,680	133,159	120,777
Total Associates canceling Associate status.....	930	2,503	5,163	3,645	4,656

NET SALES. Net sales increased 10.62% to \$122.9 million for the nine months ended September 30, 1998 from \$111.1 million for the nine months ended September 30, 1997. This increase was primarily attributable to the following:

- \$6.3 million, or 53.4% was due to the sale of several new products introduced during 1998 and existing products which were not available for sale during the first nine months of 1997 for Canada.
- \$12.2 million, or 103.4% was due to an increase in existing product sales, which increase resulted solely from increases in volumes of products sold.
- (\$6.7) million, or (56.8%) was due to an overall decrease in Associate pack sales. The decrease resulted from a decrease of approximately (\$7.4) million in Associate packs sold with respect to the enrollment of new Associates offset by a \$700,000 increase in packs sold to Associates renewing their association with the Company. The Company's fee structure remained constant throughout this period; however, the Company added some additional packs to its existing line. See "Business." Associate pack sales decreased due to a delay in introducing new Associate packs or starter packs until the second quarter of 1998. The Company believes, based upon information received from many of its Associates, that many Associates delayed signing up new Associates and their own renewal until the new packs were available and the Company's operations in Australia had begun. As the new Associate packs were not available until May 1998, it is not possible to determine if the overall decrease in Associate pack sales was attributable to a deferral of such revenue or a permanent loss.

COST OF SALES. Cost of sales increased 15.2% to \$20.6 million for the nine months ended September 30, 1998 from \$17.9 million for the comparable period in 1997. As a percentage of net sales, cost of sales increased to 16.8% from 16.1% for the nine months ended September 30, 1998 and 1997, respectively. The increase in cost of sales was due to a \$2.7 million increase in finished goods, a (\$100,000) decrease in freight due to changing vendors to save shipping costs which was offset by an increase in sales volume and a \$100,000 increase in normal costs of spoilage and shrinkage of inventory which was due to the Company utilizing a new vendor to blend raw materials used in its products.

COMMISSIONS. Commissions consist of payments to Associates for sales activity and downline growth. Commissions increased 8.0% to \$49.0 million for the nine months ended September 30, 1998 from \$45.5 million for the comparable period in 1997. As a percentage of net sales, commissions decreased to 39.8% for the nine months ended September 30, 1998 from 40.9% for the comparable period in 1997. The slight decrease as a percentage of net sales was the direct result of a decrease in the number of Associate packs sold.

GROSS PROFIT. Gross profit increased 10.7% to \$53.3 million for the nine months ended September 30, 1998 from \$47.7 million for the comparable period in 1997. As a percentage of net sales, gross profit increased to 43.4% for the nine months ended September 30, 1998 from 43.0% for the comparable period in 1997. These changes were primarily attributable to the factors described above.

SELLING AND ADMINISTRATIVE EXPENSES. Selling and administrative expenses consist of human resource expenses, including wages, bonuses and marketing expenses, and are a mixture of both fixed and variable expenses. Selling and administrative expenses increased 13.6% to \$22.6 million for the nine months ended September 30, 1998 from \$19.9 million for the comparable period in 1997. As a percentage of net sales, selling and administrative expenses increased to 18.4% for the nine months ended September 30, 1998 from 17.9% for the comparable period in 1997. The dollar amount increase was due primarily to sales increases and \$1.0 million expended on the Company's first large scale Associate meeting.

OTHER OPERATING COSTS. Other operating costs include utilities, depreciation, travel, office supplies and printing expenses. Other operating costs increased 17.2% to \$15.7 million for the nine months ended September 30, 1998 from \$13.4 million for the comparable period in 1997. As a percentage of net sales, other operating costs increased to 12.8% for the nine months ended September 30, 1998 from 12.1% for the comparable period in 1997. The dollar amount increase was primarily related to the increase in sales, additional expenses of \$700,000 related to the opening of Australia, additional depreciation expense of \$700,000 related to the addition of the laboratory located in the Company's worldwide headquarters, relocation of the distribution center to its current location in January 1998 and the incurrence of various other costs associated with the Company's planned international expansion. The remaining increase was due to the increase in sales volume.

CANCELLATION OF INCENTIVE COMPENSATION AGREEMENTS. Cancellation of incentive compensation agreements consisted of a one-time charge in 1997 totaling approximately \$1.8 million at the end of the third quarter of 1997. This charge resulted from the exchange of Common Stock for the cancellation of certain incentive compensation agreements. There were no additional cancellations during 1998. See "Certain Transactions."

WRITE-OFF OF DEFERRED OFFERING COSTS. During July 1998 the Company withdrew its original underwritten institutional/retail offering. Approximately \$940,000 related to the withdrawn offering, including underwriting expenses, printing costs and roadshow costs, was expensed in the third quarter of 1998.

OTHER (INCOME) EXPENSE, NET. Other (income) expense consists of interest income, royalties from vendors and settlement of lawsuits. Other (income) expense decreased 102.3% to \$4,000 for the nine months ended September 30, 1998 from (\$174,000) for the comparable period in 1997. As a percentage of net sales, other (income) expense decreased to 0.0% for the nine months ended September 30, 1998 from (0.2%) for the comparable period in 1997. The expense for the nine months ended September 30, 1997 related primarily to legal actions and related charges for the settlement of lawsuits totaling \$110,000 that did not occur for the comparable period in 1998.

INCOME TAX EXPENSE. Income tax expense increased 54.3% to \$5.4 million for the nine months ended September 30, 1998 compared to \$3.5 million for the comparable period in 1997. The effective tax rate increased to 38.5% for the nine months ended September 30, 1998 from 26.9% for the comparable period in 1997. The increase in the effective tax rate was primarily the result of the Company's reorganization, which began June 1, 1997. Prior to that date, the income from the Partnerships was subject to income tax only at the individual partners' level. See "Certain Transactions."

NET INCOME. Net income decreased 7.52% to \$8.6 million for the nine months ended September 30, 1998 from \$8.9 million for the comparable period in 1997. As a percentage of net sales, net income decreased to 7.0% for the nine months ended September 30, 1998 from 8.1% for the comparable period in 1997. The decrease resulted because the increase in sales was offset by the recording of the write-off of the initial public offering expenses of approximately \$1 million and the increase in the Company's effective tax rate.

YEARS ENDED DECEMBER 31, 1997 AND DECEMBER 31, 1996

NET SALES. Net sales increased 74.4% to \$150.6 million in 1997 from \$86.3 million in 1996. This increase was primarily attributable to the following:

- \$46.9 million, or 72.9%, was due to an increase in existing product sales, which increase resulted solely from increases in the volume of products sold.
- \$11.1 million, or 17.3%, was due to an increase in Associate pack sales. Associate pack sales increased due to the enrollment of new Associates and the sale of renewal packs to existing Associates. Approximately \$5.9 million of the increase in Associate pack sales related to the sign up

of new Associates and \$5.2 million related to the renewal of existing Associates. The Company's fee structure remained constant throughout this period.

- \$6.3 million, or 9.8%, was due to the introduction in July 1997 of MannaCleanse-TM-, an intestinal support product, and Bulk Ambrotose-Registered Trademark-, a cell-to-cell communication support product.

COST OF SALES. Cost of sales increased 84.3% to \$24.7 million in 1997 from \$13.4 million in 1996. As a percentage of net sales, cost of sales increased to 16.4% for 1997 from 15.5% in 1996. The increase in cost of sales was due to a \$10.8 million increase in sales of finished goods, a \$600,000 increase in shipping costs due to increased sales volume, a \$300,000 increase in shipping costs for Canadian finished goods and a (\$400,000) decrease in normal costs of spoilage and shrinkage of inventory.

COMMISSIONS. Commissions increased 75.4% to \$61.7 million in 1997 from \$35.2 million in 1996. As a percentage of net sales, commissions increased to 41.0% for 1997 from 40.7% in 1996.

GROSS PROFIT. Gross profit increased 70.0% to \$64.2 million in 1997 from \$37.8 million in 1996. As a percentage of net sales, gross profit decreased to 42.6% in 1997 from 43.8% in 1996. These changes were primarily attributable to the factors described above.

SELLING AND ADMINISTRATIVE EXPENSES. Selling and administrative expenses increased 56.8% to \$27.8 million in 1997 from \$17.8 million in 1996. As a percentage of net sales, selling and administrative expenses decreased to 18.5% in 1997 from 20.6% in 1996. The dollar amount increase was primarily attributable to an increase in bonuses and compensation paid and an increase in number of employees to support the Company's growth in net sales. The decrease in the percentage of net sales was primarily attributable to certain efficiencies achieved by the Company in managing sales growth and reductions in executive salaries beginning in June 1997 of approximately \$600,000. Executive salaries were reduced to reflect salaries commensurate with those paid by similar public companies. The Company does not expect increases in executive salaries in the foreseeable future other than those increases necessary in the marketplace to recruit, reward and retain qualified executives.

OTHER OPERATING COSTS. Other operating costs increased 65.2% to \$19.4 million in 1997 from \$11.7 million in 1996. This increase was primarily due to costs associated with the Company's relocation of its worldwide headquarters to its current location in March 1997. As a result of the relocation the Company had capital expenditures of approximately \$9.6 million, which resulted in an increase in depreciation expense of approximately \$900,000. In addition, other expenses, comprised of supplies, rent and miscellaneous equipment purchases, increased by approximately \$1.8 million. Utility and telephone expense increased by approximately \$2.0 million with the majority of the increase related to telephone expense. The increase in telephone expense is related to the increase in sales as the majority of the Company's sales are made by telephone or fax. The increased sales volume leads to increased phone usage, which results in higher costs. As a percentage of net sales, other operating costs decreased to 12.9% in 1997 from 13.6% in 1996. This decrease was primarily attributable to increased sales volume and the Company achieving certain volume-based efficiencies due to increased net sales. If sales volumes remain constant, these volume-based efficiencies are expected to remain constant as they are directly related to sales volumes.

CANCELLATION OF INCENTIVE COMPENSATION AGREEMENTS. Cancellation of incentive compensation agreements consisted of a one-time charge in 1997 totaling approximately \$2.2 million. This charge resulted from the exchange of Common Stock for the cancellation of certain incentive compensation agreements. See "Certain Transactions."

OTHER (INCOME) EXPENSE, NET. Other (income) expense decreased 62.9% to (\$43,000) in 1997 from (\$116,000) in 1996. As a percentage of net sales, other (income) expense decreased to (0.0%) in 1997 from (0.1%) in 1996. The change in 1997 was primarily attributable to the settlement in 1997 of various lawsuits totaling \$110,000 versus settlement expense of \$59,000 in 1996.

INCOME TAX EXPENSE. Income tax expense increased to \$4.1 million in 1997 compared to \$1.2 million in 1996. The effective tax rate increased significantly to 28.0% in 1997 from 14.3% in 1996. The increase in the effective tax rate was primarily the result of the Company's reorganization as of June 1, 1997. Prior to that date, the Partnerships were subject to income tax only at the individual partners' level. See "Certain Transactions."

NET INCOME. Net income increased 48.3% to \$10.6 million in 1997 from \$7.2 million in 1996. As a percentage of net sales, net income decreased to 7.0% in 1997 compared to 8.3% in 1996. This decrease was primarily related to the cancellation of the incentive compensation agreements, additional income tax expense and the reorganization of the Partnerships. See "Certain Transactions."

YEARS ENDED DECEMBER 31, 1996 AND DECEMBER 31, 1995

NET SALES. Net sales increased 169.1% to \$86.3 million in 1996 from \$32.1 million in 1995. This increase was primarily attributable to the following:

- \$29.4 million, or 54.3%, was due to an increase in existing product sales, which increase resulted solely from increases in the volume of products sold.
- \$18.0 million, or 33.2%, was due to an increase in Associate pack sales. Associate pack sales increased due to the enrollment of new Associates and the sale of renewal packs to existing Associates. Approximately \$13.3 million of the increase in Associate pack sales related to the sign up of new Associates and \$4.7 million related to the renewal of existing Associates. The Company's fee structure remained constant throughout this period.
- \$3.6 million, or 6.6%, was due to the introduction of a new nutritional supplement product line, consisting of Profile 1, Profile 2 and Profile 3, in May 1996, and the introduction of a new raw material, Ambrotose-Registered Trademark-, in October 1996.
- \$3.2 million, or 5.9%, was due to the commencement of operations in Canada in April 1996, excluding Associate pack sales.

COST OF SALES. Cost of sales increased 174.7% to \$13.4 million in 1996 from \$4.9 million in 1995. As a percentage of net sales, cost of sales increased to 15.5% in 1996 from 15.2% in 1995. The increase in cost of sales was comprised of an \$8.3 million increase in sales of finished goods and a \$200,000 increase in sales of finished goods in Canada.

COMMISSIONS. Commissions increased 184.9% to \$35.2 million in 1996 from \$12.3 million in 1995. As a percentage of net sales, commissions increased to 40.7% in 1996 from 38.5% in 1995. The increase was primarily attributable to the introduction of an additional type of commission for the Associates' compensation plan during 1995. Once a commission plan is introduced, there is generally a short time lag before the Associates begin to qualify for the payment of commissions. During 1996, this new commission structure accounted for a 4.3% increase (as a percentage of net sales) in total commissions.

GROSS PROFIT. Gross profit increased 154.2% to \$37.8 million in 1996 from \$14.9 million in 1995. As a percentage of net sales, gross profit decreased to 43.8% in 1996 from 46.3% in 1995. These changes were primarily attributable to the factors described above.

SELLING AND ADMINISTRATIVE EXPENSES. Selling and administrative expenses increased 153.3% to \$17.8 million in 1996 from \$7.0 million in 1995. As a percentage of net sales, selling and administrative expenses decreased to 20.6% in 1996 from 21.9% in 1995. The dollar amount increase was primarily attributable to sales increases. The decrease as a percentage of net sales was primarily attributable to increased sales and the Company achieving certain sales volume-based efficiencies for human resources and marketing expenses.

OTHER OPERATING COSTS. Other operating costs increased 123.6% to \$11.7 million in 1996 from \$5.3 million in 1995. As a percentage of net sales, other operating costs decreased to 13.6% in 1996 from 16.4% in 1995. The dollar amount increase was primarily attributable to the increase in sales, which was offset by the Company recording approximately \$400,000 in consulting fees associated with the Company's entry into the Canadian market.

OTHER (INCOME) EXPENSE, NET. Other (income) expense in 1996 increased to (\$116,000) from \$181,000 in 1995. In 1995, the Company incurred an expense of \$180,600 as a result of the settlement of a lawsuit related to the termination of a former employee. In 1996, the Company recorded an additional expense of \$59,000 related to the settlement of this lawsuit, which was more than offset by approximately \$160,000 of interest income and royalty income.

INCOME TAX EXPENSE. Income tax expense increased \$1.1 million to \$1.2 million in 1996 compared to \$67,000 in 1995. The effective tax rate increased to 14.3% in 1996 from 2.7% in 1995. The effective tax rate significantly varied from the statutory rate of 34% primarily due to the \$5.8 million of Partnership income included with the Company's income as discussed previously. See "-Reorganization" and "Certain Transactions."

NET INCOME. Net income increased 206.2% to \$7.2 million in 1996 from \$2.3 million in 1995. As a percentage of net sales, net income increased to 8.3% in 1996 as compared to 7.3% in 1995. The increase was the result of the factors described above.

SELECTED QUARTERLY STATEMENTS OF INCOME

The following table sets forth certain unaudited quarterly statement of income data for each of the eleven quarters ending with the quarter ended September 30, 1998. In the opinion of management, this information has been prepared on the same basis as the audited Financial Statements contained herein and includes all necessary adjustments, consisting only of normal recurring adjustments, that the Company considers necessary to present fairly this information in accordance with generally accepted accounting principles. This information should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere in this Prospectus. The Company's operating results for any one quarter are not necessarily indicative of results for any future period.

	THREE MONTHS ENDED							
	MAR. 31, 1996	JUNE 30, 1996	SEPT. 30, 1996	DEC. 31, 1996(1)	MAR. 31, 1997	JUNE 30, 1997	SEPT. 30, 1997	DEC. 31, 1997(2)
	(IN THOUSANDS)							
STATEMENT OF INCOME								
DATA:								
Net sales.....	\$ 14,432	\$ 19,651	\$ 23,424	\$ 28,804	\$ 33,383	\$ 37,973	\$ 39,746	\$ 39,468
Cost of sales.....	1,910	3,008	3,165	5,323	5,501	6,041	6,324	6,869
Commissions.....	5,891	8,060	9,554	11,650	13,685	15,586	16,189	16,217
Gross profit.....	6,631	8,583	10,705	11,831	14,197	16,346	17,233	16,382
Operating expenses:								
Selling and administrative expenses.....	2,640	4,447	3,811	6,866	5,827	7,762	6,351	7,906
Other operating costs.....	1,590	2,260	2,550	5,346	3,743	4,974	4,684	6,001
Cancellation of incentive compensation agreements(4).....	--	-	-	-	-	1,821	-	371
Write-off of deferred offering costs.....	-	-	-	-	-	-	-	-
Income (loss) from operations.....	2,401	1,876	4,344	(381)	4,627	1,789	6,198	2,104
Other (income) expense, net.....	(9)	(16)	-	(91)	139	120	(85)	(217)
Income (loss) before income taxes.....	2,410	1,892	4,344	(290)	4,488	1,669	6,283	2,321
Income tax (benefit) expense.....	349	263	637	(55)	1,261	462	1,784	632
Net income (loss)	\$ 2,061	\$ 1,629	\$ 3,707	\$ (235)	\$ 3,227	\$ 1,207	\$ 4,499	\$ 1,689
PRO FORMA INFORMATION:(5)								
Income (loss) before income taxes, as reported.....	\$ 2,410	\$ 1,892	\$ 4,344	\$ (290)	\$ 4,488	\$ 1,669	\$ 6,283	\$ 2,321
Pro forma provision for income tax (benefit) expense.....	904	710	1,629	(109)	1,727	644	2,419	893
Pro forma net income (loss).....	\$ 1,506	\$ 1,182	\$ 2,715	\$ (181)	\$ 2,761	\$ 1,025	\$ 3,864	\$ 1,427
Number of starter packs sold.....	21,114	24,368	25,613	26,718	32,547	36,134	34,881	29,899
Number of renewal packs sold.....	1,419	5,930	6,808	5,718	8,000	10,922	10,675	11,622
Total number of packs sold.....	22,533	30,298	32,421	32,436	40,547	47,056	45,556	41,521
Total Associates canceling Associate status.....	405	545	762	791	1,178	1,280	1,187	1,518
	MAR. 31, 1998	JUNE 30, 1998	SEPT. 30, 1998(3)					
STATEMENT OF INCOME								
DATA:								
Net sales.....	\$ 41,088	\$ 42,637	\$ 39,128					
Cost of sales.....	6,060	7,484	7,037					

Commissions.....	16,884	16,988	15,103
Gross profit.....	18,144	18,165	16,988
Operating expenses:			
Selling and administrative expenses.....	7,684	7,257	7,681
Other operating costs.....	4,696	5,342	5,641
Cancellation of incentive compensation agreements(4).....	-	-	-
Write-off of deferred offering costs.....	-	-	941
Income (loss) from operations.....	5,764	5,566	2,725
Other (income) expense, net.....	(62)	41	17
Income (loss) before income taxes.....	5,826	5,525	2,708
Income tax (benefit) expense.....	2,209	2,161	1,043
Net income (loss)	\$ 3,617	\$ 3,364	\$ 1,665
PRO FORMA INFORMATION: (5)			
Income (loss) before income taxes, as reported.....			
Pro forma provision for income tax (benefit) expense.....			
Pro forma net income (loss).....			
Number of starter packs sold.....	30,261	29,176	17,183
Number of renewal packs sold.....	13,892	8,636	21,629
Total number of packs sold.....	44,153	37,812	38,812
Total Associates canceling Associate status.....	1,376	1,597	1,683

(1) For the fourth quarter of 1996 cost of sales included various book-to-physical inventory adjustments and write off of identified obsolete inventory. Selling and administrative expenses included an accrual for discretionary bonuses to all employees and a charge for severance packages. Other operating costs increased due to certain year-end accruals for attorneys' fees, travel and general operating expenses.

- (2) For the fourth quarter of 1997 cost of sales included an adjustment for the abnormal conversion of approximately \$133,000 of raw materials by a manufacturer and a write-off of identified obsolete inventory. The Company now sells raw materials to its manufacturers and repurchases finished goods, which should prevent future losses on abnormal conversions. Selling and administrative expenses included accruals for (i) discretionary bonuses for all employees, (ii) termination expenses and (iii) disputed freight expenses. Other operating costs increased for the accrual of various attorney and consulting fees and compensation expenses related to the issuance of stock options to certain nonemployees.
- (3) In September 1998, the Company recorded a charge of approximately \$941,000 for the abandonment of the initial public offering which began in September 1997.
- (4) In June 1997 the Company recorded a one-time charge to operations for the issuance of Common Stock in exchange for the cancellation of certain incentive compensation agreements. An additional incentive compensation agreement was cancelled in December 1997. See "-Reorganization" and "Certain Transactions."
- (5) The pro forma information shows the Company's net income as if all income earned by the Company and the Partnerships was taxable at federal and statutory rates.

As the table above indicates, the Company has experienced a declining rate of growth in recent quarters. The decreased rate results primarily from the increased base on which the growth rate is computed and a shrinking base of potential new Associates in its existing markets. The Company has relied on its historical growth to provide the operating cash flows used to fund its current infrastructure in property, equipment and personnel. The Company believes it currently has an infrastructure capable of supporting its historical growth for the next three to five years. The Company does not anticipate that future rates of growth will be equal to historic rates of growth due to the increased base on which the rate of growth is computed. The Company's inability to maintain its historic rate of growth is not expected to have an adverse effect on operations due to the relatively high gross profit margins and current sales base. The Company expects expansion into international markets to provide expanded growth opportunities. If the Company is unable to maintain current levels of growth, seasonal declines in sales revolving around the holiday period in the fourth quarter may become apparent.

The following table sets forth certain unaudited quarterly results of operations expressed as a percentage of net sales for each of the eleven quarters ending with the period ended September 30, 1998.

	THREE MONTHS ENDED							
	MAR. 31, 1996	JUNE 30, 1996	SEPT. 30, 1996	DEC. 31, 1996	MAR. 31, 1997	JUNE 30, 1997	SEPT. 30, 1997	DEC. 31, 1997
AS A PERCENTAGE OF NET SALES:								
Net sales.....	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Cost of sales.....	13.2	15.3	13.5	18.5	16.5	15.9	15.9	17.4
Commissions.....	40.8	41.0	40.8	40.4	41.0	41.0	40.7	41.1
Gross profit.....	46.0	43.7	45.7	41.1	42.5	43.1	43.4	41.5
Operating expenses:								
Selling and administrative expenses.....	18.3	22.6	16.3	23.8	17.5	20.4	15.9	20.1
Other operating costs.....	11.0	11.5	10.9	18.6	11.2	13.1	11.7	15.2
Cancellation of incentive compensation agreements.....	--	-	-	-	-	4.8	-	0.9
Write-off of deferred offering costs.....	-	-	-	-	-	-	-	-
Income (loss) from operations.....	16.7	9.6	18.5	(1.3)	13.8	4.8	15.8	5.3
Other (income) expense, net.....	--	-	-	0.3	0.4	0.3	(0.2)	(0.5)
Income (loss) before income taxes, as reported.....	16.7	9.6	18.5	(1.0)	13.4	4.5	16.0	5.8
Income tax (benefit) expense.....	2.4	1.3	2.7	(0.2)	3.8	1.2	4.4	1.6
Net income (loss).....	14.3%	8.3%	15.8%	(0.8%)	9.6%	3.3%	11.6%	4.2%
	MAR. 31, 1998	JUNE 30, 1998	SEPT. 30, 1998					

AS A PERCENTAGE OF NET
SALES:

Net sales.....	100.0%	100.0%	100.0%
Cost of sales.....	14.7	17.6	18.0
Commissions.....	41.0	39.8	38.6
	-----	-----	-----
Gross profit.....	44.3	42.6	43.4
Operating expenses:			
Selling and administrative expenses.....	18.7	17.0	19.6
Other operating costs.....	11.4	12.5	14.4
Cancellation of incentive compensation agreements.....	-	-	-
Write-off of deferred offering costs.....	-	-	2.4
	-----	-----	-----
Income (loss) from operations.....	14.2	13.1	7.0
Other (income) expense, net.....	(0.1)	0.1	0.0
	-----	-----	-----
Income (loss) before income taxes, as reported.....	14.3	13.0	7.0
Income tax (benefit) expense.....	5.3	5.0	2.7
	-----	-----	-----
Net income (loss).....	9.0%	8.0%	4.3%
	-----	-----	-----

The Company may experience variations on a quarterly basis in its results of operations, in response to, among other things: the timing of Company-sponsored Associate events; new product introductions;

the opening of new markets; the timing of holidays, especially in the fourth quarter, which may reduce the amount of time Associates spend selling the Company's products or recruiting new Associates; the adverse effect of Associates' or the Company's failure, and allegations of their failure, to comply with applicable government regulations; the negative impact of changes in or interpretations of regulations that may limit or restrict the sale of certain of the Company's products; the operation of its network marketing system; the introduction of its products into each market; the recruitment and retention of Associates; the inability of the Company to introduce new products or the introduction of new products by the Company's competitors; general conditions in the nutritional supplement and personal care industries or the network marketing industry; and consumer perceptions of the Company's products and operations. In particular, because the Company's products are ingested by consumers or applied to their bodies, the Company is highly dependent upon consumers' perception of the safety, quality and effectiveness of its products. As a result, substantial negative publicity, whether founded or unfounded, concerning one or more of the Company's products or other products similar to the Company's products could adversely affect the Company's business, results of operations and financial condition.

As a result of these and other factors the Company's quarterly revenues, expenses and results of operations could vary significantly in the future, and period-to-period comparisons should not be relied upon as indications of future performance. There can be no assurance that the Company will be able to increase its revenues in future periods or be able to sustain its level of revenue or its rate of revenue growth on a quarterly or annual basis. Furthermore, no assurances can be given that the Company's revenue growth rate in new markets where operations have not commenced will follow this pattern. Due to the foregoing factors, the Company's future results of operations could be below the expectations of public market analysts and investors. In such event, the market price of the Common Stock would likely be materially adversely affected.

LIQUIDITY AND CAPITAL RESOURCES

The Company's principal capital requirement is to fund working capital to support its growth. To date, the Company has financed its operations primarily through cash flows derived from operating activities. Primarily as a result of the Company's investment in the infrastructure necessary to support the rapid growth of the Company, the Company had working capital deficiencies of \$2.6 million, \$9.2 million and \$11.3 million as of December 31, 1996, December 31, 1997 and September 30, 1998, respectively. During 1997 and the first nine months of 1998, the Company invested approximately \$7.5 million and \$4.9 million, respectively, in its property and equipment. These projects were funded primarily from operating cash flow which negatively impacted working capital. The Company also distributed approximately \$4.0 million during 1997 to the Partnerships and approximately \$6.9 million and \$9.3 million in dividends to its shareholders in 1997 and the first nine months of 1998, respectively. Additionally, current liabilities increased due to increased commissions, income taxes and inventory purchases, all of which are directly related to increased sales volume in 1997 and the first nine months of 1998. The Company believes its current facilities are sufficient to support near-term growth. The reduction in capital spending, combined with the Company's intention to cease future distributions to shareholders, is expected to reduce or eliminate the Company's working capital deficiencies in the future.

In January 1998, the Company entered into a \$1.5 million interim lease line-of-credit agreement (the "Line of Credit Agreement") with Banc One Leasing Corporation to fund the purchase of furniture and certain capital equipment in connection with the Company's relocation to its new facility. The Line of Credit Agreement bears interest at the prime interest rate of Bank One, Columbus, NA plus one-half percent, is secured by the leased assets, is guaranteed by two of the Company's shareholders and will expire on December 15, 1998. The Line of Credit Agreement allows the Company to convert amounts drawn thereunder into capital leases and, in March and August 1998, the Company converted \$631,000 and \$840,000, respectively which had been drawn on the Line of Credit Agreement into a capital lease (the "Capital Lease"). The Capital Lease bears interest at 9.3%, is collateralized by the leased assets and is payable in 36 installments. In July 1998, the Company entered into a thirty-six month, unsecured note

payable with an insurance company to finance its product liability insurance premium. The note bears interest at 8.0%.

The Company plans to improve its working capital position, make additional investments in its new distribution center, research and development laboratory, and complete its internally developed software program. The Company intends to fund these initiatives with proceeds from this offering, net cash provided by operating activities and additional borrowings under the Line of Credit Agreement described above. See "Use of Proceeds."

Net cash provided by operating activities was \$3.1 million, \$9.6 million, \$19.8 million and \$15.2 million in 1995, 1996, 1997 and for the nine months ended September 30, 1998, respectively. Throughout these periods, the Company experienced increases in net income as a result of increases in net sales, which were partially offset by increases in inventories.

Net cash used in investing activities was \$843,000, \$3.2 million, \$9.3 million and \$4.3 million in 1995, 1996, 1997 and the nine months ended September 30, 1998, respectively. These activities consisted primarily of purchases of property and equipment in connection with the Company's relocation to its new facility in April 1997, and the relocation of the Company's distribution center and build out of its research and development facility in the first quarter of 1998.

Net cash used in financing activities totaled \$1.6 million, \$6.2 million, \$11.6 million and \$9.6 million in 1995, 1996, 1997 and for the nine months ended September 30, 1998, respectively. In 1995, 1996 and through the reorganization of the Company in June 1997, the Company made distributions to partners of the Partnerships. Following the reorganization, the Company has paid dividends on a monthly basis to its shareholders in the amount of \$0.02-\$0.06 per share and expects to continue to pay dividends each month until the consummation of this offering. See "Dividend Policy."

The Company anticipates that its existing capital resources, including cash provided by operating activities and bank borrowings, together with the anticipated proceeds from this offering, will be adequate to fund the Company's operations for at least the next 12 months. Of the net proceeds to the Company, the Company intends to use approximately (i) \$6.06 to \$9.84 million, depending upon the number of shares sold in this offering, to cover the costs of international expansion, primarily product registration, initial inventory requirements, and similar items, (ii) \$5.0 million for working capital and general corporate purposes and (iii) \$1.6 million for the repayment of debt, assuming the sale of maximum number of shares offered by the Company hereby. The Company has no present commitments or agreements with respect to any acquisitions or purchases of manufacturing capabilities, new technologies or raw material sources. There can be no assurance that changes will not occur that would consume available capital resources before such time. The Company's capital requirements depend on numerous factors, including the timing and pace of the Company's entry into international markets, growth in the number of Associates and its research and development efforts. To the extent that the Company's existing capital resources, together with the anticipated proceeds of this offering, are insufficient to meet its capital requirements, the Company will be required to raise additional funds. There can be no assurance that additional funding, if necessary, will be available on favorable terms, if at all.

RECENT FINANCIAL ACCOUNTING STANDARDS BOARD STATEMENTS

In June 1997, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("FAS") No. 130, "Reporting Comprehensive Income." FAS 130 establishes standards for the report and display of comprehensive income and its components (revenues, expenses, gains, and losses) in a full set of general purpose financial statements. FAS 130 requires that an enterprise (i) classify items of other comprehensive income by their nature in a financial statement and (ii) display the accumulated balance of other comprehensive income separately from retained earnings and additional paid-in capital in the equity section of a statement of financial position. FAS 130 is effective for fiscal years beginning after December 15, 1997. The Company does not have any items of other comprehensive income for any period presented.

In June 1997, the FASB issued FAS No. 131, "Disclosures about Segments of an Enterprise and Related Information." FAS 131 established standards for reporting information about operating segments in annual financial statements and requires reporting of selected information about operating segments in interim financial reports issued to shareholders. FAS 131 also establishes standards for related disclosure about products and services, geographic areas and major customers. FAS 131 is effective for financial statements for periods beginning after December 15, 1997, and requires the restatement of disclosures for earlier periods for comparative purposes unless the information is not readily available, in which case a description of unavailable information is required. Currently, this pronouncement is not applicable to the Company.

In February 1998, the FASB issued FAS No. 132, "Employers' Disclosures about Pensions and Other Postretirement Benefits." FAS 132 revises footnote disclosure requirements for employer pensions and other retiree benefits, standardizes the disclosure requirements, requires additional information on changes in the benefit obligations and calculating the fair values of plan assets, and eliminates certain disclosures. FAS 132 is effective for financial statements for periods beginning after December 15, 1997. As the Company does not provide a defined benefit plan, this pronouncement will not impact the Company.

In June 1998, the FASB issued FAS No. 133, "Accounting for Derivatives, Investments and Hedging Activities." This statement establishes accounting and reporting standards for derivative financial instruments, including certain derivative financial instruments imbedded in other contracts and for hedging activities. FAS 133 is effective for all fiscal quarters beginning after June 15, 1999. As the Company does not have any derivative financial instruments, this pronouncement will not impact the Company.

YEAR 2000 COMPLIANCE

The Company's management recognizes the need to ensure that its operations and relationships with vendors, Associates and other third parties will not be adversely impacted by software processing errors arising from calculations using the Year 2000 and beyond. Many existing computer programs and databases use only two digits to identify a year in the date field (i.e., 98 would represent 1998). If not corrected, many computer systems could fail or create erroneous results in the Year 2000. The Company believes all of its internal information systems currently in use are Year 2000 ready, largely due to the short operating history of the Company. The majority of the Company's critical business applications have been developed internally, in the past two years, with Year 2000 ready tools. With respect to non-information technology systems issues, the Company is in the process of identifying, assessing and remediating, if necessary its building and utility systems for any Year 2000 issues relating to the functionality of its facilities. All remaining remediation and testing of non-information technology systems is expected to be performed and completed by June 30, 1999.

The Company has begun communications with its vendors and other third parties to determine the extent that these related systems may not be Year 2000 ready. Because the Company is still in the initial stages of these communications, the Company can not determine if such failures are possible and, if so, the extent that such failures would impact the Company. If one of the Company's primary suppliers of ingredients were to have Year 2000 problems, it is possible that these problems could have a material effect on the Company's operations.

Management expects the total cost associated with Year 2000 identification, remediation and testing to be between \$400,000 and \$800,000. The expected costs represent approximately 5-10% of the total information technology budget. The Company has spent \$20,000 at September 30, 1998 on the Year 2000 issue.

Should any or all of the applications fail to perform properly on January 1, 2000 the Company will resort to temporary manual processing, which is not expected to have a material adverse impact on its short-term operations. Failure to achieve Year 2000 readiness by any of the Company's vendors, while

expected to cause some disruption to operations in the short-term, is not expected to have a material impact on the Company's operations.

IMPACT OF INFLATION

The Company believes that inflation has not had a material impact on its historical operations or profitability.

GENERAL

Mannatech develops and sells proprietary nutritional supplements and topical products through a network marketing system. The Company sells its products in the United States and Canada, through a network consisting of approximately 226,000 active Associates (an "active" Associate has purchased products from the Company within the last 12 months) as of September 30, 1998, and has begun to expand into Australia, while continuing to assess the potential of other foreign markets. Since commencing operations in November 1993, the Company's sales have grown from approximately \$8.4 million in 1994 to approximately \$150.6 million in 1997.

The Company pursues a two-fold business strategy: (i) to develop a proprietary line of nutritional supplements having both health benefits and mass appeal to a general population demanding non-toxic healthcare alternatives and (ii) to provide an appealing framework for persons interested in the products to establish a direct sales business. To date, the Company has focused its development efforts primarily in the area of carbohydrate technology, creating a proprietary ingredient, Ambrotose-Registered Trademark- Complex, which combines the naturally occurring sugars required to support optimal cell-to-cell communication. Additional Company efforts have been focused on developing products based on scientific advances in the emerging field of phytochemistry, which has identified certain naturally occurring components of various plants, known as "phytochemicals," which, while not essential to sustain life, are fundamental to optimal health.

Ambrotose-Registered Trademark- Complex is the cornerstone of the Company's product lines. These products are designed to support various systems and functions of the human body, including (i) the cell-to-cell communication system, (ii) the immune system, (iii) the endocrine system, (iv) the intestinal system and (v) the dermal system. The Company also markets products designed to aid in sports performance and nutritional support. The Company's products, Man-Aloe-Registered Trademark-, Ambrotose-Registered Trademark- and Bulk Ambrotose-Registered Trademark-, are designed to support cell-to-cell communication. For immune system support, the Company offers Phyt-Aloe-Registered Trademark-, for adults, and Phyto-Bears-Registered Trademark-, a chewable gummi-bear nutritional supplement product marketed to children but popular with adults. Other products include MVP-TM- and Plus for endocrine system support, MannaCleanse-TM- for intestinal system support and Emprizone-Registered Trademark-, Firm and Naturalizer for dermal care. The Company offers several products designed to aid sports performance by enhancing the body's natural recovery process and supporting lean tissue development, including Em-Pact-TM-, Bulk Em-Pact-TM- and Sport with Ambrotose-Registered Trademark-. The Company also markets Profile 1, Profile 2 and Profile 3, which support the body's nutritional needs.

In March 1998, the Company introduced MannaBAR-TM-, a nutritional supplement bar in two versions that contain the equivalent of the Company's recommended minimum daily supply of Ambrotose-Registered Trademark-Complex, Phyt-Aloe-Registered Trademark- and Plus. In September 1998 the Company introduced Manna-C-TM-, a nutritional support for nasal and sinus health containing Ambrotose-Registered Trademark- Complex, monosaccharides necessary to the manufacture of glycoproteins and an herbal blend of Vitamin C and other nutrients which support most cell functions and, in October 1998, released Ambrostart-TM-, a nutritional support fiber drink containing Ambrotose-Registered Trademark- Complex, and Bulk Phyt-Aloe-TM- an immune support system product. In addition to MannaBAR-TM- and Manna-C-TM-, the Company plans to release additional products as new nutritional compounds or areas of consumer demand are identified by the Company. All new products are expected to contain proprietary components.

The Company's products are marketed exclusively through a network marketing system. The Company believes that its network marketing system is well-suited to its products, which emphasize health and nutrition, because network marketing allows in-person product education not available through traditional marketing techniques. The Company's network marketing system appeals to a broad cross-section of people, particularly those seeking to supplement family income, start a home-based business or pursue employment opportunities other than conventional, full-time employment.

INDUSTRY OVERVIEW

The nutritional supplements industry is highly fragmented and intensely competitive. It includes companies that manufacture and distribute products which are generally intended to enhance the body's performance and well being. Nutritional supplements include vitamins, minerals, dietary supplements, herbs, botanicals and compounds derived therefrom. Opportunities in the nutritional supplements industry were enhanced by the enactment of the Dietary Supplement Health and Education Act of 1994 ("DSHEA"). Under DSHEA, vendors of dietary supplements are now able to educate consumers regarding the effects of certain component ingredients.

According to Packaged Facts, an independent consumer market research firm, the retail market for nutritional supplements has experienced a compound annual growth rate in the United States of over 15% from 1992 to 1996. Sales in the principal domestic market in which the Company's products compete totaled approximately \$6.5 billion in 1996. The Company believes that growth in the nutritional supplement market is driven by several factors, including (i) the general public's heightened awareness and understanding of the connection between diet and health, (ii) the aging population, particularly the baby-boomer generation, which is more likely to consume nutritional supplements, (iii) product introductions in response to new scientific research and (iv) the nationwide trend toward preventive medicine.

Nutritional supplements are sold primarily through mass market retailers, including mass merchandisers, drug stores, supermarkets and discount stores; health food stores; mail order companies; and direct sales organizations. Direct selling, of which network marketing is a significant segment, has been enhanced in the past decade as a distribution channel due to advancements in technology and communications resulting in improved product distribution and faster dissemination of information. The distribution of products through network marketing has grown significantly in recent years. The World Federation of Direct Selling Associations (the "WFDSA") reports that, from 1990 through 1996, worldwide direct distribution of goods and services to consumers increased approximately 65%, resulting in the sale of nearly \$80 billion of goods and services in 1996. According to the "Survey of Attitudes toward Direct Selling," commissioned by the Direct Selling Association (the "DSA"), and conducted and prepared by Wirthlin Worldwide (the "Wirthlin Report"), among the three categories experiencing the greatest gains in the direct selling industry since 1976 are food, nutrition and wellness products.

According to the Wirthlin Report, approximately 51% of the American public has purchased products or services from a direct selling company at some point in the past, with 29% of those having made such a purchase in the last 12 months. Four in 10 adult Americans have expressed an interest in direct selling as a method of buying products and services, and 23% of those who have never purchased products and services from direct selling companies are interested in direct selling. The Company believes it is positioned to capitalize on the trends of growth in direct sales and demand for nutritional supplement products.

OPERATING STRENGTHS

The Company's two-fold business strategy is to (i) develop a proprietary line of nutritional supplements having both health benefits and mass appeal to a general population demanding non-toxic healthcare alternatives, and (ii) provide an appealing framework for persons interested in the products to establish a direct sales business. The Company believes that it will be able to continue its growth by capitalizing on the following operating strengths:

PROPRIETARY PRODUCT OFFERINGS. The Company offers an innovative line of products based upon its proprietary, patent-pending research. The Company believes that the discovery and development of products containing certain carbohydrates necessary to optimum health represents an expanding business opportunity for the Company. The Company recognized the nutritional need for the eight known

monosaccharides to support optimal health, and developed and filed a patent application on a compound containing these monosaccharides. The Company includes this compound, Ambrotose-Registered Trademark-Complex, in each of its products. The Company believes that maintaining a proprietary line of products is important for two reasons: (i) it is a marketing factor that differentiates the Company from its competitors; and (ii) the limited availability helps to drive demand and enables premium pricing.

SUPERIOR RESEARCH AND DEVELOPMENT CAPABILITY. The Company believes that its experienced personnel and new research and development facilities will allow it to develop and market additional new proprietary products. The Company's research and development efforts are led by two scientists with an aggregate of 34 years of experience designing products based on emerging carbohydrate technology. In March 1998, the Company completed construction of a technologically advanced laboratory to be used for both quality assurance and product development. As a complement to its in-house staff and facilities, the Company has sought, and will continue to seek, strategic alliances with several large manufacturers of nutritional supplements. These companies work with the Company to create, develop and manufacture its proprietary products and lend additional guidance which is helpful to the Company's strategic planning. In addition, the Company works with other smaller product companies to identify and develop new innovative niche products.

STRONG ASSOCIATE SUPPORT PHILOSOPHY. The Company is committed to providing the highest level of support services to its Associates. The Company believes that it meets the needs of, and builds loyalty with, its Associates through its highly personalized and responsive customer service. Company-sponsored Associate events held several times throughout the year provide education and motivation for thousands of Associates. These conferences feature a schedule of events that offers information, aids in business development for Associates and provides a venue for Associates to interact with the leading distributors and researchers of the Company. In addition, the Company believes it offers one of the most financially rewarding compensation plans offered to Associates in the direct selling industry. Commissions as a percentage of net sales were 38.5%, 40.7%, 41.0%, and 39.8% for 1995, 1996, 1997 and the nine months ended September 30, 1998, respectively.

FLEXIBLE OPERATING STRATEGY. The Company considers flexibility to be a key component of its existing and ongoing success. The Company outsources production and forms strategic alliances to minimize capital expenditure where practicable. However, the Company maintains control of key operating functions, including product development and formulation, product warehousing and distribution, financial and operating functions and proprietary product raw material sourcing. The Company believes it is positioned to enter international markets in an efficient and cost-effective manner by leveraging the expertise and resources of its strategic allies in the areas of distribution and logistics, call center operations, product registration and export requirements. Information technology also plays a key role in providing operating flexibility to the Company. The proprietary technology systems used by the Company are designed to be quickly and easily adaptable in order to support expansion into new markets. By developing this technology infrastructure, the Company believes it has reduced the risks associated with operational inefficiencies typically encountered by network marketing companies during periods of rapid growth.

EXPERIENCE AND DEPTH OF MANAGEMENT TEAM. The Company's management team is comprised of experienced individuals drawn from a variety of backgrounds and expertise in certain fields, including product research and development, marketing, direct sales, legal and compliance, information technology and product distribution. All principal managers have substantial business experience, most with larger concerns, and bring the perspective of traditional business to the multi-level marketing endeavor of the Company. The goal of the management team is to provide a sound, systematic, reliable framework within which each Associate can fit his or her personal style of conducting business.

GROWTH STRATEGY

The Company's primary growth strategy is to increase product sales through existing distribution channels, to continue to expand operations in existing markets in the United States and Canada and to enter select foreign markets. The Company believes that its growth will be based on the following factors:

INTRODUCE NEW PRODUCTS. The Company's product development strategy is to expand its existing product lines and bring new proprietary and, where possible, patentable products to market that can be developed into new product lines. Since its inception, the Company has introduced new products each year, including, in the first nine months of 1998, MannaBARS-TM-, Manna-C-TM-, Ambrostart-TM- and Bulk Phyt-Aloe-TM-. The Company currently intends to introduce new products each year, which are expected to contain one or more proprietary components and complement existing products. The Company believes that its newly enhanced research and development capabilities will facilitate its ability to develop these new products.

ATTRACT NEW ASSOCIATES AND ENHANCE ASSOCIATE PRODUCTIVITY. The Company has enjoyed significant growth in the number of Associates by leveraging its operating strengths and creating a business climate which promotes growth in the number of Associates qualifying for recognition and increases the retention, motivation and productivity of high-level Associates. The Company plans to introduce new Associate achievement levels in part to encourage greater retention, motivation and productivity. In addition, the Company plans to encourage growth in the number of Presidential Associates, currently the highest level of achievement attainable by an Associate, by modifying Associate events and recognition programs.

ENTER NEW MARKETS. In October 1998, the Company opened its Australian headquarters in St. Leonards, Australia and is further exploring the possibilities for further expansion in several additional countries. By employing its flexible operating strategy in the international sector, the Company believes it will be able to enter new markets in a cost-effective and efficient manner. In addition, the Company will evaluate the following factors in its decision to expand into new markets: (i) size of market; (ii) anticipated demand; and (iii) ease of entry. The Company believes that growth potential exists in international markets. See "Risk Factors-Risks Associated with International Expansion."

PRODUCTS

The Company markets a line of quality, proprietary products, including 20 different nutritional products and three topical products. The Company also offers a variety of sales aids, including enrollment and renewal packs (which include products), brochures and videotapes which accounted for approximately 24.7% of net sales in 1997. The Company believes its focused product line contributes to efficient distribution and inventory management.

The Company believes that the discovery and use of certain carbohydrates offers significant potential for nutritional benefits. Healthy bodies, comprised of many sophisticated components working together, must have accurate internal communication to function at an optimal level. In its most basic form, this communication occurs at the cellular level and is referred to by molecular biologists as cell-to-cell communication. To maintain a healthy body, cells must "talk" to other cells. Scientists have learned that glycoproteins, or molecules found on the surface of all cells, play a key role in all cell-to-cell communication. The name, glycoprotein, is derived from the molecules' composition: sugar (glyco) and protein. Because up to 85% of glycoproteins are composed of specific monosaccharides, the body's need for these carbohydrates is important.

HARPER'S BIOCHEMISTRY, a leading biochemistry reference source, lists eight monosaccharides commonly found in human glycoproteins which are known to be important to the healthy functioning of cell-to-cell communications in the human body. These monosaccharides are fucose, galactose, glucose, mannose, N-acetylgalactosamine, N-acetylglucosamine, N-acetylneuraminic acid and xylose, and belong to a universe of approximately 200 monosaccharides found in nature.

The Company recognized the human body's need for these monosaccharides to support optimal health. In response, the Company developed and filed a patent application on Ambrotose-Registered Trademark- Complex, which is directed at these monosaccharides and their various uses. By filing this patent application, the Company seeks to establish a proprietary position in the nutritional supplement market. This proprietary glyconutritional compound, Ambrotose-Registered Trademark- Complex, is a component of each of the Company's products.

The following chart lists the Company's products as of November 15, 1998.

	CELL-TO-CELL COMMUNICATION	IMMUNE SYSTEM	ENDOCRINE SYSTEM	INTESTINAL SYSTEM	DERMAL SYSTEM
Ambrostart-TM-.....	X			X	
Ambrotose-Registered Trademark-.....	X				
Bulk Ambrotose-Registered Trademark-.....	X				
Bulk Em-Pact.....					
Bulk Phyt-Aloe-TM-.....		X			
Em-Pact-TM-.....					
Emprizone-Registered Trademark-..					X
Firm.....					X
Man-Aloe-Registered Trademark-..	X				
MannaBAR-TM- Carbohydrate Formula.....	X	X	X		
MannaBAR-TM- Protein Formula.....	X	X	X		
Manna-C-TM-.....		X			
MannaCleanse-TM-.....				X	
Mannatonin.....			X		
MVP-TM-.....			X		
Naturalizer.....					X
Phyt-Aloe-Registered Trademark-..		X			
Phyto-Bears-Registered Trademark-..		X			
Plus.....			X		
Profile 1.....					
Profile 2.....					
Profile 3.....					
Sport with Ambrotose-Registered Trademark-.....					
	SPORTS PERFORMANCE	NUTRITIONAL NEEDS			
Ambrostart-TM-.....	X				
Ambrotose-Registered Trademark-.....					
Bulk Ambrotose-Registered					

Trademark-.....		
Bulk Em-Pact-.....	X	

Bulk Phyt-Aloe-TM-.....		
Em-Pact-TM-.....	X	

Emprizone-Registered Trademark Firm.....		

Man-Aloe-Registered Trademark- MannaBAR-TM- Carbohydrate Formula.....		

MannaBAR-TM- Protein Formula.....		
Manna-C-TM-.....		

MannaCleanse-TM-.....		
Mannatonin.....		

MVP-TM-.....		
Naturalizer.....		

Phyt-Aloe-Registered Trademark Phyto-Bears-Registered Tradema		

Plus.....		
Profile 1.....		X

Profile 2.....		X
Profile 3.....		X

Sport with Ambrotose-Registered Trademark-.....		X

PRODUCT DEVELOPMENT

The Company's overall product strategy is to develop proprietary nutritional supplements which capitalize on existing and emerging scientific knowledge and the growing worldwide interest in alternative healthcare and optimal health. The Company focuses on bringing new proprietary and, where

possible, patentable products to market that can be developed into new product lines, while expanding its existing product line. The Company believes it is well positioned to take advantage of the ability to provide educational information regarding dietary supplements and the increased development of nutritional supplements and functional foods resulting from the enactment of DSHEA.

The Company intends to launch new products each year at its corporate events. Selection of the products developed will be based on the marketability and proprietary nature of the product, taking into account regulatory considerations, the availability of components and the existence of data supporting claims of functionality. To support and validate the proprietary nature of the Company's product line, appropriate research is conducted under the direction of the Company's research and development department both before and after product launch. The Company believes that the completion of its new laboratory will help to accelerate and improve new product development.

The following chart indicates the year of introduction of each of the Company's products:

YEAR	PRODUCTS INTRODUCED
1994	Man-Aloe-Registered Trademark-, Plus, MVP-TM-, Sport, Naturalizer, Phyt-Aloe-Registered Trademark-, Firm
1995	Phyto-Bears-Registered Trademark-, Em-Pact-TM-, Emprizone-Registered Trademark-
1996	Ambrotose-Registered Trademark-, Mannatonin, Profile 1, 2 and 3, Sport with Ambrotose-Registered Trademark-
1997	Bulk Ambrotose-Registered Trademark-, Bulk Em-Pact-TM-, MannaCleanse-TM-
1998	MannaBAR-TM- Carbohydrate Formula, MannaBAR-TM- Protein Formula, Manna-C-TM-, Ambrostart-TM-, Bulk Phyt-Aloe-TM-

PRODUCT DISTRIBUTION SYSTEM

OVERVIEW. The foundation of the Company's sales philosophy and distribution system is network marketing. As with most network marketing systems, the Company's Associates purchase products for retail sale and personal consumption. The Company believes network marketing is an effective vehicle to distribute the Company's products for the following reasons: (i) the benefits of the Company's products are more readily explained on an individual, educational basis, which emphasizes the manner in which its products work, and is more direct than the use of television and print advertisements; (ii) direct sales allow for actual product testing by a potential consumer; (iii) the impact of Associate and consumer testimonials is enhanced; and (iv) as compared to other distribution methods, Associates can provide higher levels of customer service and attention by, among other things, following up on sales to ensure proper product usage and customer satisfaction, and encouraging repeat purchases.

The Company encourages Associates to enroll new Associates with whom the Associates may have an ongoing relationship as a family member, friend, business associate, neighbor or otherwise. To become an Associate of the Company, a person may enroll as a Preferred Customer and subsequently execute an Associate Application, sponsor new Associates or purchase a starter pack. Alternatively, one can become an Associate by purchasing one of the Associate starter packs. Each starter pack includes some combination of nutritional products, promotional materials, and free admission to the Company's events. Each pack also allows the Associate to purchase product at the Company's wholesale price. The components, purchase price of the pack, and wholesale value of the included items for the periods for which financial data is presented are detailed in the table below.

SUMMATION OF PACKS FOR MAY 1998 AND PRIOR YEARS

	ALL STAR BUSINESS PACK	MASTER ASSOCIATE AND ALL STAR TRAINING PACK	ALL STAR TRAINING PACK	MASTER STARTER PACK	NEW ASSOCIATE PROMO PACK	PREFERRED CUSTOMER PACK
Associate Cost.....	\$ 1,000.00	\$ 568.00	\$ 339.00	\$ 229.00	\$ 49.00	\$ 29.00
Number of Nutritional Products Included.....	27	15	9	6	1	-
Wholesale Value of Nutritional Products.....	\$ 736.00	\$ 412.50	\$ 253.00	\$ 166.00	\$ 28.50	\$ -
Number of Promotional Materials Included.....	108	26	3	23	15	15
Whole Value of Promotional Materials.....	\$ 345.99	\$ 298.04	\$ 186.90	\$ 111.14	\$ 12.59	\$ 14.50
Events Admission Included.....	Yes	Yes	Yes	No	No	No
Implied Admission Value.....	50	50	50	-	-	-
Total Wholesale and Implied Value.....	\$ 1,131.99	\$ 760.54	\$ 489.90	\$ 277.14	\$ 41.09	\$ 14.50

SUMMATION OF PACKS BEGINNING JUNE 1998

	ALL STAR BUSINESS PACK	MASTER ASSOCIATE AND ALL STAR TRAINING PACK	MASTER STARTER PACK	NEW ASSOCIATE PROMO PACK	PREFERRED CUSTOMER PACK
Associate Cost.....	\$ 1,000.00	\$ 664.00	\$ 289.00	\$ 49.00	\$ 29.00
Number of Nutritional Products Included.....	26	17	9	1	-
Wholesale Value of Nutritional Products.....	\$ 750.50	\$ 491.00	\$ 216.74	\$ 28.50	\$ -
Number of Promotional Materials Included.....	131	26	23	14	14
Whole Value of Promotional Materials.....	\$ 357.52	\$ 276.32	\$ 115.37	\$ 16.12	\$ 16.12
Events Admission Included.....	Yes	Yes	No	No	No
Implied Admission Value.....	\$ 50.00	\$ 50.00	\$ -	\$ -	\$ -
Total Wholesale and Implied Value.....	\$ 1,158.02	\$ 817.32	\$ 332.11	\$ 44.62	\$ 16.12

The Company also requires Associates to renew their status each year by either renewing as a Preferred Customer and continuing to sponsor New Associates or by purchasing a renewal pack. Prior to June 1998 the Associates renewed at the \$49.00, \$229.00 and \$568.00 levels. The renewal packs were identical to the starter packs in the table above sold at the same price. Beginning June 1998 the Associates renew at the \$29.00, \$200.00 or \$350.00 level. If an Associate chose not to renew his Associate status he could continue to purchase the Company's products at the wholesale price and resell the products if he desired; however, he would not be qualified to earn commissions or bonuses under the Company's compensation plan.

In May 1998 the Company introduced a new starter pack priced at \$29.00 which consists of 15 promotional materials which would cost \$14.50 if purchased separately at their wholesale value, which can also be used to renew Associate status, if elected.

Total associate packs sold were 67,530, 117,688, 174,680 and 120,777 for 1995, 1996, 1997 and the nine months ended September 30, 1998 respectively. Sales of renewal packs were 907, 19,875, 41,219, and 44,157 respectively for the same periods. The number of starter packs sold were 66,623, 97,813, 133,461, and 76,620 during the respective periods. See "Management's Discussion and Analysis of Financial Condition and Results of Operations".

The Company believes that Associates will be more likely to remain with the Company if they are enrolled with the Company by someone with whom they have an ongoing relationship. The Company also believes that its network marketing system will continue to build a base of potential consumers for additional products. The Company encourages, but does not require, Associates to use the Company's products, nor does the Company require a person to be an Associate in order to be a consumer of the Company's products. The Company believes its network marketing system is particularly attractive to prospective Associates because of the potential for supplemental income and because Associates are not required to purchase any inventory, have no account collection issues, have minimal paperwork requirements and have a flexible work schedule. The sales efforts of Associates are supported through various means, including Company-sponsored events held periodically throughout the year.

The effectiveness of direct selling as a distribution channel has been enhanced in the past decade through advancements in communications, including telecommunications, and the proliferation of the use of videotape players, fax machines and personal computers. The Company produces high-quality video tapes and audio tapes for use in product education, demonstrations and sponsoring sessions that project a desired image for the Company and its product line. The Company believes that high quality sales aids play an important role in the success of Associate efforts. The Company is committed to fully utilizing current and future technological advances to continue to enhance the effectiveness of direct selling.

Associates pay for products prior to shipment. The Company carries no accounts receivable from Associates, except for minor amounts owing to check returns or other exceptions. Associates pay for products primarily by credit card, with cash, money orders and checks representing a small portion of all payments. Associates may automatically order product, applied to a credit card, on a continuous basis, and receive a discount. Automatic orders accounted for approximately 36.9% of net sales for the year ended December 31, 1997.

ASSOCIATE DEVELOPMENT. The Company believes that the key contributing factors to its long-term growth and success are the recruitment of new Associates and retention of existing Associates. The Company is active in the development of Associates, including in the areas of recruitment, support, motivation and compensation.

The Company primarily relies on current Associates to sponsor new Associates. The sponsoring of new Associates creates multiple levels in the network marketing structure. Persons whom an Associate sponsors are referred to as "downline" or "sponsored" Associates. Once a person becomes an Associate, he or she is able to purchase products directly from the Company at wholesale prices for resale to consumers or for personal consumption. The Associate is also entitled to sponsor other Associates in order to build a network of Associates and product users.

The Company also relies heavily on existing Associates to train new Associates, utilizing a new training program for Associates ("Accredited Training") developed using both the expertise of experienced corporate trainers and the experience of seasoned Associates. While the Company provides brochures, magazines and other sales materials, Accredited Training is specially designed to provide systematic and uniform training to Associates about the Company, its products, methods of doing business and compensation plan. As of January 1998, only Associates who have participated in Accredited Training are eligible to receive remuneration for training other Associates.

The Company makes the needs of its Associates a priority, in accordance with its stated corporate philosophy. The Company provides a high level of support services tailored to the needs of its Associates, including motivational meetings, educational and informative conference calls, automated fax services, ordering and distribution system, personalized customer service via telephone, the Internet and e-mail, 24-hour, seven days per week access to certain information through touch-tone phones and a liberal product return policy. The Company's support system includes a current database of all Associates and their upline and downline Associates. The Company also provides business development materials that

the Company believes will increase both product sales and recruitment. The Company believes that enhancing an Associate's efforts through effective support mechanisms has been and will continue to be important to the success of the Company.

The Company currently recognizes Associate performance with four levels of Associate leadership achievement: Regional; National; Executive; and Presidential. Each leadership level is vested with the opportunity for additional compensation ranging from 4% of commissionable sales at the Regional Director level to 16% of commissionable sales at the Presidential level. The Company intends to develop additional achievement levels in the future specially designed to stimulate continued production and downline growth by motivating Associates at the highest levels. Additionally, the Company intends to expand its program of Associate recognition to express its appreciation for increased levels of performance and to further motivate Associates.

ASSOCIATE COMPENSATION. All Associate compensation is paid directly by the Company and is based on sales of the Company's products, the achievement of certain leadership levels and the training of other Associates. The Company offers a compensation plan which combines aspects of two widely-used multi-level marketing compensation plans. The Company's compensation plan integrates a single downline, or "unilateral" element, with a multiple downline, or "binary" element, and adds additional compensation based upon attainment of certain Associate leadership levels and training performance. The "unilateral" and "binary" elements of the compensation plan are similar to other multi-level marketing compensation plans. All commissions are based on wholesale prices. Associates may, at their discretion, determine the resale price of products purchased at wholesale. Leadership bonuses pay associates as much as 16% of commissionable sales as various leadership levels are attained. The compensation plan includes bonuses or commissions for qualified associates ranging from \$20 to \$180 earned based on downline growth. Associates who have completed "accredited training" can receive a commission of \$25 for each additional Associate they train. Bonuses or commissions ranging from \$10 to \$200 are also earned on products included in starter or introductory packs. The result of this "hybrid" structure is to compensate both Associates in the early stages of building their business and Associates with more established organizations, by rewarding Associates for breadth as well as depth in their downline organizations. In addition to the "hybrid" compensation plan, Associates earn compensation for retail sales of products.

Based upon its knowledge of other industry-related network marketing compensation plans, the Company believes that its compensation plan is among the most financially rewarding plans offered in the industry, with commissions as a percentage of net sales of 38.5%, 40.7%, 41.0% and 39.8% for 1995, 1996, 1997 and the nine months ended September 30, 1998, respectively.

The Company, in configuring its international compensation plans, will not employ its existing compensation plan outside of the United States and Canada. In the international sector, the Company intends to use substantially similar unilateral plans from country to country, which will be tailored to fit the applicable laws and other considerations governing compensation of Associates in each country. The Company plans to seamlessly integrate its international compensation plans across all markets in which the Company's products are, or will be, sold. This will allow Associates to receive commissions for global product sales, rather than merely local product sales. The seamless downline structure will be designed to allow an Associate to build a global network by creating downlines in international markets. Associates will not be required to establish new downlines or requalify for higher levels of commissions within each new country in which they begin to operate. The Company intends to develop international compensation plans which will be designed to pay approximately the same percentage compensation as in the United States and which will stimulate both product sales as well as the development of width and breadth in downline organizations in accordance with local laws.

MANAGEMENT OF ASSOCIATES. The Company takes an active role in the management of its Associates. Many multi-level marketing companies encounter difficulty with regulatory authorities due to lack of

oversight of Associate activities. Any oversight process is complicated by the fact that Associates are not legally employees of the Company, but are independent contractors. However, the Company seeks to restrict the statements and conduct of Associates regarding the Company's business by contractually binding Associates to abide by the Associate Policies and Procedures (the "Policies and Procedures") promulgated by the Company. Each Associate receives a copy of the Policies and Procedures which must be followed in order to maintain the Associate's status in the organization. Associates are expressly forbidden from making any representation as to the possible earnings of any Associate, other than through statements of the Company indicating the range of actual earnings by all Associates and other required information, prepared in accordance with applicable law. Associates are also prohibited from creating any marketing literature that has not been approved by the Company or a qualified attorney. The Company monitors Associate web sites and Internet conduct on a regular and continuing basis.

The Company enforces the Policies and Procedures through its disciplinary procedure, which is instituted through the filing of a complaint against the Associate, followed by a response from the Associate, an investigation of the facts, and the presentation of the facts to a committee of corporate managers not within the Company's compliance department (the "Compliance Department") for determination. The Compliance Department is also free to evaluate complaints, and, where the conduct complained of is not within the scope of the Policies and Procedures, refer the complaint to an Associate Advisory Counsel for intervention to address Associate ethics. The Compliance Department also has the discretion to intervene with Associates at a lower level of discipline, while still creating a record of the possible infraction and educating the Associate through its practice of issuing warning letters. The Associate is educated as to the nature of the complaint against him or her, the policy alleged to have been violated, and then, without a finding of whether the conduct occurred or not, is asked to confirm in writing that he or she understands the policy in question, agreeing that he or she will thereafter follow all of the Policies and Procedures of the Company.

The Compliance Department and the Director of Specialized Information monitor Company-related meetings at various locations and at corporate events, generating a "report card" for the presenting Associate, offering critiques and employing the Associate disciplinary process, where necessary. The Compliance and Legal Departments, in cooperation with the other departments of the Company, regularly evaluate Associate conduct and the need for new and revised rule-making. The Company also tracks Associate compliance intervention and communication through a system that allows both corporate personnel and regulatory officials to review details about Associate compliance intervention, timing and disposition. The Company believes that the compliance program reflects positively on the Company, helps in the maintenance of Associate ethics and aids the Company's recruiting activities.

PRODUCT RETURN POLICY. The Company's product return policy provides that retail customers may return the unused portion of any product to the selling Associate and receive a full cash refund. Any Associate who provides a refund to a customer is reimbursed with product by the Company upon providing proper documentation and the remainder of the product. Historically, product returns have not been significant. Returns as a percentage of net sales were 0.6%, 1.2%, 1.5% and 1.3% in 1995, 1996, 1997 and the nine month period ended September 30, 1998, respectively.

INFORMATION TECHNOLOGY AND SYSTEMS

The Company believes that maintaining sophisticated and reliable transaction processing systems is essential to the long-term success of the Company. The Company's systems are designed to: (i) reduce the time required to supply an Associate or customer with the products of the Company; (ii) provide detailed and customized billing information; (iii) respond quickly to Associate needs and information requests; (iv) provide detailed and accurate information concerning qualification and downline activity; (v) provide detailed and customized Associate commission payments; (vi) support the functions of the Company's Customer Service Department; and (vii) monitor, analyze and report financial and operating trends. In order to meet these needs and expand transaction processing systems to accommodate the

Company's expected growth, capital and operating expenditures for information technology operations and development activities are expected to be approximately \$4 million during 1998.

The suppliers of computer hardware to the Company are Dell Computer Corporation, Hewlett-Packard Company, Compaq Computer Corporation and Digital Equipment Corp. ("DEC"). The DEC hardware systems are linked to provide a high level of availability for critical business applications. The Company believes the global presence of these suppliers will be an important factor in supporting the Company's expansion plans.

The Company's financial software was upgraded at the end of 1996 with the acquisition of a sophisticated financial system, capable of operating on several platforms. The system exists in a client-server environment, employs a graphical interface and has a relational and scaleable database to accommodate the need for business modifications and growth. In addition, the Company has purchased a decision-support system which interfaces with its financial systems. These systems, used in tandem, enable the Company to track and analyze financial information and operations efficiently and effectively, as well as create and produce custom reports. The Company believes that its computer systems have been developed and operate using products which are Year 2000 compliant.

The Company believes that its significant investment in software, hardware and personnel will enable it to (i) respond rapidly to its business needs for information technology assessment and development, (ii) manage international growth and its seamless downline structure, and (iii) reduce expenses as a percentage of sales as revenues increase.

PRODUCTION AND DISTRIBUTION

All of the Company's products are manufactured by outside contractors. Production outsourcing provides the Company with the production capacity necessary to respond to fluctuations in sales, and significantly limits investment in capital equipment. In order to meet the Company's needs, relationships were developed with three large contractors in 1997. With the increased capacity, the Company believes that it currently has in place the manufacturers necessary to meet its volume requirements over the next several years, including expansion into foreign markets. The Company, however, continues to identify new quality-driven manufacturers to supply the products necessary to the Company's success. The Company seeks to obtain cost efficiencies by reviewing, from time to time, pricing considerations and by requiring competitive bids from various manufacturers meeting its quality and performance requirements.

The Company currently acquires ingredients solely from suppliers that are considered by the Company to be the superior suppliers of such ingredients. The Company believes it has developed dependable alternative sources for all of its ingredients except Manapol-Registered Trademark- and arabinogalactan, which are components of the Company's proprietary raw material. The Company believes that, in the event it is unable to source any ingredients from its current suppliers, such ingredients could be produced by the Company or replaced with substitute ingredients. However, any delay in replacing or substituting such ingredients would have a material adverse effect on the Company's business, results of operations and financial condition. See "Risk Factors-Reliance on and Concentration of Outside Manufacturers."

Two ingredients are proprietary to the Company: (i) Ambrotose-Registered Trademark- Complex, a glyconutritional dietary supplement consisting of a blend of plant polysaccharides, which is a component of each of the Company's products and (ii) Dioscorea Complex, a blend of herbal extracts. The Company plans to bring the blending of all proprietary formulas in-house, further protecting the confidential nature and high quality standards of its proprietary formulations. In the meantime, the Company continues to identify high quality sources of supply for its ingredients. The Company's employees audit all critical contract vendors and suppliers on a semi-annual basis. See "Risk Factors-Dependence on Proprietary Ingredient."

In January 1998, the Company's Texas distribution operation relocated to a new \$1.3 million, 75,000 square foot facility in Coppell, Texas. The facility includes an automated pick-to-light system that the Company believes will enhance productivity and support order volume growth, and is capable of processing 6,000 orders per shift. The facility also contains a warehouse, distribution offices and an ingredient mixing area that is expected to be operational in 1999. The Canadian distribution center is a contract operation occupying a 6,000 square foot compartment in a 100,000 square foot building which currently fills approximately 800 orders per day. The Australian distribution center, located in Banksmeadow, Australia, is a contract operation occupying a 3,000 square feet compartment in a 100,000 square foot building which can fill approximately 20,000 orders per day.

In March 1998, the Company completed construction of its technologically advanced research and development laboratory that includes gas and liquid chromatographs and mass spectrometers which will be used to maintain quality standards, support the Company's research and development commitment in the area of new herbal complexes, and support the development of new products as well as its existing product line.

GOVERNMENT REGULATION

In addition to regulation of its direct selling activities, the Company, in both the United States and foreign markets, is or will be subject to and affected by extensive laws, governmental regulations, administrative determinations, court decisions and similar constraints (as applicable, at the federal, state and local levels) including, among other things, regulations pertaining to (i) the formulation, manufacturing, packaging, labeling, distribution, importation, sale and storage of the Company's products, (ii) product claims and advertising (including direct claims and advertising by the Company as well as claims and advertising by Associates, for which the Company may be held responsible), (iii) the Company's network marketing system, (iv) transfer pricing and similar regulations that affect the level of foreign taxable income and customs duties and (v) taxation of Associates, which in some instances may impose an obligation on the Company to collect the taxes and maintain appropriate records. See "Risk Factors-Government Regulation of Products and Marketing; Import Restrictions."

PRODUCTS. The formulation, manufacturing, packaging, storing, labeling, advertising, distribution and sale of the Company's products are subject to regulation by one or more governmental agencies, including the FDA, the Federal Trade Commission ("FTC"), the Consumer Product Safety Commission, the Department of Agriculture, the Environmental Protection Agency and the Postal Service. The Company's activities are also regulated by various agencies of the states, localities and foreign countries in which the Company's products are manufactured, distributed and sold. The FDA, in particular, regulates the formulation, manufacture, packaging, storage, labeling, promotion, distribution and sale of foods, dietary supplements and OTC drugs, such as those distributed by the Company. FDA regulations require the Company and its suppliers to meet relevant good manufacturing practice ("GMP") regulations for the preparation, packing and storage of drugs. The FDA has published a Notice of Advanced Rule Making for GMPs for dietary supplements, but it has not yet issued a proposal.

DSHEA revised the provisions of the Federal Food, Drug and Cosmetic Act ("FFDCA") concerning the composition and labeling of dietary supplements and, the Company believes, is generally favorable to the dietary supplement industry. The legislation creates a new statutory class of "dietary supplements." This new class includes vitamins, minerals, herbs, amino acids and other dietary substances for human use to supplement the diet, and the legislation grandfathered, with certain limitations, dietary ingredients that were on the market before October 15, 1994. A dietary supplement which contains a new dietary ingredient (I.E., one not on the market before October 15, 1994) will require evidence that the supplement contains only ingredients that have been present in the food supply in a certain form or evidence of a history of use or other evidence of safety establishing that it is reasonably expected to be safe. Manufacturers of dietary supplements which make a "statement of nutritional support," which is a statement describing certain types of product performance characteristics, must have substantiation that

the statement is truthful and not misleading, must make a disclaimer in the statement itself and must notify the FDA of the statement no later than 30 days after it is first made.

The majority of the products marketed by the Company are classified as dietary supplements under the FFDCA. In September 1997 the FDA issued regulations governing the labeling and marketing of dietary supplement products. The regulations cover: (i) the identification of dietary supplements and their nutrition and ingredient labeling; (ii) the terminology to be used for nutrient content claims, health content claims and statements of nutritional support; (iii) labeling requirements for dietary supplements for which "high potency" and "antioxidant" claims are made; (iv) notification procedures for statements on dietary supplements; and (v) premarket notification procedures for new dietary ingredients in dietary supplements. The notification procedures became effective in October 1997, while the new labeling requirements will not become effective until March 23, 1999. The Company will be required to revise a substantial number of its product labels to reflect the new requirements prior to the 1999 effective date, although the Company does not expect the cost or impact of such actions to be material. In addition, the Company will be required to continue its ongoing program of securing substantiation of its product performance claims, and of notifying the FDA of certain types of performance claims made for its products. The Company's substantiation program involves compiling and reviewing the scientific literature pertinent to the ingredients contained in the Company's products.

In addition, in certain markets, including the United States, claims made with respect to dietary supplement, personal care or other products of the Company may change the regulatory status of the products. In the United States, for example, it is possible that the FDA could take the position that claims made for certain of the Company's products make those products new drugs requiring preliminary approval or place those products within the scope of an FDA OTC drug monograph. OTC monographs prescribe permissible ingredients and appropriate labeling language, and require the marketer or supplier of the products to register and file annual drug listing information with the FDA. Of the products sold by the Company, only Emprizone-Registered Trademark- is labeled as an OTC monograph drug, and the Company believes that it is in compliance with the applicable monograph. In the event that the FDA asserted that product claims for other products caused them to be new drugs or fall within the scope of OTC monographs, the Company would be required either to file a New Drug Application, comply with the applicable monographs or change the claims made in connection with the products.

Dietary supplements are subject to the Nutrition, Labeling and Education Act ("NLEA"), and regulations promulgated thereunder, which regulates health claims, ingredient labeling and nutrient content claims characterizing the level of a nutrient in the product. NLEA prohibits the use of any health claim for dietary supplements, unless the health claim is supported by significant scientific agreement and is pre-approved by the FDA.

In foreign markets, prior to commencing operations and prior to making or permitting sales of its products in the market, the Company may be required to obtain an approval, license or certification from the country's ministry of health or comparable agency. Where a formal approval, license or certification is not required, the Company will nonetheless seek a favorable opinion of counsel regarding the Company's compliance with applicable laws. Prior to entering a new market in which a formal approval, license or certificate is required, the Company will work with local authorities in order to obtain the requisite approvals, license or certification. The approval process generally requires the Company to present each product and product ingredient to appropriate regulators and, in some instances, arrange for testing of products by local technicians for ingredient analysis. Such approvals may be conditioned on reformulation of the Company's products or may be unavailable with respect to certain products or certain ingredients. The Company must also comply with product labeling and packaging regulations that vary from country to country.

The FTC, which exercises jurisdiction over the marketing practices and advertising of all the Company's products, has in the past several years instituted enforcement actions against several dietary

supplement companies for false and misleading marketing practices and advertising of certain products. These enforcement actions have resulted in consent decrees and monetary payments by the companies involved. In addition, the FTC has increased its scrutiny of the use of testimonials, which are utilized by the Company. Importantly, the FTC requires substantiation for product claims at the time such claims are first made. A failure to have substantiation when product claims are first made violates the Federal Trade Commission Act. While the Company has not been the subject of FTC enforcement action for the advertising of its products, there can be no assurance that the FTC will not question the Company's advertising or other operations in the future.

Through its manuals, seminars and other training materials and programs, the Company attempts to educate Associates as to the scope of permissible and impermissible activities in each market. The Company also investigates allegations of Associate misconduct. However, Associates are generally independent contractors, and the Company is not able to monitor directly all Associate activities. As a consequence, there can be no assurance that Associates comply with applicable regulations.

The Company is unable to predict the nature of any future laws, regulations, interpretations or applications, nor can it predict what effect additional governmental regulations or administrative orders, when and if promulgated, would have on its business in the future. They could, however, require the reformation of certain products not able to be reformulated, imposition of additional recordkeeping requirements, expanded documentation of the properties of certain products, expanded or different labeling and scientific substantiation regarding product ingredients, safety or usefulness. Any or all of such requirements could have a material adverse effect on the Company's business, results of operations and financial condition.

NETWORK MARKETING SYSTEM. The Company's network marketing system, which includes its compensation plan, is subject to a number of federal and state statutes and regulations administered by the FTC and various state agencies. The legal requirements applicable to network marketing organizations are generally directed at ensuring that product sales are ultimately made to consumers and that advancement within such organizations be based on sales of the organizations' products rather than compensation derived principally from the recruitment of additional associates, investments in the organizations or other non-retail sales related criteria. For instance, in certain markets there are limits on the extent to which Associates may earn royalties on sales generated by Associates that were not directly sponsored by the Associate. Where required by law, the Company will obtain regulatory approval of its network marketing system or, where such approval is not required, the favorable opinion of local counsel as to regulatory compliance. The FTC regulates trade practices related to network marketing systems.

Under a consent decree entered into in February 1997 as a result of negotiation with the Attorney General of the State of Michigan, the Company has agreed to monitor product purchases by its Associates in Michigan. The purpose of the monitoring is to identify and correct any instances of coerced sales. The Company also conducts a number of random audits of Associates in Michigan for evidence of stockpiling. To date, the Company has not found evidence of coerced sales or stockpiling by its Associates in Michigan, and the Company's commission policies are designed to provide no incentive or reward to Associates for engaging in such activities.

In Canada, the regulation of the Company's network marketing system is subject to both federal and provincial law. Under Canada's Federal Competition Act (the "Competition Act"), the Company must ensure that any representations relating to Associate compensation to a prospective Associate constitute fair, reasonable and timely disclosure and that it meets other legal requisites of the Competition Act. The Company's compensation plan has been reviewed by the appropriate Canadian authorities. In addition, all Canadian provinces and territories other than Ontario have legislation requiring the registration or licensing of the Company as a direct seller within that jurisdiction. Licensing is designed to maintain the standards of the direct selling industry and to protect the consumer. Some provinces require that both

the Company and its Associates be licensed. The Company currently holds the requisite provincial or territorial direct sellers' licenses.

In Australia, the Company's network marketing system is subject to both federal and state regulation. The compensation plan employed in Australia is a unilateral plan, which is designed and disclosed to meet the requisites of applicable state requirements and the requirements of the Trade Practices Act. Business and solicitation practices of the Company and its associates are regulated by state law and the Trade Practices Act. Claims and representations relating to products are regulated by both the Trade Practices Act and the Therapeutic Goods Act.

OTHER REGULATIONS. The Company is also subject to a variety of other regulations in various foreign markets, including regulations pertaining to social security assessments and value added taxes, employment and severance pay requirements, import/export regulations and antitrust issues. As an example, in many markets the Company is substantially restricted in the amount and types of rules and termination criteria that it can impose on Associates without causing social security assessments to be payable by the Company on behalf of such Associates and without incurring severance obligations to terminated Associates. In some countries, the Company may be subject to such obligations in any event. See "Risk Factors-Government Regulation of Products and Marketing; Import Restrictions."

In certain countries, including the United States, the Company may also be affected by regulations applicable to the activities of its Associates because in some countries the Company is, or regulators may assert that the Company is, responsible for its Associates' conduct, or such regulators may request or require that the Company take steps to ensure its Associates' compliance with regulations. The types of regulated conduct include, among other things, representations concerning the Company's products, income representations made by the Company or Associates and sales of products in markets in which such products have not been approved, licensed or certified for sale. In certain markets, including the United States, it is possible that improper product claims by Associates could result in the Company's products being reviewed or re-reviewed by regulatory authorities and, as a result, being classified or placed into another category as to which stricter regulations are applicable. In addition, certain labeling changes might be required.

COMPLIANCE PROCEDURES. The Company, its products and its network marketing system are subject, both directly and indirectly through Associates' conduct, to numerous federal, state and local regulations both in the United States and foreign markets. Beginning in 1997, the Company began to institute formal regulatory compliance measures by developing a system to identify specific complaints against Associates and to remedy any violations by Associates through appropriate sanctions, including warnings, suspensions and, when necessary, terminations. At the same time the Company instituted internal policies for compliance with FDA and FTC rules and regulations. See "-Product Distribution System-Management of Associates."

In order to comply with regulations that apply to both the Company and its Associates, the Company continues to conduct research into the applicable regulatory framework prior to entering any new market to identify all necessary licenses and approvals and applicable limitations on the Company's operations in that market. The Company will devote substantial resources to obtaining such licenses and approvals and bringing its operations into compliance with such limitations. The Company will also research laws applicable to Associate operations and revise or alter its business system, compensation plan, Associate requirements and other materials and programs to provide Associates with guidelines for operating a business, marketing and distributing the Company's products and similar matters, as required by applicable regulations in each market. However, the Company is not able to fully monitor its Associates effectively to ensure that they refrain from distributing the Company's products in countries where the Company has not commenced operations, and the Company does not devote significant resources to such monitoring.

COMPETITION

The nutritional supplements industry is large and intensely competitive. The Company competes directly with companies that manufacture and market nutritional products in each of the Company's product lines, including General Nutrition Companies, Inc., Solgar Vitamin and Herb Company, Inc., Twinlab Corporation and Weider Nutrition International, Inc. Many of the Company's competitors in the nutritional supplements market have longer operating histories and greater name recognition and financial resources than the Company. In addition, nutritional supplements can be purchased in a wide variety of distribution channels. While the Company believes that consumers appreciate the convenience of ordering products from home through a sales person, the buying habits of many consumers accustomed to purchasing products through traditional retail channels are difficult to change. The Company's product offerings in each product category are also relatively small compared to the wide variety of products offered by many other nutritional product companies.

The Company also competes in the nutritional supplements market and for new associates with other retail, multi-level marketing and direct selling companies in the nutritional supplements industry by emphasizing the proprietary nature, value, proprietary components and the quality of the Company's products and the convenience of the Company's distribution system. The Company also competes with other direct selling organizations, many of which have longer operating histories and greater name recognition and financial resources than the Company. They include Amway Corporation, Nu Skin Enterprises, Inc., Body Wise International, Inc., ENVION International, Herbalife International, Inc., Enrich International, Rexall Showcase International, Forever Living Products, Inc. and Melaleuca, Inc. The Company competes for new Associates on the basis of its compensation plan and its proprietary and quality products. The Company believes that many more direct selling organizations will enter the marketplace as this channel of distribution expands over the next several years. The Company also competes for the commitment of its Associates. Given that the pool of individuals interested in direct selling tends to be limited in each market, the potential pool of Associates for the Company's products is reduced to the extent other network marketing companies successfully recruit these individuals into their businesses.

EMPLOYEES

As of September 30, 1998, the Company employed approximately 265 people, ten of whom occupy executive positions. This number does not include Associates, who are independent contractors rather than employees of the Company. A limited number of employees are also Associates, having enrolled prior to a policy instituted in May 1997, which precludes any further enrollment by employees as Associates. The Company only allows employees to be Associates if they have disclosed their status to the Company and have executed an agreement not to use their employment status to assist in building their business as an Associate. The Company is currently evaluating ways in which existing employee-Associates can be fairly treated or compensated for the extinguishment of their rights as Associates. The Company's employees are not unionized, and the Company believes its relationship with its employees is good.

PROPERTIES

The Company leases approximately 110,000 square feet in Coppell, Texas for its headquarters. The Company leases 75,000 square feet in Coppell, Texas for its warehouse and distribution center. Each of the leases is for a term of 10 years, expiring in January 2007 and January 2008, respectively. The Company also leases approximately 9,000 square feet in St. Leonards, Australia for its Australian headquarters. The lease is for a term of five years, expiring in August 2003.

LEGAL PROCEEDINGS

The Company, in the ordinary course of business, is involved in various legal proceedings. The Company does not believe the outcome of any of these proceedings, other than those described below, would have a material adverse effect on the Company's business, results of operations or financial condition.

The Company received a demand letter (the "Demand Letter") from Dr. Joe Glickman, Jr. an Associate of the Company, alleging that the Company had, among other things, breached various contracts, agreements and promises, and stating an intention to pursue these claims in the United States District Court for Montana. In March 1998, the Company commenced an arbitration proceeding against Dr. Glickman individually and as trustee of Dr. Joe Glickman, Jr. Phyto Trust d/b/a/ Alotek (collectively, "Alotek"), for the recovery of certain funds and the cancellation of Associate positions claimed by Alotek. Based upon Alotek's refusal to arbitrate and the Demand Letter, the Company sought and obtained a temporary restraining order in Texas state district court restraining Alotek from filing an action against the Company in any other court or forum pending the court's ruling on whether Alotek's claims were subject to commercial arbitration in Dallas, Texas. Thereafter, Alotek removed the state court action to Federal District Court in Dallas, Texas ("Dallas Court"), and concurrently commenced a suit in Federal District Court in Montana ("Montana Court"). In May 1998, the Company also received a demand letter from Alotek threatening to institute a "class action" on behalf of all of the Company's Associates in federal court against the Company for alleged fraud and misrepresentation. In September 1998, the Dallas Court entered an order referring the case to arbitration, and thereafter administratively closed the case. The order of the Dallas Court was appealed by Glickman to the Fifth Circuit Court of Appeals in October 1998. In October 1998, the Montana Court dismissed the case of Glickman in its entirety. The arbitration is in its earliest stages and discovery has not yet begun. The Company believes that Alotek's claims are without merit and has sought declaratory relief to that effect. The Company further believes that it has valid defenses to all allegations raised by Alotek. Nevertheless, an adverse resolution of this matter would have a material adverse effect on the Company's business, results of operations and financial condition.

In October 1997, the Company filed an objection to the issuance of a registered trademark to IntraCell Nutrition, Inc., which had filed a trademark application for the name, "Manna." The Company contended in its objection, among other things, that "Manna" is a general descriptor often applied to nutritional products, and accordingly, is not entitled to trademark protection. The Company therefore believes that there is a substantial likelihood that the Company will prevail in its objection to the granting of the tradename.

MANAGEMENT

EXECUTIVE OFFICERS AND DIRECTORS

The Company's executive officers and directors and their ages as of September 30, 1998 are as follows:

NAME	AGE	POSITION
Charles E. Fioretti.....	52	Chairman of the Board and Chief Executive Officer
Samuel L. Caster.....	48	President and Director
Anthony E. Canale.....	46	Chief Operating Officer
Patrick D. Cobb.....	46	Vice President, Chief Financial Officer, Secretary and Director
Deanne Varner.....	45	General Counsel and Vice President of Compliance
Jeffrey P. Bourgoyne.....	37	Vice President of Operations
Peter E. Hammer.....	43	Vice President of New Business and International Development
Bill H. McAnalley, Ph.D.....	54	Vice President of Research and Product Development
Ronald D. Norman.....	39	Vice President of Accounting and Treasurer
Eoin Redmond.....	33	Vice President of Information Technology
Steven A. Barker.....	49	Director
Chris T. Sullivan.....	50	Director

Charles E. Fioretti co-founded the Company in November 1993, has served as Chairman of the Board and Chief Executive Officer since May 1997 and as a director since November 1993. His current term as director expires in 2001. Mr. Fioretti served as Chief Operating Officer of the Company from November 1993 to July 1996. From June 1990 until April 1995, Mr. Fioretti was an owner and operator of several Outback Steakhouse, Inc. restaurants in Arizona, Indiana and Kentucky. Prior to his involvement with Outback Steakhouse, Inc., Mr. Fioretti occupied executive positions with several national restaurant chains, including Bennigan's, ChiChi's Mexican Restaurants, El Chico and Steak & Ale. Mr. Fioretti is Peter E. Hammer's brother-in-law.

Samuel L. Caster co-founded the Company in November 1993 and since then has served as President and as a director of the Company. His current term as director expires in 2000. From April 1992 until August 1993, Mr. Caster also served as co-founder, owner and President of Funds-4-Kids, Inc., a multi-level marketing company that sold healthy alternative candy bars for children. From January 1990 until April 1992, Mr. Caster served as a consultant for Metabolic Technologies, Inc., a nutritional supplement multi-level marketing company that sold metabolic vitamins. From April 1986 until December 1989, Mr. Caster was President of Eagle Shield, Incorporated, a multi-level marketing company which sold radiant barrier insulation. Eagle Shield, Incorporated filed for protection under Chapter 11 of the United States Bankruptcy Code in December 1989.

Anthony E. Canale joined the Company in January 1997 and since then has served as Chief Operating Officer of the Company. From February 1993 until October 1996, Mr. Canale was President of Canale and Associates, an Outback Steakhouse, Inc. joint venture partnership. Prior to that time, Mr. Canale served as Regional Vice President and Vice President of Franchise Operations and Food/Beverage Development for ChiChi's, Inc., Regional General Manager and National Director of Operation Services for Kentucky Fried Chicken Corporation and Executive Vice President and Chief Operating Officer of Kenny Rogers Roasters Restaurants, Inc., all national restaurant chains. Mr. Canale holds a B.S. in Management from American International College in Springfield, Massachusetts.

Patrick D. Cobb joined the Company in August 1994 and since then has served as Chief Financial Officer and Vice President. Mr. Cobb has served as Secretary of the Company since February 1997 and as a director since November 1997. His current term as director expires in 2000. From January 1994 until

August 1994, Mr. Cobb was President of Industrial Gasket, Inc., a metal stamping facility in Oklahoma City. From August 1989 until October 1993, he was head of a Small Business Management Program with the Oklahoma VO-Tech System. From May 1981 until October 1993, Mr. Cobb was employed by General Motors Corporation as a Senior Accountant and Financial Forecaster. Mr. Cobb holds a B.S. in Finance from the University of Oklahoma and is a Certified Public Accountant.

Deanne Varner joined the Company in January 1996 and since May 1996 has served as General Counsel and Vice President of Compliance. From 1986 until January 1996, Ms. Varner maintained a law practice in Dallas, Texas focusing on business law and related transactions. Ms. Varner has over 20 years of experience in business, corporate and transactional law. Ms. Varner holds a B.A. in Social Sciences and a J.D. from Southern Methodist University.

Jeffrey P. Bourgoyne joined the Company in December 1996 and since February 1998 has served as Vice President of Operations. From May 1995 until December 1996, Mr. Bourgoyne served as facility manager for DSC Logistics, Inc., a third-party logistics provider. From June 1993 until May 1995, Mr. Bourgoyne was a Transportation Services Manager for Abbott Laboratories, a pharmaceutical company. Mr. Bourgoyne holds a B.S. in Management from University of New Orleans and an M.B.A. from Lake Forest Graduate School of Management.

Peter E. Hammer joined the Company in March 1995 and since January 1998 has served as Vice President of New Business and International Development. From November 1991 until February 1995, Mr. Hammer served as the Vice President and Chief Information Officer of The Network, Inc., a business abuse solutions company in Atlanta, Georgia. Prior to that, Mr. Hammer worked for several companies developing and installing complex computer and information systems. Mr. Hammer holds a B.A. in Liberal Arts from State University College at Buffalo and an A.A.S. in Electronics from Suffolk Community College. Mr. Hammer is Charles E. Fioretti's brother-in-law.

Bill H. McAnalley, Ph.D. joined the Company in July 1996 and since December 1997 has served as Vice President of Research and Product Development and Chief Scientific Officer. From March 1995 until July 1996, Dr. McAnalley served as a consultant to the Company. From March 1987 until February 1995, Dr. McAnalley was Vice President of Research and Product Development at Carrington Laboratories, Inc., a pharmaceutical research, development and manufacturing company. Dr. McAnalley holds a Ph.D. in Pharmacology and Toxicology from the University of Texas Health Science Center in Dallas, Texas.

Ronald D. Norman joined the Company in May 1996 and since September 1998 has served as Treasurer and since June 1998 as Vice President of Accounting. From August 1997 to September 1998 he served as Controller. From September 1994 to April 1996 Mr. Norman was a tax manager with Belew Averitt LLP, a public accounting firm in Dallas, Texas. From January 1989 until September 1994 Mr. Norman worked for Coopers & Lybrand LLP (now PricewaterhouseCoopers LLP), an international public accounting firm. Mr. Norman holds an M.A. in Tax and a B.B.A. in Accounting from Baylor University and is a Certified Public Accountant.

Eoin Redmond joined the Company in July 1997 and since then has served as Vice President of Information Technology. From August 1996 through June 1997, Mr. Redmond was employed by the Company as a computer systems consultant. From October 1995 until August 1996, Mr. Redmond was Head of Client Services for Tate Bramald Ltd., an accounting software provider. From December 1993 until September 1995, Mr. Redmond was employed as Technology Services Manager-Europe for SSA Europe Ltd., an industrial software provider. From October 1987 until October 1993, Mr. Redmond was employed as a Senior Software Manager for Team Systems Group, Ltd., a reseller of turn-key software systems. Mr. Redmond matriculated at Presentation College, County Wicklow, Ireland and subsequently attended AnCo Technology Center, County Dublin, Ireland.

Steven A. Barker became a director of the Company in January 1998. His current term as director expires in 1999. Dr. Barker has been a full professor of Physiology, Pharmacology and Toxicology at

Louisiana State University since April 1990. Dr. Barker holds a B.S. and an M.S. in Chemistry and a Ph.D in Chemistry/Neurochemistry from the University of Alabama-Birmingham.

Chris T. Sullivan became a director of the Company in October 1997. His current term as director expires in 2001. Mr. Sullivan has been the Chairman of the Board and Chief Executive Officer of Outback Steakhouse, Inc. since founding that company in 1988. Mr. Sullivan serves on the executive committee for The Outback/Gary Koch Pro-Am, the Tampa Bay Devil Rays, the Employment Policies Institute and the Presidents Conference. Mr. Sullivan holds a degree in Business and Economics from the University of Kentucky.

The Company has a classified Board of Directors. At each annual meeting of shareholders, a class of directors will be elected to serve a three-year term and until his successor is duly elected and qualified. See "Description of Capital Stock-Anti-Takeover Considerations-Classified Board of Directors." Officers serve at the discretion of the Board of Directors. Except as described above, there are no family relationships among the directors and executive officers.

COMMITTEES OF THE BOARD OF DIRECTORS

Subsequent to this offering, the Board of Directors will establish an audit committee (the "Audit Committee") and a compensation committee (the "Compensation Committee"). The Audit Committee will be comprised solely of two independent directors and will be charged with reviewing the Company's annual audit and meeting with the Company's independent accountants to review the Company's internal controls and financial management practices. The Compensation Committee will be comprised solely of independent directors. The Compensation Committee will be responsible for establishing salaries, bonuses and other compensation for the Company's executive officers.

Also, subsequent to this offering, the Board of Directors will establish an option committee (the "Option Committee"). Pursuant to the terms of the 1997 Stock Option Plan and the 1998 Stock Option Plan, the authority to determine the terms and conditions of each option to be issued under both the 1997 Stock Option Plan and the 1998 Stock Option Plan and the responsibility for administration of each such plan, which currently rests with the Board of Directors, will be assumed by the Option Committee. The Option Committee will be comprised solely of at least two "Non-Employee Directors," as such term is used in Rule 16b-3 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

DIRECTOR COMPENSATION

Each director of the Company who is not an officer or employee of the Company receives an annual fee of \$30,000 for serving on the Board of Directors. In addition, directors of the Company are reimbursed for their reasonable out-of-pocket expenses in connection with their travel to and attendance at meetings of the Board of Directors or committees thereof. Prior to his appointment as a director, Dr. Barker was a consultant to the Company and was paid \$2,500 in consulting fees in 1997.

EXECUTIVE COMPENSATION

The following table summarizes the compensation paid to or earned during the year ended December 31, 1997 by each person who served as the chief executive officer of the Company during 1997 and the four other most highly compensated executive officers of the Company (collectively, the "Named Executive Officers").

SUMMARY COMPENSATION TABLE

NAME AND PRINCIPAL POSITION	ANNUAL COMPENSATION		LONG-TERM COMPENSATION	ALL OTHER COMPENSATION
	SALARY	BONUS	NUMBER OF SHARES UNDERLYING OPTIONS GRANTED(#)	
Charles E. Fioretti(1) Chairman of the Board and Chief Executive Officer	\$ 403,434	\$ 760,000	-	\$ 109,765(2)
Ronald E. Kozak(3) Chief Executive Officer	94,101	150,000	200,000	297,347(4)
Samuel L. Caster President	403,434	760,000	-	16,012(5)
Anthony E. Canale Chief Operating Officer	221,978	190,172	250,000	-
Deanne Varner General Counsel and Vice President of Compliance	187,019	159,884	228,000	-
Patrick D. Cobb Vice President, Chief Financial Officer and Secretary	214,011	171,666	100,000	43,000(6)

- (1) Mr. Fioretti became Chief Executive Officer of the Company on May 1, 1997.
- (2) Represents the amount paid to Mr. Fioretti under his incentive compensation agreement.
- (3) Mr. Kozak resigned from his position as Chief Executive Officer of the Company on May 1, 1997.
- (4) Represents the amount distributed to Mr. Kozak pursuant to a severance agreement between Mr. Kozak and the Company consisting of cash payments totalling \$175,000, incentive compensation payments totalling \$73,412 and the transfer of a Company vehicle and certain furniture valued at \$48,935.
- (5) Represents the amount paid to Mr. Caster under his incentive compensation agreement.
- (6) Represents the value of a Company vehicle transferred to Mr. Cobb in 1997.

The following table provides information on options granted to the Named Executive Officers during the fiscal year ended December 31, 1997. As of December 31, 1997, the Company had not granted any options to acquire shares of Common Stock to Charles E. Fioretti, Chairman of the Board and Chief Executive Officer, or Samuel L. Caster, President.

OPTION GRANTS IN LAST FISCAL YEAR

NAME	INDIVIDUAL GRANTS				POTENTIAL REALIZABLE VALUE AT ASSUMED ANNUAL RATES OF STOCK PRICE APPRECIATION FOR OPTION TERM(2)	
	NUMBER OF SHARES UNDERLYING OPTIONS GRANTED(#)(1)	PERCENT OF TOTAL OPTIONS GRANTED TO EMPLOYEES	EXERCISE OR BASE PRICE (\$/SHARE)	EXPIRATION DATE	5%	10%
Ronald E. Kozak.....	200,000	12.5%	\$ 1.35	6/23/03	\$ 91,825	\$ 208,321
Anthony E. Canale.....	250,000	15.6	1.35	5/14/07	212,252	537,888
Deanne Varner.....	228,000	14.3	1.35	5/14/07	193,574	490,554
Patrick D. Cobb.....	100,000	6.3	1.35	5/14/07	84,901	215,155

- (1) Options granted become exercisable 90 days after the completion of an initial public offering of the Company's securities but in no event earlier than the first anniversary of the date of grant.
- (2) The 5% and 10% assumed annual compound rates of stock appreciation are mandated by the rules of the Securities and Exchange Commission (the "Commission") and do not represent the Company's estimate or projection of future Common Stock prices. The actual value realized may be greater or less than the potential realizable value set forth in the table.

The following table sets forth, as of December 31, 1997, the number of options and the value of unexercised options held by the Named Executive Officers. As of December 31, 1997, there had been no stock options exercised by any Named Executive Officers.

FISCAL YEAR-END OPTION VALUES

NAME	NUMBER OF SHARES UNDERLYING UNEXERCISED OPTIONS AT FISCAL YEAR-END(1)		VALUE OF UNEXERCISED IN-THE-MONEY OPTIONS AT FISCAL YEAR-END(1)	
	EXERCISABLE(2)	UNEXERCISABLE	EXERCISABLE	UNEXERCISABLE
Ronald E. Kozak.....	-	200,000	-	\$ 1,330,000
Anthony E. Canale.....	-	250,000	-	1,662,500
Deanne Varner.....	-	228,000	-	1,516,200
Patrick D. Cobb.....	-	100,000	-	665,000

(1) There was no public trading market for the Common Stock at December 31, 1997. Accordingly, as permitted by the Commission, these values have been calculated based on an assumed initial public offering price of \$8.00 per share less the per share exercise price of \$1.35.

(2) Options granted become exercisable 90 days after the completion of an initial public offering of the Company's securities but in no event earlier than the first anniversary of the date of grant.

EMPLOYMENT AGREEMENTS

The Company has entered into employment agreements with each of Charles E. Fioretti, Patrick D. Cobb, Anthony E. Canale, Bill H. McAnalley and Deanne Varner, effective as of September 1, 1998, which entitle each such employee to receive their current base salary and bonus compensation based upon the Management Bonus Plan formula. See "--Management Bonus Plan." The agreements have an initial term of five years and extend automatically each year for one additional year unless both parties agree to termination prior to the end of any term. If the Company terminates the employment agreement for any reason other than specified events, the executive is entitled to receive an amount equal to the sum of all salary and bonus which would have been paid in the five years subsequent to such termination.

STOCK OPTION PLANS

1997 STOCK OPTION PLAN. The 1997 Stock Option Plan was adopted on May 14, 1997 by the Board of Directors and approved by the shareholders of the Company on the same date. The 1997 Stock Option Plan is intended to encourage investment by the officers, employees, non-employee directors and consultants of the Company in shares of Common Stock, thus creating in such persons an increased interest in and greater concern for the welfare of the Company.

Options granted under the 1997 Stock Option Plan may either be options that qualify ("Incentive Stock Options") or options that do not qualify for treatment as Incentive Stock Options under Section 422 of the Internal Revenue Code of 1986, as amended (the "Code").

Incentive Stock Options may be granted under the 1997 Stock Option Plan to any person who is an officer or other employee (including officers and employees who are also directors) of the Company or any parent or subsidiaries that may exist in the future. Non-qualified options may be granted to consultants or non-employee directors of the Company. The exercise price of Incentive Stock Options must be at least the fair market value of a share of Common Stock on the date of grant. A total of 2,000,000 shares of Common Stock have been reserved for issuance upon the exercise of options granted or to be granted under the 1997 Stock Option Plan. As of September 30, 1998, options to purchase 2,000,000 shares of Common Stock were outstanding, with a weighted average exercise price of \$2.75 per share, none of which were vested or exercisable at such date and 1,600,000 of which will become vested and exercisable

90 days after the effective date of the Prospectus and 400,000 of which will become vested and exercisable on July 31, 1999, assuming completion of this offering. No shares remain available for future option grants under the 1997 Stock Option Plan.

The 1997 Stock Option Plan provides that until such time as shares of Common Stock are registered under Section 12 of the Exchange Act it is to be administered by the Board of Directors and, after such registration, by the Option Committee. The Option Committee will consist of at least two, but not more than three, "Non-Employee Directors" as such term is defined in Rule 16b-3 promulgated under the Exchange Act. The Option Committee will have full and final authority in its discretion, subject to the 1997 Stock Option Plan's provisions, to determine, among other things, (i) the individuals to whom options shall be granted, (ii) whether the option granted shall be an Incentive Stock Option or a non-qualified stock option, (iii) the number of shares of Common Stock covered by each option, (iv) the time or times at which options will be granted, (v) the option vesting schedule, (vi) the exercise price of the options and (vii) the duration of the options granted. The Option Committee will also have the power to construe and interpret the 1997 Stock Option Plan and make certain determinations and take certain other actions deemed necessary or advisable for the proper administration of the 1997 Stock Option Plan. The 1997 Stock Option Plan may be amended, supplemented, suspended or terminated by the Board of Directors at any time without the approval of the shareholders of the Company, subject to certain exceptions, provided, however, that any such action may not affect options previously granted under the 1997 Stock Option Plan.

1998 STOCK OPTION PLAN. The 1998 Stock Option Plan was adopted by the Board of Directors on April 8, 1998 and was amended on September 4, 1998 to increase the number of shares reserved for issuance. The 1998 Stock Option Plan is intended to encourage investment by the officers and employees of the Company in shares of Common Stock, thus creating in such persons an increased interest in and greater concern for the welfare of the Company.

Options granted under the 1998 Stock Option Plan shall be Incentive Stock Options. Incentive Stock Options may be granted under the 1998 Stock Option Plan to any person who is an officer or other employee (including officers and employees who are also directors) of the Company or any parent or subsidiaries that may exist in the future. The exercise price of Incentive Stock Options must be at least the fair market value of a share of Common Stock on the date of grant. Under the 1998 Stock Option Plan, as originally adopted, a total of 500,000 shares of Common Stock were reserved for issuance upon the exercise of options granted or to be granted under the 1998 Stock Option Plan; the amendment to the 1998 Stock Option Plan increased this to 1,000,000. As of the date of this Prospectus, options to purchase 243,000 shares of Common Stock were outstanding with an exercise price of \$8.00 per share, none of which were vested or exercisable at such date and 228,000 of which will become vested and exercisable on July 31, 1999, assuming the completion of this offering and 15,000 of which will become vested and exercisable ratably over a three year period.

The 1998 Stock Option Plan provides that it is to be administered by the Board of Directors or by an Option Committee appointed by the Board of Directors and consisting of at least two "Non-Employee Directors" as such term is defined in Rule 16b-3 promulgated under the Exchange Act. The Option Committee will have the authority, in its discretion, subject to the 1998 Stock Option Plan's provisions, to (i) grant Incentive Stock Options, in accordance with Section 422 of the Code; (ii) determine, upon review of relevant information and in accordance with the 1998 Stock Option Plan, the fair market value of the Common Stock; (iii) determine the exercise price per share of options to be granted; (iv) determine the employees to whom, and the time or times at which, options shall be granted and the number of shares to be represented by each option; (v) interpret the 1998 Stock Option Plan; (vi) prescribe, amend and rescind rules and regulations relating to the 1998 Stock Option Plan; (vii) determine the terms and provisions of each option granted; (viii) accelerate or defer (with the consent of the optionee) the exercise date of any option; (ix) authorize any person to execute on behalf of the Company any instrument required to effectuate the grant of an option previously granted by the

Board of Directors; and (x) make all other determinations deemed necessary or advisable for the administration of the 1998 Stock Option Plan. The 1998 Stock Option Plan may be amended or terminated by the Board of Directors or the Option Committee at any time without the approval of the shareholders of the Company, subject to certain exceptions.

MANAGEMENT BONUS PLAN

The executive officers and certain other members of corporate management are eligible to receive bonuses in addition to their base salaries. The bonus plan is based upon the attainment by management of certain financial goals of the Company. The amount of the bonuses paid pursuant to the bonus plan, prior to this offering, has been reviewed and approved by the Board of Directors. After this offering, amounts to be paid under the bonus plan will be reviewed and approved by the Compensation Committee.

401(K) PLAN

Effective May 9, 1997, the Company adopted a 401(k) Pre-tax Savings Plan (the "401(k) Plan"). All employees who have been employed by the Company for at least 90 days at the beginning of a quarter and are at least 21 years of age are eligible to participate. Employees may contribute to the 401(k) Plan up to 15% of their current compensation, subject to a statutorily prescribed annual limit. The 401(k) Plan provides that the Company will make regular matching contributions to the 401(k) Plan in the amount of \$0.25 for each \$1.00 contributed by the participant, up to 6% of the participant's annual compensation, including overtime. The 401(k) Plan also provides that the Company may determine to make a discretionary profit-sharing contribution to the plan each year based upon the Company's profitability for that year. Employee contributions and the Company's matching contributions are paid to a corporate trustee and invested in various funds at the discretion of the participant. The Company's contribution vests over five years or earlier upon attainment of retirement at age 65, retirement for disability or upon death of the employee or termination of the 401(k) Plan. Distributions may also be made in the case of a financial hardship. Distributions may be made in the form of a lump sum. The 401(k) Plan is intended to qualify under Section 401 of the Code, so that contributions made by employees or by the Company to the 401(k) Plan, and income earned on such contributions, are not taxable to employees until withdrawn from the 401(k) Plan. As of the date of this Prospectus, the Company has not made any profit-sharing contributions to the 401(k) Plan.

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

During 1997 the Company had no compensation committee or other committee of the Board of Directors performing similar functions. Decisions concerning compensation of executive officers were made by the Board of Directors, which included Charles E. Fioretti, Samuel L. Caster, Patrick D. Cobb and William C. Fioretti, who was the Chief Scientific Officer and a director of the Company until November 1997. Charles E. Fioretti and William C. Fioretti are cousins. It is contemplated that the Board of Directors will establish the Compensation Committee, consisting solely of independent directors, subsequent to consummation of this offering.

CERTAIN TRANSACTIONS

PARTNERSHIP TRANSACTIONS

Prior to June 1, 1997, certain shareholders of the Company (the "Partners") directly owned all of the limited partnership interests in three limited partnerships: Beta M. Partners, Ltd. ("Beta"), Eleven Point Partners, Ltd. ("Eleven Point") and Power Three Partners, Ltd. ("Power Three"). All of the limited partnership interests in Beta were owned by Charles E. Fioretti, Chairman of the Board and Chief Executive Officer of the Company, Samuel L. Caster, President and director of the Company, and William C. Fioretti, who at the time was a director of the Company. Messrs. Charles E. Fioretti, Samuel L. Caster and William C. Fioretti also owned all of the limited partnership interests in Power Three. The limited partnership interests in Eleven Point were owned equally by four other shareholders of the Company, including Patrick D. Cobb, Chief Financial Officer and Secretary, and currently a director, of the Company. The limited partnership interests in another limited partnership, Dynamic Eight Partners, Ltd. ("Dynamic" and, collectively with Power Three, Beta and Eleven Point, the "Partnerships") were all owned by Power Three and Eleven Point. The corporate general partners of each of the Partnerships were also owned and controlled by Messrs. Charles E. Fioretti, Samuel L. Caster and William C. Fioretti.

The Partnerships were formed in 1994 to achieve certain tax efficiencies and to protect certain of the Company's proprietary rights. In December 1994, the Company transferred certain of its rights and interests in intellectual property and the Company's right to use the trademark "Manapol-TM-," to Beta. The Company then entered into a 17-year agreement to pay Beta a royalty based on the Company's sales volume for the use of the intellectual property and trademark. During 1995, 1996 and 1997, the Company, under this royalty agreement, incurred expenses of approximately \$979,000, \$2,554,000 and \$1,780,000, respectively. Also in December 1994, the Company transferred certain marketing rights to Dynamic. The Company paid Dynamic a commission, based on a specified sales volume, in exchange for marketing and consulting services. During 1995, 1996 and 1997, the Company, under its marketing agreement with Dynamic, expensed approximately \$1,395,000, \$3,295,000 and \$2,275,000, respectively, for consulting fees.

On June 1, 1997, the Company entered into a merger agreement with the corporate general partners of the Partnerships, Eight Point Services, Inc., Triple Gold Business, Inc., Five Small Fry, Inc. and Beta Nutrient Technology, Inc. (collectively, the "General Partners"). Pursuant to the merger agreement, the General Partners were merged with and into the Company, and the issued and outstanding shares of common stock of each such entity were converted into the right to receive a certain number of shares of the Company's Common Stock. On the same date, the Company entered into an exchange agreement among the Company and the Partners, pursuant to which the Company acquired all of the Partners' limited partnership interests in the Partnerships in exchange for Common Stock. As a result of these transactions, an aggregate of 10,000,000 shares of Common Stock were issued to the Partners, including 3,094,946, 3,094,946, 2,867,284 and 235,706 shares issued to Messrs. William C. Fioretti, Samuel L. Caster, Charles E. Fioretti and Patrick D. Cobb, respectively.

INCENTIVE COMPENSATION AGREEMENTS

In 1994, the Company entered into incentive compensation agreements with Charles E. Fioretti, the Chairman of the Board and Chief Executive Officer of the Company, which was provided in lieu of ownership interests in the Partnerships, Ray Robbins, a shareholder of the Company, which was provided in part in lieu of ownership interests in the Partnerships, and certain other employees of the Company. These incentive compensation agreements required the Company to compensate such shareholders and employees based on the Company achieving specified monthly sales volumes and certain levels of monthly growth in the number of new Associates. Pursuant to these agreements, during 1995, 1996 and 1997, the Company paid Mr. Fioretti approximately \$21,196, \$96,522 and \$93,753, respectively, and, during 1995, 1996 and 1997, the Company paid Mr. Robbins approximately \$144,985, \$510,996 and \$466,603, respectively. In May and June 1997, the Company terminated the incentive compensation agreements and issued 227,662 shares of Common Stock to Mr. Fioretti, 607,333 shares of Common Stock to Mr. Robbins and an aggregate of 1,192,576 shares of Common Stock to the other employees in exchange for the termination of their incentive compensation agreements. In March 1998, the Company terminated the remaining incentive compensation agreement and issued 74,167 shares of Common Stock to an employee in exchange for the termination of such agreement.

LOANS TO OFFICERS

Pursuant to an oral agreement to advance certain officers monies for the payment of taxes due in connection with the cancellation of their incentive compensation agreements, on December 31, 1997, the Company made loans of \$162,052 to Dr. Bill H. McAnalley, Vice President of Research and Product Development of the Company, and of \$121,782 to Peter E. Hammer, Vice President of New Business and International Development of the Company. The loans bear no interest and are due upon the earlier of December 31, 1998 or the date of a public offering of the Common Stock, whichever is first to occur. The loans are secured by shares of Common Stock owned by the shareholders and stock powers have been executed allowing the Company to transfer such shares in the event the loans are not repaid.

TRANSACTIONS WITH MULTI-VENTURE PARTNERS, LIMITED

In July 1997, in exchange for \$10.00 and the agreement of Mr. Chris T. Sullivan to serve on the Board of Directors, the Company issued Multi-Venture Partners, Limited, an investment partnership formed by Mr. Sullivan and two other partners ("Multi-Venture"), an option to purchase 100,000 shares of Common Stock at an exercise price of \$2.00 per share. In addition, in July 1997, Messrs. Charles E. Fioretti, Samuel L. Caster and William C. Fioretti sold an aggregate of 399,000 shares of Common Stock to Multi-Venture for an aggregate consideration of \$798,000 (\$2.00 per share).

CION, LTD. AGREEMENT

In October 1995, certain shareholders of the Company, including Charles E. Fioretti, William C. Fioretti, Samuel L. Caster, Patrick D. Cobb and Gary L. Watson, formed Cion, Ltd. ("Cion"). The Company transferred to Cion its exclusive international rights to market, sell, manufacture and distribute the Company's products, excluding the United States, Canada and Mexico. The rights conferred to Cion under the agreement also included the right to relicense the rights conferred in various international territories. In return, Cion was to pay the Company royalties based on future sales plus a 1% ownership of Cion. During 1995, Cion did not record any sales and in late 1995, Cion ceased operations. In May 1996, Cion transferred all of its rights and agreements to Mannatech, Ltd., an Isle of Man corporation, 99% owned by certain employees and shareholders of the Company and 1% owned by the Company. On January 1, 1997, Mannatech, Ltd. ceased operations and transferred all of its exclusive international rights to market, sell, manufacture and distribute the Company's products back to the Company, exclusive of certain licenses covering a number of Far Eastern countries which were granted by Cion.

LOANS TO AGRITECH LABS, INC.

During 1996 and 1997, the Company made advances to Agritech Labs, Inc. and Agritech Technology, Ltd. (together "Agritech") in the aggregate amount of approximately \$918,000. Over 90% of the capital stock of Agritech is owned by William C. Fioretti, Charles E. Fioretti, Samuel L. Caster and Patrick D. Cobb. On August 31, 1997, due to concerns about the ability of Agritech to repay the loans, each of Messrs. William C. Fioretti, Charles E. Fioretti, Samuel L. Caster and Patrick D. Cobb and another shareholder of both Agritech and the Company assumed the obligations of Agritech owed to the Company and issued individual promissory notes to the Company representing the aggregate amount of approximately \$918,000. Each of the promissory notes bears interest at six percent per annum and is payable on the earlier of December 31, 1998 or the date that the maker sells Common Stock in an initial public offering of the Company's securities. The principal amount outstanding under the notes issued by each of Messrs. William C. Fioretti, Charles E. Fioretti and Samuel L. Caster is approximately \$275,400 and the principal amount outstanding under the note made by Mr. Patrick D. Cobb is approximately \$45,900. Each of Messrs. William C. Fioretti, Charles E. Fioretti, Samuel L. Caster and Patrick D. Cobb will repay to the Company all amounts owing under their respective notes with proceeds received by them in this offering as Selling Shareholders.

CONSULTANT'S FEES

On October 20, 1998, the Company paid William C. Fioretti \$250,000 for consulting services rendered to the Company with respect to sports marketing and product development issues. Mr. Fioretti is a founder of the Company, a significant shareholder and the cousin of the Chairman of the Board and Chief Executive Officer, Charles E. Fioretti.

PRINCIPAL AND SELLING SHAREHOLDERS

The following table sets forth as of September 30, 1998, and as adjusted to reflect the sale by the Company of, respectively, 1,500,000 shares and 2,200,000 shares of Common Stock in this offering, the number of shares of Common Stock and the percentage of the outstanding shares of such class that are beneficially owned by (i) each person who is the beneficial owner of more than 5% of the outstanding shares of Common Stock, (ii) each of the directors and the Named Executive Officers of the Company, (iii) each Selling Shareholder and (iv) all of the current directors and executive officers of the Company as a group.

NAME AND ADDRESS	SHARES BENEFICIALLY OWNED			SHARES BENEFICIALLY OWNED AFTER OFFERING(1)(2)		NUMBER OF SHARES OFFERED(3)	SHARES BENEFICIALLY OWNED AFTER OFFERING(1)(3)
	PRIOR TO OFFERING(1)		NUMBER OF SHARES OFFERED(2)	NUMBER	PERCENT		
	NUMBER	PERCENT					
Samuel L. Caster c/o Mannatech, Incorporated 600 S. Royal Lane, Suite 200 Coppell, Texas 75019	5,886,946	26.6%	105,980	5,780,966	24.5%	360,000	5,526,946
William C. Fioretti(4) c/o Agritech Labs, Inc. 6333 N. St. Highway 161, Suite 350 Irving, Texas 75063	5,896,946	26.7	300,620	5,596,326	23.7	760,000(6)	5,136,946
Charles E. Fioretti c/o Mannatech, Incorporated 600 S. Royal Lane, Suite 200 Coppell, Texas 75019	5,584,946	25.3	105,980	5,478,966	23.2	360,000	5,224,946
Chris T. Sullivan(7).....	399,000	1.8	38,928	360,072	1.5	105,000	294,000
Patrick D. Cobb(8).....	376,456	1.7	48,660	327,796	1.4	150,000	226,456
H. Reginald McDaniel.....	546,600	2.5	37,031	509,569	2.2	55,000	491,600
Christopher A. Marlett(9).....	475,015	2.1	17,031	457,984	1.9	475,015	0
Dick Hankins, Jr.....	458,956	2.1	97,320	361,636	1.5	300,000	158,956
Don Herndon.....	458,956	2.1	29,196	429,760	1.8	60,000	398,956
Gary Watson.....	366,456	1.7	48,660	317,796	1.3	200,000	166,456
Phillip P. Brous.....	350,000	1.5	100,000	250,000	1.1	100,000	250,000
Bill H. McAnalley(10).....	298,667	1.3	29,196	269,471	1.1	60,000	238,667
Peter E. Hammer.....	228,206	1.0	19,500	208,706	*	65,000	163,206
Kim Snyder.....	114,103	*	12,165	101,938	*	25,000	89,103
Kathy Schiffer.....	30,000	*	9,733	20,267	*	20,000	10,000
All executive officers and directors as a group (12 persons).....	12,774,221	57.7	348,244	12,425,977	52.6	2,135,000	10,639,221

NAME AND ADDRESS	PERCENT
Samuel L. Caster c/o Mannatech, Incorporated 600 S. Royal Lane, Suite 200 Coppell, Texas 75019	22.3%
William C. Fioretti(4) c/o Agritech Labs, Inc. 6333 N. St. Highway 161, Suite 350 Irving, Texas 75063	20.7
Charles E. Fioretti c/o Mannatech, Incorporated 600 S. Royal Lane, Suite 200 Coppell, Texas 75019	21.1
Chris T. Sullivan(7).....	1.2
Patrick D. Cobb(8).....	*
H. Reginald McDaniel.....	1.2
Christopher A. Marlett(9).....	*
Dick Hankins, Jr.....	*
Don Herndon.....	1.6
Gary Watson.....	*
Phillip P. Brous.....	1.0
Bill H. McAnalley(10).....	*
Peter E. Hammer.....	*
Kim Snyder.....	*

Kathy Schiffer.....	*
All executive officers and directors as a group (12 persons).....	42.9

- -----

* Less than 1%.

- (1) The information contained in this table with respect to beneficial ownership reflects "beneficial ownership" as defined in Rule 13d-3 under the Exchange Act. All information with respect to the beneficial ownership of any shareholder has been furnished by such shareholder and, except as otherwise indicated or pursuant to community property laws, each shareholder has sole voting and investment power with respect to shares listed as beneficially owned by such shareholder. Pursuant to the rules of the Commission, in calculating percentage ownership, each person is deemed to beneficially own shares subject to options or warrants exercisable within 60 days of the date of this Prospectus, but shares subject to options or warrants owned by others (even if exercisable within 60 days) are deemed not to be outstanding.
- (2) Reflects the sale of an aggregate of 1,000,000 shares of Common Stock by certain Selling Shareholders, including 17,031 Exercised Warrant Shares.
- (3) Reflects the sale of an aggregate of 3,095,015 shares of Common Stock by certain Selling Shareholders, including 475,015 Exercised Warrant Shares.
- (4) Includes 1,590,949 shares of Common Stock held by the Fioretti Family Partnership, Ltd. of which William C. Fioretti is the general partner and he, his wife and trusts for the benefit of their children are the limited partners.

- (5) Of the 300,620 shares offered by William C. Fioretti, 200,413 are held of record by William C. Fioretti and 100,207 are held of record by the Fioretti Family Partnership, Ltd.
- (6) Of the 760,000 shares offered by William C. Fioretti, 506,667 are held of record by William C. Fioretti and 253,333 are held of record by the Fioretti Family Partnership, Ltd.
- (7) All of these shares of Common Stock are held by Multi-Venture. The management of Multi-Venture is controlled by its sole general partner, SBG Investments, L.L.C. ("SBG"), which owns a .6% general partnership interest in Multi-Venture. Mr. Sullivan owns a 27.2% interest in SBG. Mr. Sullivan shares voting and dispositive power with respect to Common Stock owned by Multi-Venture.
- (8) Includes 60,000 shares of Common Stock held by Joni J. Cobb, Mr. Cobb's spouse, and 10,000 shares held by trusts established for the benefit of Mr. Cobb's children and stepchildren.
- (9) Includes 475,015 shares of Common Stock subject to the Warrant, all of which are currently exercisable, and up to 475,015 of which may be exercised and sold in this offering.
- (10) Includes 15,000 shares of Common Stock held by Dr. McAnalley's children.

DESCRIPTION OF CAPITAL STOCK

GENERAL

As of the date of this Prospectus, the authorized capital stock of the Company consists of 99,000,000 shares of Common Stock, par value \$0.0001 per share, and 1,000,000 shares of Preferred Stock, par value \$0.01 per share (the "Preferred Stock"). Prior to this offering there were 22,101,738 shares of Common Stock outstanding, held by 36 holders of record. Following this offering, a minimum of 23,618,769 shares and a maximum of 24,776,753 shares of Common Stock will be issued and outstanding. No shares of Preferred Stock are outstanding. The following description is a summary and is subject to and qualified in its entirety by reference to the provisions of the Articles and the Bylaws, each of which is filed as an exhibit to the Registration Statement of which this Prospectus forms a part.

COMMON STOCK

The holders of Common Stock are entitled to one vote for each share on all matters voted upon by shareholders, including the election of directors, and do not have cumulative voting rights. The holders of the Common Stock are entitled to such dividends as may be declared at the discretion of the Board of Directors out of funds legally available therefor. See "Dividend Policy." Holders of Common Stock are entitled to share ratably in the net assets of the Company upon liquidation after payment or provision for all liabilities. The holders of Common Stock have no preemptive rights to purchase shares of stock in the Company. Shares of Common Stock are not subject to any redemption provisions and are not convertible into any other securities of the Company. All outstanding shares of Common Stock are, and the shares of Common Stock to be issued by the Company pursuant to this offering will be, upon payment therefor, fully paid and nonassessable.

PREFERRED STOCK

The Board of Directors may from time to time authorize the issuance of one or more classes or series of Preferred Stock without shareholder approval. Subject to the provisions of the Articles and limitations prescribed by law, the Board of Directors is authorized to change the number of shares constituting any series and fix and determine the designation and preferences, limitations and relative rights, including voting rights, of the shares of any series of Preferred Stock so established, in each case without any action or vote by the shareholders. The Company has no current plans to issue any shares of Preferred Stock of any class or series.

One of the effects of undesignated Preferred Stock may be to enable the Board of Directors to discourage an attempt to obtain control of the Company by means of a tender offer, proxy contest, merger or otherwise, and thereby protect the Company's management. The issuance of Preferred Stock pursuant to the Board of Directors' authority described above may adversely affect the rights of the holders of Common Stock. For example, Preferred Stock issued by the Company may rank senior to the Common Stock as to dividend rights, liquidation preference or both, may have full or limited voting rights and may be convertible into shares of Common Stock. Accordingly, the issuance of shares of Preferred Stock may discourage bids for the Common Stock or may otherwise adversely affect the trading price of the Common Stock.

WARRANT SHARES

On May 1, 1997, pursuant to an agreement with a consultant, the Company issued a warrant (the "Warrant") exercisable for 475,015 shares of Common Stock (the "Warrant Shares") at an exercise price of \$1.35 per share. The exercise price and the number of shares issuable upon exercise of the Warrant are subject to adjustment upon the occurrence of certain events, including (i) the issuance of Common Stock as a dividend on shares of Common Stock, (ii) subdivisions or combinations of the Common Stock, (iii) the issuance of rights or warrants to purchase the Common Stock for less than the market price or

(iv) the distribution of evidences of indebtedness or assets to the holder of Common Stock or similar events. A holder of the Warrant is not entitled to any voting, dividend or other rights as a shareholder of the Company. The Warrant expires upon the earlier to occur of May 1, 2003 or 36 months after the registration of the Warrant Shares.

Holders of Warrant Shares are entitled to certain registration rights for such Warrant Shares, including piggyback and demand registration rights. If the Company proposes to register securities under the Securities Act, the holders of Warrant Shares may require the Company, subject to certain volume and other limitations, to include all or any portion of such Warrant Shares in such registration at the Company's expense. Pursuant to such registration rights, a minimum of 17,031 and a maximum of 475,015 shares are being offered hereby. In addition, on two occasions during the term of the Warrant, holders of a majority of the Warrant Shares (in the event any part of the Warrant is transferred) can require the Company to file a registration statement under the Securities Act covering all or any part of the Warrant Shares. The expense of the registration will be paid by the Company only with respect to the first demand registration.

CERTAIN EFFECTS OF AUTHORIZED BUT UNISSUED STOCK

Under the Articles, upon completion of this offering there will be a minimum of 74,223,247 shares and a maximum of 75,381,231 shares of Common Stock available for future issuance without shareholder approval, depending on the actual amount sold in this offering. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital or facilitate acquisitions. The Company does not currently have any plans to issue additional shares of Common Stock, other than shares of Common Stock that may be issued upon the exercise of options and Warrants that have been granted or may be granted in the future.

SPECIAL PROVISIONS OF THE ARTICLES, THE BYLAWS AND TEXAS LAW

The Texas Miscellaneous Corporation Laws Act (the "Texas Miscellaneous Laws") authorizes corporations to limit or eliminate the personal liability of directors to corporations and their shareholders for monetary damages for breach of their fiduciary duty as directors except for liability of a director resulting from (i) a breach of such director's duty of loyalty to the corporation or its shareholders, (ii) an act or omission that is not in good faith or that involves intentional misconduct or a knowing violation of laws, (iii) a transaction from which the director received an improper personal benefit or (iv) an act or omission for which the liability of the director is expressly provided by an applicable statute. The Articles limit the liability of directors of the Company (in their capacity as directors but not in their capacity as officers) to the Company or its shareholders to the fullest extent permitted by any applicable law. The inclusion of this provision in the Articles may reduce the likelihood of derivative litigation against directors and may discourage or deter shareholders from suing directors for breach of their duty of care, even though such an action, if successful, might otherwise benefit the Company and its shareholders. The inclusion of such provisions in the Articles together with a provision in the Bylaws requiring the Company to indemnify its directors, officers and certain other individuals against certain liabilities, is intended to enable the Company to attract qualified persons to serve as directors who might otherwise be reluctant to do so. The Commission has taken the position that personal liability of directors for violations of the federal securities laws cannot be limited and that indemnification by the issuer for such violations is unenforceable.

The Company has entered into separate indemnification agreements with each of its directors that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors to the maximum extent permitted under the TBCA and advance their expenses incurred as a result of any proceeding against them for which they could be indemnified, obtain directors' and officers' insurance or maintain self-insurance in lieu thereof.

Under the TBCA, the board of directors of a corporation has the power to amend and repeal the corporation's bylaws unless the corporation's articles of incorporation reserve the power exclusively to the shareholders or a particular bylaw expressly provides that the board of directors may not amend or repeal the bylaw. The Bylaws give the Board of Directors the power to alter, amend or repeal the Bylaws or adopt new bylaws. The Bylaws also provide that the number of directors shall be fixed from time to time by resolution of the Board of Directors. These provisions, in addition to the existence of authorized but unissued capital stock, may have the effect, either alone or in combination with each other, of discouraging an acquisition of the Company deemed undesirable by the Board of Directors.

ANTI-TAKEOVER CONSIDERATIONS

ANTI-TAKEOVER STATUTE. On September 1, 1997, the Company became subject to newly enacted Part 13 of the TBCA ("Part 13"), which subject to certain exceptions, prohibits a Texas corporation from engaging in any "business combination" with an "affiliated shareholder" for three years following the date that such shareholder became an affiliated shareholder, unless: (i) prior to such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the shareholder becoming an affiliated shareholder; or (ii) the business combination is authorized at a meeting of shareholders called not less than six months after such date by the affirmative vote of at least two-thirds of the outstanding voting shares not owned by the affiliated shareholder.

Part 13 generally defines a "business combination" to include (i) any merger, share exchange or conversion involving the corporation and the affiliated shareholder, (ii) any sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more of the assets of the corporation to the affiliated shareholder, (iii) subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the affiliated shareholder, (iv) any transaction involving the corporation that has the effect of increasing the proportionate ownership percentage of the stock of any class or series of the corporation beneficially owned by the affiliated shareholder, (v) any receipt by the affiliated shareholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation or (vi) any adoption of a plan or proposal for the liquidation or dissolution of the corporation proposed by, or pursuant to any agreement or understanding with, an affiliated shareholder. In general, Part 13 defines an "affiliated shareholder" as any entity or person beneficially owning 20% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person. The provisions of Part 13 could have the effect of delaying, deferring or preventing a change of control of the Company even if a change of control were in the shareholders' interests.

CLASSIFIED BOARD OF DIRECTORS. The Bylaws provide for the Board of Directors to be divided into three classes serving staggered three-year terms. The term of office of the first class of directors will expire at the 1999 annual meeting of shareholders, the term of office of the second class will expire at the 2000 annual meeting of shareholders and the term of office of the third class will expire at the 2001 annual meeting of shareholders. The terms of office of the current directors of the Company are set forth herein under "Management-Executive Officers and Directors."

At each annual meeting of shareholders, the class of directors to be elected at such meeting will be elected for a three-year term, and the directors in the other two classes will continue in office. The staggered terms for directors may affect the shareholders' ability to change control of the Company even if a change of control were in the shareholders' interests.

SHAREHOLDER ACTION. As permitted by the TBCA, the Articles provide that any action which is required to be, or may be, taken at any annual or special meeting of the shareholders, may be taken without a meeting, without prior notice, and without a vote, if a consent or consents in writing is signed by the holder or holders of shares having not less than the minimum number of votes that would be necessary to take such action at a meeting at which the holders of all shares entitled to vote on the action

were present and voted. This provision could cause shareholders to approve proposals in a more expeditious manner, which at times could be detrimental to the minority shareholders.

TRANSFER AGENT AND REGISTRAR

The transfer agent and registrar for the Common Stock is First Chicago Trust Company of New York.

SHARES ELIGIBLE FOR FUTURE SALE

Prior to this offering, there has been no market for the Common Stock of the Company. Future sales of substantial amounts of Common Stock in the public market, or the perception that such sales might occur, could adversely affect the market price of the Common Stock and could impair the ability of the Company to raise equity capital in the future.

Upon completion of this offering, the Company will have a minimum of 23,618,769 shares and a maximum of 24,776,753 shares of Common Stock outstanding. All of the shares offered hereby will be freely tradeable without restriction or further registration under the Securities Act, unless purchased by an "affiliate" of the Company, as that term is defined in Rule 144, as described below.

SALES OF RESTRICTED SHARES

The shares of Common Stock which are not being sold in this offering are "restricted securities" within the meaning of Rule 144. Depending on whether the minimum or maximum number of shares of Common Stock offered hereby are sold, there will be, respectively, 22,118,769 or 19,481,738 Restricted Shares outstanding upon the completion of this offering. Of such Restricted Shares, 20,999,602 shares or 19,362,571 shares, respectively, will be eligible for sale in the public market after the date of this Prospectus, all under and subject to the restrictions contained in Rule 144.

In general, under Rule 144, a person (or persons whose shares are required under Rule 144 to be aggregated), including an "affiliate" of the Company, as that term is defined under the Securities Act and the regulations promulgated thereunder (an "Affiliate"), who has beneficially owned Restricted Shares for at least one year is entitled to sell, within any three-month period, a number of such shares that does not exceed the greater of (i) one percent of the then outstanding shares of Common Stock (approximately 236,188 shares or 247,767 shares, respectively, immediately after this offering) or (ii) the average weekly trading volume in the Common Stock during the four calendar weeks preceding the date on which notice of such sale is filed, provided certain requirements concerning availability of public information, manner of sale and notice of sale are satisfied. In addition, Affiliates must comply with the restrictions and requirements of Rule 144, other than the one-year holding period requirement, in order to sell shares of Common Stock which are not restricted securities. Under Rule 144(k), a person who is not an Affiliate and has not been an Affiliate for at least three months prior to the sale and who has beneficially owned Restricted Shares for at least two years may resell such shares without compliance with the foregoing requirements. In meeting the one- and two-year holding periods described above, a holder of Restricted Shares can include the holding periods of a prior owner who was not an Affiliate. The one- and two-year holding periods described above do not begin to run until the full purchase price or other consideration is paid by the person acquiring the Restricted Shares from the issuer or an Affiliate.

LOCK-UP ARRANGEMENT

Prior to the completion of this offering, the Company intends to enter into the Lock-up Agreements with each of its shareholders and option holders, with the exception of the holder of the Exercised Warrant Shares. Under the Lock-up Agreements, such shareholders will agree, subject to certain exceptions, not to offer, sell, contract to sell or otherwise dispose of any shares of Common Stock until the Lock-up Expiration Date. Upon the expiration of the Lock-up Agreements, those shares subject to Lock-up Agreements will not, absent registration, be freely tradeable, but will become eligible for sale under Rule 144 on various dates in the future.

OPTIONS

Rule 701 also provides that the shares of Common Stock acquired upon the exercise of currently outstanding options issued under the Company's stock plans may be resold by persons, other than Affiliates, beginning 90 days after the effective date of this Prospectus, subject only to the manner of sale

provisions of Rule 144, and by Affiliates under Rule 144, without compliance with its one-year minimum holding period, subject to certain limitations. As of September 30, 1998, 2,000,000 shares of Common Stock were subject to options issued under the Company's 1997 Stock Option Plan 1,600,000 of which will become exercisable 90 days after the completion of this offering and 400,000 of which will become vested and exercisable on July 31, 1999, assuming completion of this offering. No shares remained available for future grants under the 1997 Stock Option Plan. Under the Company's 1998 Stock Option Plan, as of September 30, 1998, options to purchase 243,000 shares of Common Stock were outstanding, of which 228,000 will become vested and exercisable on July 31, 1999, assuming the completion of this offering, and 15,000 of which will become vested and exercisable ratably over a three year period. Options to purchase an additional 757,000 shares of Common Stock may be granted under the 1998 Stock Option Plan. In addition, the Non-Plan Option to acquire 100,000 shares of Common Stock is outstanding, but was not exercisable as of the date of this Prospectus. As soon as practicable following this offering, the Company intends to file a registration statement under the Securities Act to register shares of Common Stock issuable or previously issued upon the exercise of stock options granted under the Company's stock option plans. Shares issued upon the exercise of stock options after the effective date of this Prospectus or previously issued on exercise generally will be available for sale in the open market.

REGISTRATION RIGHTS

The Company has also issued the Warrant to purchase 475,015 shares of Common Stock, which is currently fully exercisable, a minimum of 17,031 and a maximum of 475,015 shares of which may be exercised and sold in this offering. The holder of the Warrant has certain registration rights with respect to such shares of Common Stock. See "Description of Capital Stock-Warrant Shares."

PLAN OF DISTRIBUTION

GENERAL

The Company and the Selling Shareholders are offering to sell up to 5,295,015 shares of the Company's Common Stock. The Common Stock will be offered by the Company and the Selling Shareholders on a "best efforts" basis. Of the minimum of 2,500,000 shares, 1,500,000 are being offered by the Company and 1,000,000 are being offered by the Selling Shareholders. The next 1,055,000 shares to be sold are being offered by certain of the Selling Shareholders. Sales of an amount of shares in excess of 3,555,000 up to 4,955,000 will be divided equally between the Company and the Selling Shareholders and sales in excess of 4,955,000 up to the maximum of 5,295,015 will be made by the Selling Shareholders. If the Company is unable to sell at least 2,500,000 shares of the Common Stock offered hereby, the Company will cancel this offering and return all monies collected from subscribers and held in escrow without interest or deduction. None of the employees, officers or directors of the Company will receive any compensation in connection with any offers or sales of Common Stock in this offering. The Company has retained the Placement Agent to assist the Company in certain aspects of the offering. There are no underwriters involved in this offering. The Company will pay the Placement Agent a fee of 4.0% of the gross offering proceeds. The Company and the Placement Agent have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act of 1933.

The Common Stock will be sold at the price of \$8.00 per share. The minimum number of shares a subscriber is required to purchase in order to subscribe to the offering hereby will be 100 shares. The Company reserves the right to withdraw, cancel or modify the offering hereby and to reject subscriptions, in whole or in part, for any reason.

DETERMINATION OF OFFERING PRICE

Prior to the offering hereby, there has been no public market for the Common Stock. The offering price has been arbitrarily determined by the Company and may not be indicative of the market price for the Common Stock after this offering. In determining the offering price, the Board of Directors considered, among other things, the Company's earnings, its view of the Company's prospects, the earnings of comparable publicly traded nutritional supplement companies and the trading price of the stock of those companies. The Company makes no representations as to any objectively determinable value of the Common Stock.

SUBSCRIPTION PROCEDURES

After the Registration Statement has been declared effective, the Company will provide to each prospective investor a copy of the final Prospectus relating to this offering which includes an agreement to purchase shares of the Common Stock (the "Subscription Agreement"). Completed Subscription Agreements, together with the appropriate payment for the Common Stock, must be mailed to the Placement Agent. See "Summary-How to Purchase Shares." The Company's acceptance of a subscription shall be evidenced solely by the delivery to the subscriber of a written confirmation of sale. Receipt by the Placement Agent of a Subscription Agreement and/or deposit with the Escrow Agent or the Placement Agent of payment for the subscribed shares as described below shall not constitute acceptance of a subscription. All subscription payments and executed Subscription Agreements will be delivered to Bank One, Kentucky, NA. Until the Initial Closing, the subscription payments will be deposited into an escrow account established with the Escrow Agent, subject to the Initial Closing on such escrowed funds once the Company has accepted subscriptions for at least 2,500,000 shares and certain additional conditions have been satisfied. After the Initial Closing, if all shares of Common Stock offered hereby are not sold as of the date of the Initial Closing, subscription proceeds shall be deposited by the Placement Agent in a segregated account, subject to subsequent closings on additional subscriptions received from time to

time as determined by the Company. The Company, through the Placement Agent, will process and consider for acceptance all qualified subscriptions in the order received.

Stock certificates will not be issued to subscribers until such time as good funds related to the purchase of Common Stock by such subscribers are released from the escrow account to the Company or the Selling Shareholders by the Escrow Agent with respect to the Initial Closing, or from the segregated subscription account to the Company or the Selling Shareholders, with respect to subsequent closings. Until such time as stock certificates are issued to the subscribers, the subscribers will not be considered shareholders of the Company.

Subscribers will have no right to a return of their subscription payment held in the escrow account or the segregated subscription account until the Company decides not to accept such subscription payment; all interest earned on such funds will belong to the Company.

TERMINATION OF OFFERING

This offering will commence on the date of this Prospectus and will continue until the earlier of (i) the date upon which the proceeds for all 5,295,015 shares of Common Stock offered hereby are received by the Escrow Agent or Placement Agent; (ii) January 15, 1999 (subject to the right of the Company to extend the offering to February 12, 1999); or (iii) the date upon which the Company terminates this offering for any reason other than the sale of at least 2,500,000 shares of Common Stock. The Company has the right to terminate the offering and purchase the shares held in escrow at any time after the Escrow Agent has received the subscription proceeds for 2,500,000 shares. The Company may terminate this offering at any time until all 5,295,015 shares of Common Stock offered hereby have been sold. If the Company terminates this offering before the subscription proceeds for 2,500,000 shares have been received by the Escrow Agent, all subscription proceeds will be promptly returned to subscribers without interest or deduction.

LOCK-UP ARRANGEMENT

Prior to the completion of this offering, the Company intends to enter into the Lock-up Agreements with each of its shareholders and option holders, with the exception of the holder of the Exercised Warrant Shares. Under the Lock-up Agreements, such shareholders will agree, subject to certain exceptions, not to offer, sell, contract to sell or otherwise dispose of any shares of Common Stock until the Lock-up Expiration Date. Upon the expiration of the Lock-up Agreements, those shares subject to Lock-up Agreements will not, absent registration, be freely tradeable, but will become eligible for sale under Rule 144 on various dates in the future.

LEGAL MATTERS

The validity of the issuance of the shares of Common Stock offered hereby will be passed upon for the Company by Akin, Gump, Strauss, Hauer & Feld, L.L.P., Dallas, Texas.

EXPERTS

The financial statements of the Company as of December 31, 1997, and for the year ended December 31, 1997 included in this Prospectus have been so included in reliance on the report of PricewaterhouseCoopers LLP, independent accountants, given on the authority of said firm as experts in auditing and accounting.

The financial statements of the Company as of December 31, 1995 and 1996, and for each of the two years in the period ended December 31, 1996, included in this Prospectus have been so included in reliance on the report of Belew Averitt LLP ("Belew Averitt"), independent accountants, given on the authority of said firm as experts in accounting and auditing.

In November 1997, the Company advised Belew Averitt that it would no longer retain the firm as independent accountants. The reports of Belew Averitt on the Company did not contain an adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles. The decision to change accountants was precipitated by the Company's plan to complete an initial public offering in 1998 and was approved by the Board of Directors in November 1997. During the periods audited by Belew Averitt and through November 1997 there were no disagreements with Belew Averitt on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreement(s) if not resolved to the satisfaction of Belew Averitt, would have caused it to make reference to the subject matter of the disagreements in connection with its reports. PricewaterhouseCoopers was engaged by the Company as its independent accountants in November 1997.

ADDITIONAL INFORMATION

The Company has filed with the Commission a Registration Statement (which term shall include any amendments thereto) on Form S-1 under the Securities Act with respect to the Common Stock offered hereby. This Prospectus, which constitutes a part of the Registration Statement, does not contain all of the information set forth in the Registration Statement, certain portions of which have been omitted as permitted by the rules and regulations of the Commission. Statements contained in this Prospectus as to the contents of any contract or other document are not necessarily complete, and in each instance reference is made to the copy of such contract or other document filed as an exhibit to the Registration Statement, each statement being qualified in all respects by such reference. For further information with respect to the Company and the Common Stock, reference is made to the Registration Statement, including the exhibits and schedules thereto, copies of which may be examined without charge at the Commission's principal office at 450 Fifth Street, N.W., Washington, D.C. 20549 and the regional offices of the Commission located at 7 World Trade Center, 13th Floor, New York, New York 10048 and Citicorp Center, 500 West Madison Street, 14th Floor, Chicago, Illinois 60661-2511. Copies of such materials may be obtained from the Public Reference Section of the Commission, Judiciary Plaza, 450 Fifth Street, N.W., Washington, D.C. 20549 and at its public reference facilities in New York, New York, and Chicago, Illinois, at prescribed rates. The Commission also maintains a World Wide Web site that contains reports, proxy and information statements and other information regarding registrants (which, after this offering, will include the Company) that file electronically with the Commission (at <http://www.sec.gov>).

Immediately following this offering, the Company will become subject to the periodic reporting and other informational requirements of the Exchange Act. As long as the Company is subject to such periodic reporting and information requirements, it will file with the Commission all reports, proxy statements, and other information required thereby. The Company intends to furnish holders of the Common Stock with annual reports containing financial statements audited by an independent certified public accounting firm and may furnish to shareholders quarterly reports containing unaudited financial information for the first three quarters of each fiscal year.

MANNATECH, INCORPORATED
INDEX TO FINANCIAL STATEMENTS

Annual Financial Statements:	
Report of Independent Accountants.....	F-2
Independent Auditor's Report.....	F-3
Balance Sheets as of December 31, 1996 and 1997 and September 30, 1998.....	F-4
Statements of Income for the Years ended December 31, 1995, 1996 and 1997 and the nine months ended September 30, 1997 and 1998.....	F-5
Statements of Changes in Shareholders' Equity (Deficit) for the Years ended December 31, 1995, 1996 and 1997 and the nine months ended September 30, 1998...	F-6
Statements of Cash Flows for the Years ended December 31, 1995, 1996 and 1997 and the nine months ended September 30, 1997 and 1998.....	F-7
Notes to Financial Statements.....	F-8

REPORT OF INDEPENDENT ACCOUNTANTS

To Board of Directors and Shareholders of
Mannatech, Incorporated

In our opinion, the accompanying balance sheet and the related statements of income, of changes in shareholders' equity (deficit) and of cash flows present fairly, in all material respects, the financial position of Mannatech, Incorporated at December 31, 1997, and the results of its operations and its cash flows for the year in conformity with generally accepted accounting principles. These financial statements are the responsibility of the Company's management; our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit of these statements in accordance with generally accepted auditing standards which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for the opinion expressed above.

PRICEWATERHOUSECOOPERS LLP

Dallas, Texas
March 26, 1998

INDEPENDENT AUDITOR'S REPORT

Shareholders and Board of Directors
of Mannatech, Incorporated

We have audited the accompanying balance sheet of Mannatech, Incorporated as of December 31, 1996, and the related statements of income, of changes in shareholders' equity (deficit) and of cash flows for each of the years in the two-year period ended December 31, 1996. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Mannatech, Incorporated as of December 31, 1996, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 1996, in conformity with generally accepted accounting principles.

BELEW AVERITT LLP

Dallas, Texas
August 21, 1997

MANNATECH, INCORPORATED

BALANCE SHEETS

DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998

	DECEMBER 31,		SEPTEMBER 30, 1998 (UNAUDITED)
	1996	1997	
ASSETS			
Cash and cash equivalents.....	\$ 1,159,937	\$ 61,148	\$ 1,373,343
Restricted cash.....	-	199,619	-
Accounts receivable, less allowance for doubtful accounts of \$194,000 in 1997.....	26,991	549,904	353,070
Receivable from related parties.....	502,417	148,888	131,103
Notes receivable from shareholders.....	-	934,929	993,788
Refundable income taxes.....	741,000	-	-
Inventories.....	4,947,337	5,323,056	6,630,208
Prepaid expenses and other current assets.....	166,471	542,978	1,123,695
Deferred tax assets.....	349,651	399,368	321,068
Total current assets.....	7,893,804	8,159,890	10,926,275
Property and equipment, net.....	3,049,572	10,583,910	13,809,558
Other assets.....	466,603	470,952	431,007
Deferred offering costs.....	-	343,672	1,444,393
Total assets.....	\$ 11,409,979	\$ 19,558,424	\$ 26,611,233
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current portion of capital lease obligations.....	\$ -	\$ 249,655	\$ 597,290
Current portion of note payable.....	26,400	-	172,426
Accounts payable.....	2,540,116	4,287,159	4,443,852
Accrued expenses.....	7,270,164	11,540,577	17,042,097
Dividends payable.....	100,000	1,321,654	-
Accounts payable to related parties.....	537,472	-	-
Total current liabilities.....	10,474,152	17,399,045	22,255,665
Capital lease obligations and notes payable, excluding current portion.....	-	110,482	1,204,939
Deferred tax liabilities.....	105,000	505,000	912,700
Total liabilities.....	10,579,152	18,014,527	24,373,304
Commitments and contingencies (note 11).....	-	-	-
Redeemable warrants.....	-	300,000	300,000
Shareholders' equity			
Preferred stock, \$.01 par value, 1,000,000 shares authorized, no shares issued and outstanding, respectively.....	-	-	-
Common stock, \$.0001 par value, 99,000,000 shares authorized, 20,626,971 and 22,101,738 shares issued and outstanding, respectively.....	2,063	2,210	2,210
Additional paid-in capital.....	-	2,632,238	2,632,238
Notes receivable from shareholders.....	-	(636,418)	(636,418)
Retained earnings (deficit).....	828,764	(754,133)	(60,101)
Total shareholders' equity.....	830,827	1,243,897	1,937,929
Total liabilities and shareholders' equity.....	\$ 11,409,979	\$ 19,558,424	\$ 26,611,233

See accompanying notes to financial statements.

MANNATECH, INCORPORATED

STATEMENTS OF INCOME

FOR THE YEARS ENDED DECEMBER 31, 1995, 1996 AND 1997
AND THE NINE MONTHS ENDED SEPTEMBER 30, 1997 AND 1998

	DECEMBER 31,			SEPTEMBER 30,	
	1995	1996	1997	1997	1998
	(UNAUDITED)				
Net sales.....	\$32,070,758	\$86,311,972	\$ 150,569,843	\$ 111,101,921	\$ 122,852,871
Cost of sales.....	4,880,331	13,406,303	24,735,616	17,865,973	20,580,911
Commissions.....	12,338,513	35,155,231	61,677,103	45,459,917	48,974,543
	17,218,844	48,561,534	86,412,719	63,325,890	69,555,454
Gross profit.....	14,851,914	37,750,438	64,157,124	47,776,031	53,297,417
Operating expenses:					
Selling and administrative expenses.....	7,012,199	17,764,415	27,845,502	19,939,329	22,621,662
Other operating costs.....	5,252,817	11,746,003	19,402,317	13,401,671	15,679,390
Cancellation of incentive compensation agreements.....	-	-	2,191,610	1,820,774	-
Write-off of deferred offering costs....	-	-	-	-	940,782
Total operating expenses.....	12,265,016	29,510,418	49,439,429	35,161,774	39,241,834
Income from operations.....	2,586,898	8,240,020	14,717,695	12,614,257	14,055,583
Other (income) expense, net.....	180,970	(116,009)	(43,170)	174,132	(3,625)
Income before income taxes.....	2,405,928	8,356,029	14,760,865	12,440,125	14,059,208
Income tax expense.....	67,013	1,193,640	4,138,822	3,507,663	5,413,000
Net income.....	\$ 2,338,915	\$ 7,162,389	\$ 10,622,043	\$ 8,932,462	\$ 8,646,208
Earnings per common share:					
Basic.....	\$.11	\$.35	\$.50	\$.42	\$.39
Diluted.....	\$.11	\$.35	\$.47	\$.41	\$.37
Unaudited pro forma data (note 1)					
Income before income taxes, as reported.....	2,405,928	8,356,029	14,760,865	12,440,125	
Pro forma provision for income taxes....	902,223	3,133,511	5,682,933	4,789,448	
Pro forma net income.....	\$ 1,503,705	\$ 5,222,518	\$ 9,077,932	\$ 7,650,677	
Pro forma earnings per common share:					
Basic.....	\$.07	\$.25	\$.42	\$.36	
Diluted.....	\$.07	\$.25	\$.41	\$.34	

See accompanying notes to financial statements.

MANNATECH, INCORPORATED

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)

FOR THE YEARS ENDED DECEMBER 31, 1995, 1996 AND 1997

AND THE NINE MONTHS ENDED SEPTEMBER 30, 1998

	COMMON STOCK		ADDITIONAL PAID-IN CAPITAL	NOTES RECEIVABLE FROM SHAREHOLDERS	RETAINED EARNINGS (DEFICIT)	TOTAL SHAREHOLDERS' EQUITY (DEFICIT)
	SHARES	PAR VALUE				
Balance at December 31, 1994.....	20,626,971	\$ 2,063	\$ -	-	\$ (352,784)	\$ (350,721)
Dividends declared (\$1.00 per share)(1).....	-	-	-	-	(10,000)	(10,000)
Net income.....	-	-	-	-	2,338,915	2,338,915
Distributions to partners.....	-	-	-	-	(2,369,631)	(2,369,631)
Balance at December 31, 1995.....	20,626,971	2,063	-	-	(393,500)	(391,437)
Dividends declared (\$10.00 per share)(1).....	-	-	-	-	(100,000)	(100,000)
Net income.....	-	-	-	-	7,162,389	7,162,389
Distributions to partners.....	-	-	-	-	(5,840,125)	(5,840,125)
Balance at December 31, 1996.....	20,626,971	2,063	-	-	828,764	830,827
Issuance of common stock to cancel incentive compensation agreements.....	1,474,767	147	2,191,463	-	-	2,191,610
Vesting of nonemployee stock options.....	-	-	155,503	-	-	155,503
Tax benefit of shares issued for merger of partnerships.....	-	-	285,272	-	-	285,272
Issuance of notes receivable to shareholders.....	-	-	-	(636,418)	-	(636,418)
Dividends declared (\$.37 per share).....	-	-	-	-	(8,150,201)	(8,150,201)
Net income.....	-	-	-	-	10,622,043	10,622,043
Distributions to partners.....	-	-	-	-	(4,054,739)	(4,054,739)
Balance at December 31, 1997.....	22,101,738	2,210	2,632,238	(636,418)	(754,133)	1,243,897
Dividends declared (\$.36 per share) (unaudited).....	-	-	-	-	(7,952,176)	(7,952,176)
Net income (unaudited).....	-	-	-	-	8,646,208	8,646,208
Balance at September 30, 1998 (unaudited).....	22,101,738	\$ 2,210	\$ 2,632,238	(636,418)	\$ (60,101)	\$ 1,937,929

(1) Dividends are based on the shares outstanding prior to the reorganization and the 1000-for-1 stock split (10,000 shares) as discussed in notes 1 and 12, respectively.

See accompanying notes to financial statements

MANNATECH, INCORPORATED

STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 1995, 1996 AND 1997
AND THE NINE MONTHS ENDED SEPTEMBER 30, 1997 AND 1998

	DECEMBER 31			SEPTEMBER 30	
	1995	1996	1997	1997	1998
	(UNAUDITED)				
Cash flows from operating activities:					
Net income.....	\$ 2,338,915	\$ 7,162,389	\$ 10,622,043	\$ 8,932,462	\$ 8,646,208
Adjustments to reconcile net income to net cash provided by operating activities:					
Depreciation and amortization.....	75,341	414,299	1,189,494	844,217	1,584,453
Loss (gain) on disposal of assets.....	46,523	3,876	411,202	130,201	68,430
Noncash charge for cancellation of incentive compensation agreements.....	-	-	2,191,610	1,264,295	-
Vesting of nonemployee stock options and warrants.....	-	-	455,503	355,503	-
Loss on settlement of contract.....	180,600	-	-	-	-
Write-off of investment.....	-	115,000	-	-	-
Deferred income tax expense (benefit).....	60,013	(136,829)	350,283	(37,825)	486,000
Changes in operating assets and liabilities:					
Accounts and notes receivable.....	139,302	(449,899)	(1,740,731)	(1,008,724)	155,760
Refundable income taxes.....	(285,911)	(455,089)	741,000	741,000	-
Inventories.....	(2,319,350)	(1,801,879)	(375,719)	(3,214,053)	(1,307,152)
Prepaid expenses and other current assets.....	(106,878)	(50,330)	(376,507)	(578,812)	(580,717)
Other assets.....	(166,261)	70,798	(4,749)	(3,603)	39,945
Accounts payable.....	1,136,863	191,504	1,747,043	2,747,287	156,693
Accrued expenses.....	1,991,606	4,531,725	4,555,685	5,486,077	5,937,190
Net cash provided by operating activities.....	3,090,763	9,595,565	19,766,156	15,658,025	15,166,928
Cash flows from investing activities:					
Proceeds from sale of equipment.....	-	-	-	75,000	-
Acquisition of property and equipment and construction in progress.....	(768,505)	(2,660,108)	(8,737,232)	(7,230,640)	(3,406,544)
Security deposits.....	-	(460,350)	-	-	-
Deposits of restricted cash.....	-	-	(199,619)	(730,416)	199,617
Deferred offering costs, net of write-offs.....	-	-	(343,672)	(199,293)	(1,100,721)
Other assets.....	(75,000)	(40,000)	-	-	-
Net cash used in investing activities.....	(843,505)	(3,160,458)	(9,280,523)	(8,085,349)	(4,307,648)
Cash flows from financing activities:					
Distributions to partners.....	(1,904,611)	(5,268,033)	(4,054,739)	(4,054,739)	-
Payment of dividends.....	-	(20,000)	(6,928,547)	(2,963,584)	(9,273,830)
Repayment of capital lease obligations.....	-	-	(37,265)	-	(264,261)
Advances from shareholders and employees.....	159,486	26,436	61,055	61,055	-
Repayments to shareholders and employees.....	-	(688,293)	(598,527)	(598,527)	-
Advances from an affiliated company.....	206,660	-	-	-	-
Repayment to an affiliated company.....	-	(206,660)	-	-	-
Payment of notes payable.....	(39,537)	(71,200)	(26,400)	(26,400)	(28,876)
Net cash used in financing activities.....	(1,578,002)	(6,227,751)	(11,584,423)	(7,582,195)	(9,566,967)
Net increase (decrease) in cash and cash equivalents.....	669,256	207,356	(1,098,789)	(9,519)	1,312,195
Cash and cash equivalents:					
Beginning of year.....	283,325	952,581	1,159,937	1,159,937	61,148
End of year.....	\$ 952,581	\$ 1,159,937	\$ 61,148	\$ 1,150,418	\$ 1,373,343
Supplemental disclosure of cash flow information:					
Income taxes paid.....	\$ 296,000	\$ 1,716,100	\$ 68,800	\$ 105,000	\$ 3,258,000
Interest paid.....	\$ 8,000	\$ -	\$ 10,885	\$ 2,000	\$ 20,000
Interest received.....	\$ -	\$ -	\$ -	\$ -	\$ 67,000
A summary of non-cash investing and financing activities follows:					
Accrued dividends and distributions.....	\$ 475,020	\$ 672,091	\$ 1,321,654	\$ 1,321,654	-
Tax benefit of shares granted for merger of partnerships.....	\$ -	\$ -	\$ 285,272	\$ 285,272	-
Assets acquired through capital lease obligations.....	\$ -	\$ -	\$ 397,402	\$ -	\$ 1,471,985
Assets acquired through note payable.....	\$ -	\$ -	\$ -	\$ -	\$ 435,670

See accompanying notes to financial statements

NOTES TO FINANCIAL STATEMENTS

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Mannatech, Incorporated (the "Company") was incorporated in the State of Texas on November 4, 1993, as Emprise International, Inc. Effective October 25, 1995, the Company changed its name to Mannatech, Incorporated. The Company, located in Coppell, Texas, develops and sells proprietary nutritional supplements and topical products through a network marketing system. The Company sells its products in the United States and Canada and is currently planning to expand into Australia, while continuing to assess the potential of other foreign markets. Independent associates ("Associates") purchase products, at wholesale, for the primary purpose of selling to retail consumers or for personal consumption. In addition, Associates earn commissions on their sales volume.

REORGANIZATION

In December 1994, to achieve certain tax efficiencies and to protect certain of the Company's proprietary rights, the Company transferred certain of its rights and interests in intellectual property, the right to use a supplier's trademark and its marketing rights to two affiliated partnerships ("Royalty Partnership" and "Marketing Partnership," respectively, or collectively "the Partnerships"). The Marketing Partnership was owned by two affiliated partnerships that also shared common ownership with the Company. The respective ownership interests in the Partnerships were structured with the intention of retaining the same economic interests among the partners as that of the shareholders of the Company. In the case of the intellectual property and trademark transferred to the Royalty Partnership, the Company entered into a 17-year agreement with the Royalty Partnership to pay a royalty based on sales volume. In the case of the Marketing Partnership, the Company paid a commission based on a specified percentage of sales volume. At the time of transfer, the rights and interest in intellectual property, supplier's trademark and marketing rights had a minimal basis. During 1994, the Company also entered into separate incentive compensation agreements with two of its shareholders pursuant to which the Company agreed to pay commissions based on specified monthly sales volumes and increases in number of new enrolled Associates. These agreements were designed to compensate for the differences in ownership in the Partnerships for one of the principal shareholders and to provide compensation to a shareholder in lieu of receiving a Partnership interest.

On June 1, 1997, in order to simplify the Company's ownership structure and consolidate all operating activities, the Company entered into agreements to effect a reorganization through merging with the corporate general partners of the Partnerships (with the Company as the surviving corporation) and exchanging 10,000,000 shares of Common Stock for the entire ownership interests of the corporate general partners and the Partnerships and issued 2,027,571 shares of Common Stock in consideration for the cancellation of incentive compensation agreements with the two shareholder-employees and four other employees of the Company. The net effect of the foregoing transactions was to increase the Company's common shares outstanding by 12,027,571 while retaining substantially the same relative original ownership of the Company. The only ownership percentage change among the original shareholders related to 208,024 shares granted to one shareholder in recognition of significant contributions to the Company, which resulted in minor dilution to the other original seven shareholders at the time of the exchange. The fair value of these additional shares was expensed, and is included in cancellation of incentive compensation agreements in the income statement. No monetary consideration changed hands and the changes were designed to reestablish the original economic characteristics of the Company. Aside from the new shares issued to the four employees to cancel their incentive compensation agreements, relative ownership interests, as evidenced by retention of economic risks and benefits, remained virtually the same. After the exchange, the Company terminated and liquidated the Partnerships at no gain or loss.

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

The accompanying financial statements include the accounts of the Partnerships and the Company as if the merger was consummated on December 31, 1994. The merger was accounted using the historical basis for each entity, effectively combining the entities as a pooling of interests.

USE OF ESTIMATES

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make certain estimates and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. Actual results may differ from such estimates.

CASH AND CASH EQUIVALENTS

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.

RESTRICTED CASH

At December 31, 1997, \$199,619 of cash was held by the Company's former credit card processor under the terms of the credit card processing agreement. The Company expects the restricted funds to be released early in 1998.

INVENTORIES

Inventories consist of raw materials, work-in-progress and finished goods and are stated at the lower of cost (using the first-in, first-out method) or market.

PROPERTY AND EQUIPMENT

Property and equipment are stated at cost, less accumulated depreciation which is computed using the straight-line method over the estimated useful life of each asset. Expenditures for maintenance and repairs are charged to expense as incurred. The cost of property and equipment sold or otherwise retired and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in other (income) expense.

Property and equipment are reviewed for impairment whenever an event or change in circumstances indicates the carrying amount of an asset or group of assets may not be recoverable. The impairment review includes a comparison of future cash flows expected to be generated by the asset or group of assets with their associated carrying value. If the carrying value of the asset or group of assets exceeds expected cash flows (undiscounted and without interest charges), an impairment loss is recognized to the extent the carrying amount of the asset exceeds its fair value.

OTHER ASSETS

Other assets consist of deposits, deferred offering costs and organization costs. Organization costs are being amortized on a straight-line basis over five years. Deferred offering costs will be deducted from the proceeds of the anticipated public offering of the Company's Common Stock.

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
ACCOUNTS PAYABLE

The Company records book overdrafts in its cash accounts as accounts payable. Included in accounts payable are book overdrafts of \$334,374 and \$1,028,676 at December 31, 1996 and 1997, respectively.

INCOME TAXES

The Company accounts for income taxes using the asset and liability approach to financial accounting and reporting for income taxes. In the event that differences between the financial reporting bases and the tax bases of the Company's assets and liabilities result in net deferred tax assets, the Company evaluates the probability of realizing the future benefits indicated by such assets. A valuation allowance is provided for a portion or all of the net deferred tax assets when it is more likely than not that such portion, or all of such deferred tax assets, will not be realized.

Prior to the merger of the Partnerships, the Company and the Partnerships filed separate tax returns. Prior to June 1, 1997, no provision for income taxes was necessary in the financial statements for the income attributable to the Partnerships because, as partnerships, they were not subject to federal income tax because the tax effect of their activities flowed through directly to the individual partners. Beginning June 1, 1997, all income earned by the Company became subject to income tax.

PRO FORMA INFORMATION (UNAUDITED)

Pro forma income tax information has been provided, using the statutory tax rate of the Company, as if all of the Company's and the Partnerships' income had been subject to income taxes.

REVENUE RECOGNITION

Revenue is recognized for product sales upon shipment of the products to the Associates. Revenues are received for promotional packs provided to Associates, which include nutritional products and sales aids.

The Company defers revenue received from the sale of the starter and renewal packs which is in excess of the wholesale value of the individual items included in such packs. Such deferrals are amortized over a twelve-month period. Revenues from the packs are allocated between products and event admission based on the proportionate fair value of these items. Allocated event revenue from the sales of these packs was approximately \$38,100, \$405,000 and \$906,000 in 1995, 1996 and 1997, respectively. The allocated event revenues are amortized over a twelve-month period. Total net deferred revenue was \$521,171 and \$808,749 at December 31, 1996 and 1997 respectively.

Substantially all product sales are made to Associates at a published wholesale price. Net sales also reflect product returns and the related refund.

ACCOUNTING FOR STOCK-BASED COMPENSATION

The Company has adopted Statement of Financial Accounting Standards No. 123 ("FAS 123"), "Accounting for Stock-Based Compensation," for stock-based compensation issued to nonemployees. FAS 123 requires that stock-based compensation be measured by the fair value at the date of grant. The

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Company measures the cost of stock-based compensation issued to employees under Accounting Principles Board Opinion 25, "Accounting for Stock Issued to Employees" ("APB 25"), and its related interpretations. The Company has, however, provided pro forma disclosures in note 10 for stock-based compensation accounted for under APB 25, as required by FAS 123.

ADVERTISING COSTS

Advertising and promotional expenses are included in selling and administrative expenses and are charged to operations when incurred. Advertising and promotional expenses were approximately \$450,000, \$1,475,000 and \$2,241,000 for 1995, 1996 and 1997, respectively. Literature and promotional items are sold to Associates to support their sales effort. Such items are included in inventories and charged to cost of sales when sold.

RESEARCH AND DEVELOPMENT COSTS

The Company expenses research and development costs when incurred. Research and development costs are included in other operating expenses and were approximately \$3,000, \$283,000 and \$381,000 in 1995, 1996 and 1997, respectively.

SOFTWARE DEVELOPMENT COSTS

The Company capitalizes qualifying costs relating to the development of internal use software. Capitalization of qualifying costs begins after the conceptual formulation stage has been completed, and such costs are amortized over the estimated useful life of the software, which is estimated at five years. Capitalized costs totaled \$58,000 and \$1,713,000 in 1996 and 1997, respectively. The Company did not capitalize any such costs during 1995. The amounts capitalized in 1997 are included in construction in progress and are expected to be completed during 1998.

During January 1998, the American Institute of Certified Public Accountants issued Statement of Position 98-1 "Accounting for the Costs of Computer Software Developed or Obtained for Internal Use" ("SOP 98-1"). SOP 98-1 becomes effective for all fiscal years beginning after December 15, 1998. The Company does not expect the adoption of SOP 98-1 to have a material impact on Company's financial statements.

EARNINGS PER SHARE

The Company calculates earnings per share pursuant to Statement of Financial Accounting Standards No. 128, "Earnings per Share" ("FAS 128"). FAS 128 requires dual presentation of basic and diluted earnings per share ("EPS") on the face of the statement of income for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS calculations are based on the weighted-average number of common shares outstanding during the period, while diluted EPS calculations are based on the weighted-average common shares and dilutive common share equivalents outstanding during each period.

CONCENTRATIONS OF CREDIT RISK

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and receivables from related parties. The Company utilizes financial

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
institutions which the Company considers to be of high credit quality. The Company believes its receivables from related parties at December 31, 1997 and its notes receivables from shareholders are fully collectible.

FAIR VALUE OF FINANCIAL INSTRUMENTS

The fair value of the Company's financial instruments, including cash and cash equivalents, notes receivable, note payable, capital leases and accrued expenses, approximate their recorded values due to their relatively short maturities.

COMMISSIONS

Commissions to Associates are based on several factors, including direct and indirect sales, downline growth and training of associates. Commissions are accrued when earned and generally paid at various times within the following month.

SEGMENT INFORMATION

The Company conducts its business within one industry segment. No Associate accounted for more than 10% of total sales for the years ended December 31, 1995, 1996 and 1997. Sales to Canadian Associates began in 1996 and were less than 10% of total sales in 1996. Such sales were 14% of total sales in 1997.

RECLASSIFICATIONS

Certain prior years' amounts have been reclassified to conform with the current year presentation.

UNAUDITED INTERIM FINANCIAL INFORMATION

In the opinion of management, all adjustments, consisting only of normal recurring adjustments that are necessary for fair presentation, have been included in the unaudited financial information for the interim periods ended September 30, 1997 and 1998.

2. INVENTORIES

Inventories at December 31, 1996 and 1997 consist of the following:

	1996	1997
	-----	-----
Raw materials.....	\$ 3,447,362	\$ 1,827,823
Work-in-progress.....	150,140	-
Finished goods.....	1,349,835	3,495,233
	-----	-----
	\$ 4,947,337	\$ 5,323,056
	-----	-----

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

3. PROPERTY AND EQUIPMENT

Property and equipment at December 31, 1996 and 1997 consist of the following:

	ESTIMATED USEFUL LIVES	1996	1997
Office furniture and equipment.....	5 to 7 years	\$ 740,170	\$ 3,087,775
Computer equipment.....	3 to 5 years	1,201,657	2,724,579
Automobiles.....	5 years	327,202	298,722
Leasehold improvements.....	10 years	88,165	3,162,714
		2,357,194	9,273,790
Less accumulated depreciation and amortization.....		(390,278)	(1,389,233)
		1,966,916	7,884,557
Construction in progress.....		1,082,656	2,699,353
		\$ 3,049,572	\$ 10,583,910

Construction in progress primarily consists of the construction of a new warehouse facility, a research and development laboratory and the internal development of a new computer software package. Included in the December 31, 1997 balance are capital leases of \$397,402 related to the warehouse equipment.

4. ACCRUED EXPENSES

Accrued expenses at December 31, 1996 and 1997 consist of the following:

	1996	1997
Commissions payable.....	\$ 2,481,755	\$ 3,801,324
Income taxes payable.....	-	2,692,248
Accrued royalties and compensation.....	2,361,703	1,251,215
Accrued inventory purchases.....	211,702	1,218,975
Sales and other taxes payable.....	900,154	812,368
Deferred revenue.....	521,171	808,749
Customer deposits.....	536,037	216,436
Other accrued expenses.....	257,642	739,262
	\$ 7,270,164	\$ 11,540,577

5. NOTES PAYABLE

The Company had an unsecured noninterest bearing promissory note payable to a former employee, payable in monthly installments of \$6,600 through May 1997. The note was repaid during 1997.

In May 1995, the Company and a shareholder entered into a \$500,000 line-of-credit agreement with a bank. This line was collateralized by personal assets of the shareholder. The interest rate was equal to the bank's prime rate, which was 8.25% at December 31, 1996. During 1996, the shareholder borrowed \$250,000 of the line-of-credit for personal use, which was subsequently repaid in full. The line of credit expired in September 1997, and there were no amounts outstanding at December 31, 1996.

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

6. CAPITAL LEASE OBLIGATIONS

The Company leases certain furniture and equipment under various capital leases agreements. These agreements have terms which range from three to five years and contain either a bargain purchase option or a buyout provision which the Company intends to exercise. A summary of future minimum payments under these capital lease agreements are as follows:

YEAR ENDING DECEMBER 31,	

1998.....	\$ 265,907
1999.....	37,586
2000.....	37,586
2001.....	37,586
2002.....	28,189
Present value of future minimum lease payments.....	406,854
Less imputed interest (approximately 12%).....	(46,717)

	360,137
Less current portion of capital lease obligations.....	(249,655)

Capital lease obligations, excluding current portion.....	\$ 110,482

In January 1998, the Company entered into a \$1.5 million interim lease line-of-credit agreement (the "Line of Credit Agreement") with Banc One Leasing Corporation to fund the purchase of furniture and certain capital equipment in connection with the Company's relocation to its new facility. The Line of Credit Agreement bears interest at the prime interest rate of Bank One, Columbus, NA plus one-half percent, is secured by the leased assets, is guaranteed by two of the Company's shareholders and will expire on December 15, 1998. The Line of Credit Agreement allows the Company to convert amounts drawn thereunder into capital leases and, in March and August 1998, the Company converted \$631,000 and \$841,000 respectively which had been drawn on the Line of Credit Agreement into a capital leases (the "Capital Lease"). The Capital Lease bears interest at 9.3%, is collateralized by the leased assets and is payable in 36 installments.

7. INCOME TAXES

The components of the Company's income tax provision for 1995, 1996 and 1997 were as follows:

	1995	1996	1997
	-----	-----	-----
Current provision:			
Federal.....	\$ 5,844	\$ 1,147,481	\$ 3,324,855
State.....	1,156	182,988	463,685
	-----	-----	-----
	7,000	1,330,469	3,788,540
	-----	-----	-----
Deferred provision:.....			
Federal.....	54,170	(124,397)	291,223
State.....	5,843	(12,432)	59,059
	-----	-----	-----
	60,013	(136,829)	350,282
	-----	-----	-----
	\$ 67,013	\$ 1,193,640	\$ 4,138,822
	-----	-----	-----
	-----	-----	-----

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

7. INCOME TAXES (CONTINUED)

A reconciliation of income tax based on the U.S. federal statutory rate is summarized as follows for the years ended December 31:

	1995	1996	1997
Federal statutory income taxes.....	34.0%	34.0%	35.0%
Partnership income.....	(36.1)	(23.8)	(9.6)
State income taxes, net of federal benefit.....	0.3	2.0	2.4
Nondeductible expenses.....	1.4	3.0	0.5
Other.....	3.2	(0.9)	(0.2)
	2.8%	14.3%	28.1%

Deferred taxes consisted of the following at December 31:

	1996	1997
Deferred tax assets:		
Current:		
Deferred revenue.....	\$ 200,651	\$ 311,368
Inventory capitalization.....	119,000	86,000
Capital loss carryforward.....	20,000	-
Other.....	10,000	2,000
Total current deferred tax assets.....	349,651	399,368
Noncurrent:		
Compensation expense.....	-	318,000
Capital loss carryforward.....	-	20,000
Total noncurrent deferred tax assets.....	-	338,000
Total gross deferred tax assets.....	\$ 349,651	\$ 737,368
Deferred tax liabilities:		
Noncurrent:		
Depreciation and amortization.....	\$ 105,000	\$ 843,000

The net deferred tax assets (liabilities) are classified in the financial statements as follows:

	1996	1997
Current deferred tax assets.....	\$ 349,651	\$ 399,368
Noncurrent deferred tax liabilities.....	(105,000)	(505,000)
Net deferred tax assets (liabilities).....	\$ 244,651	\$ (105,632)

It is the opinion of the Company's management that the deferred tax assets will more likely than not be realized; therefore, a valuation allowance is not required.

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

8. TRANSACTIONS WITH RELATED PARTIES AND AFFILIATES

In April 1994, the Company entered into an incentive compensation agreement with Ray Robbins, a shareholder of the Company. The agreement and its subsequent amendments required the Company to pay commissions based on a specified monthly sales volume and admittance of independent Associates. During 1995, 1996 and 1997, the Company paid commissions to Mr. Robbins of approximately \$145,000, \$511,000 and \$467,000, respectively. During 1995, the Company paid a shareholder of an affiliated company professional fees of approximately \$162,000 to serve as the Company's in-house counsel.

During 1995, 1996 and 1997, the Company advanced to certain employees, shareholders and an affiliated company funds of which \$502,417 and \$148,888 remained unpaid at December 31, 1996 and 1997, respectively. During 1997, the Company converted certain accounts receivable from an affiliated company to notes receivable from the shareholders of the affiliated company. These shareholders are also shareholders of the Company. The notes receivable bear interest at 6.0%, and are due upon the earlier of the sale of the affiliated company or December 31, 1998. The total amount of such notes outstanding at December 31, 1997 was \$934,929.

On December 31, 1997, the Company advanced \$283,834 to two officers and \$352,584 to two directors of the Company to pay taxes due in connection with the cancellation of their incentive compensation agreements. These advances are also evidenced by notes receivable from the shareholders. These notes are noninterest bearing, are collateralized by 203,101 shares of stock held by such shareholders and are due upon the earlier of December 31, 1998 or upon sale of the stock. These notes will be repaid out of the proceeds expected to be received by the shareholders from the sale of their stock in the offering. The total amount of these notes outstanding at December 31, 1997 was \$636,418.

9. CANCELLATION OF INCENTIVE COMPENSATION AGREEMENTS

Prior to June 1, 1997, the Company paid certain shareholders and employees commissions which were based on sales volume. During 1997, the Company issued 2,027,571 shares of its Common Stock to shareholders and employees to cancel these agreements. These shares included 626,971 of shares issued to cancel incentive compensation agreements which had been provided to two shareholders in lieu of ownership interests in the Partnerships (Note 1). The shares issued were valued at \$1.30 per share, which was based on an appraisal at the date of the transaction. In December 1997, the Company agreed to cancel another incentive compensation agreement by issuing 74,167 shares of Common Stock valued at \$5.00 per share. As a result of these transactions, during 1997 the Company recognized additional nonrecurring compensation expense of \$2,191,610.

10. EMPLOYEE BENEFIT PLAN

EMPLOYEE RETIREMENT PLAN

Effective May 9, 1997, the Company adopted a defined contribution 401(k) and profit-sharing plan (the "Plan"). The Plan covers all full-time employees who have completed three months of service and attained the age of twenty-one. Employees can contribute up to 15% of their annual compensation.

The Company will match 25% of the first 6% contributed and may also make discretionary contributions to the Plan, which may not exceed 100% of the first 15% of the employees annual compensation. Company contributions to employees vest ratably over a five-year period. During 1997, the Company contributed approximately \$49,000 to the Plan.

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

10. EMPLOYEE BENEFIT PLAN (CONTINUED)
STOCK OPTION PLAN

In May 1997, the Board of Directors approved the 1997 Stock Option Plan (the "Stock Option Plan") which provides incentive and nonqualified stock options to employees and nonemployees, respectively. The Company reserved 2,000,000 shares of common stock for issuance pursuant to the stock options granted under the Stock Option Plan. As of December 31, 1997, 1,600,000 stock options were outstanding, but not exercisable as follows:

	SHARES	WEIGHTED AVERAGE EXERCISE PRICE
Outstanding at January 1, 1997.....	-	-
Granted.....	1,600,000	\$ 1.45
Exercised.....	-	-
Canceled.....	-	-
Outstanding at December 31, 1997.....	1,600,000	\$ 1.45
Options exercisable at December 31, 1997.....	-	-
Weighted-average fair value of options granted during the year.....	\$ 1.11	

Under the Stock Option Plan, incentive stock options granted to employees are valued using the intrinsic method, are nontransferable and are granted for terms no longer than ten years and at a price which may not be less than 100% of the fair value of the common stock on the date of grant. During 1997, the Company issued 1,244,000 stock options to employees at a price ranging from \$1.35 to \$2.00 per share. No compensation cost was recognized as the exercise price of the options was equal to the fair value of options at the date of grant. Had compensation cost for employee stock options been determined based on the Black-Scholes option-pricing model at the grant date, pro forma net income and earnings per share for 1997 using the following weighted-average assumptions would have been as follows:

Dividend yield.....	4%
Expected volatility.....	0%
Risk-free rate of return.....	5%
Expected life.....	10 years

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

10. EMPLOYEE BENEFIT PLAN (CONTINUED)

For purposes of pro forma disclosures, the estimated fair value of the options is amortized to expense over the vesting period. The Company's pro forma information follows:

	1997

Net income	
As reported.....	\$ 10,622,043
Pro forma.....	\$ 10,542,364
Basic EPS	
As reported.....	\$ 0.50
Pro forma.....	\$ 0.49
Diluted EPS	
As reported.....	\$ 0.47
Pro forma.....	\$ 0.47

Under the Stock Option Plan, nonqualified stock options granted to nonemployees are valued using the fair value method, are nontransferable and are granted for terms no longer than six years and at a price which may not be less than 100% of the fair value of the common stock on the date of grant. During 1997, the Company issued 356,000 nonqualified stock options to nonemployees at an exercise price of \$1.35 per share. Additionally, the Company issued 100,000 nonqualified stock options in July 1997. These options are priced at \$2.00, vest immediately, are exercisable after one year and have a term of six years.

During 1997, compensation expense of \$155,503 was included in other operating expenses for the nonemployee options. This expense was determined by calculating the fair value of options granted on the date of grant using the Black-Scholes option-pricing model and the following weighted-average assumptions:

Dividend yield.....	4%
Expected volatility.....	30%
Risk-free rate of return.....	5%
Expected life.....	6 years

During 1997, the Company granted to a consulting firm 475,015 warrants to purchase the same number of shares of the Company's common stock which are nontransferable and vest as follows: 178,125 shares at issuance and 26,990 each month through March 1, 1998. The warrants are exercisable at \$1.35 per share and expire on the earlier of May 1, 2003 or 36 months after the warrant shares are registered for public resale under the Securities Act of 1933. At December 31, 1997, 394,015 of the warrants were vested.

As a provision of the warrant agreement, the consulting firm can require the Company to repurchase the outstanding warrants between May 1998 and May 1999 for \$300,000. Accordingly, it was determined that the fair value of the warrants as of December 31, 1997 was \$300,000.

11. COMMITMENTS AND CONTINGENCIES

The Company leases certain office space and equipment under various noncancelable operating leases, and has options to renew and renegotiate most of the leases. The leases expire at various times

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

11. COMMITMENTS AND CONTINGENCIES (CONTINUED)

through January 2007. The Company also leases equipment under month-to-month cancelable operating leases. Total rent expense was \$124,000, \$317,000 and \$702,000 in 1995, 1996 and 1997, respectively.

Approximate future minimum rental commitments for the operating leases are as follows:

YEARS ENDING DECEMBER 31,

1998.....	\$	835,000
1999.....		794,000
2000.....		717,000
2001.....		706,000
2002.....		771,000
Thereafter.....		3,250,000
	\$	7,073,000

In 1995 and 1996, the Company entered into various cancellable employment agreements with some of its key employees which provide for minimum annual salaries based on sales volume. However, in 1997 the Company terminated several of these contracts. As a result of the terminations, the Company incurred approximately \$499,000 in severance of which \$145,000 was accrued at December 31, 1997. In December 1997, the Company entered into a purchase commitment with a supplier to purchase approximately \$2.6 million worth of raw materials over the next twelve months.

The Company utilizes royalty agreements with individuals or entities to provide compensation for items such as:

- Reprints of articles or speeches relating to the Company
- Sales of promotional videos featuring sports personalities
- Promotional efforts in product sales or attracting new associates.

In addition, the Company pays a monthly fee of \$20,000 to a research foundation for promoting and conducting health studies of Associates. The total expenses for all of these agreements were \$473,000, \$1,345,000 and \$1,568,000 in 1995, 1996 and 1997, respectively.

12. STOCK SPLIT

On May 14, 1997, the Board of Directors declared a 1,000-for-1 stock split of the Company's common stock. The Board also approved a change in the stated par value of common shares from \$.01 per share to \$.0001 per share, and increased the number of authorized shares to 100,000,000. All share and per share data have been retroactively adjusted for this split.

Subsequent to year end, on April 8, 1998, the Company amended its Articles of Incorporation to reduce the number of authorized shares of common stock to 99,000,000 from 100,000,000. Additionally, the Company has authorized 1,000,000 shares of preferred stock with a par value of \$0.01 per share.

13. LITIGATION

In 1995, the Company entered into a settlement and mutual release agreement related to the termination of a former employee. Under the terms of the agreement, the Company agreed to pay the

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

13. LITIGATION (CONTINUED)

former employee \$83,000 in cash and issued a \$97,600 promissory note (note 5). In 1996, the Company paid an additional \$59,000 to the former employee related to this lawsuit. The settlement is recorded in other (income) expense, net in the accompanying financial statements.

The Company has pending claims incurred in the normal course of business which, in the opinion of management, can be settled without material effect on the accompanying financial statements.

14. EARNINGS PER SHARE

The following data show the amounts used in computing earnings per share and the effect on the weighted average number of shares of dilutive common stock. The number of shares used in the calculations for 1995 and 1996 reflect the 1,000-for-1 stock split on April 15, 1997.

	1995	1996	1997
	-----	-----	-----
Net income available to common shareholders.....	\$ 2,338,915	\$ 7,162,389	\$ 10,622,043
	-----	-----	-----
Weighted average number of shares in basic EPS.....	20,626,971	20,626,971	21,448,551
Effect of dilutive securities:			
Stock options.....	-	-	770,018
Stock warrants.....	-	-	181,815
	-----	-----	-----
Weighted average number of common shares and dilutive potential common shares used in diluted EPS.....	20,626,971	20,626,971	22,400,384
	-----	-----	-----

MANNATECH, INCORPORATED
SUBSCRIPTION AGREEMENT

1. SUBSCRIPTION. The undersigned hereby subscribes to purchase _____ shares of the common stock, par value \$0.0001 per share (the "Common Stock"), of Mannatech, Incorporated (the "Company") for a purchase price equal to \$8.00 per share or \$_____ total. A cashier's check payable to "Mannatech Subscription Account" in the full amount of the purchase price is enclosed with this Subscription Agreement.

2. SUBSCRIPTION FUNDS. The undersigned understands that the subscription funds will be held in an escrow account at Bank One, Kentucky, NA ("Escrow Agent") or in a segregated account established for such purpose by the placement agent, if such funds are received after the initial closing on the Common Stock has taken place. In the event this Subscription Agreement is rejected in whole by the Company, or if subscriptions for a minimum of 2,500,000 shares have not been received and accepted by the Escrow Agent, the funds will be promptly returned to the undersigned without interest or deduction, and this Subscription Agreement will be null and void. In the event this Subscription Agreement is accepted, in whole or in part, the funds deposited in the escrow account or the segregated subscription account will be paid over to the Company at a closing and applied as described in the Prospectus (and any amounts which the undersigned has tendered in excess of the cash subscription price for the Shares allocated to the undersigned will be returned).

3. ACKNOWLEDGEMENT. The undersigned acknowledges that, prior to signing this Subscription Agreement, he or she has received the Prospectus describing the offering of shares of Common Stock by the Company and has carefully reviewed the risks of, and other considerations relevant to, a purchase of the Common Stock, including those described under the caption "Risk Factors" in the Prospectus.

4. SUBSCRIPTION IRREVOCABLE. This Subscription Agreement is not transferable or assignable and is irrevocable, except that the execution and delivery of this Subscription Agreement will not constitute an agreement between the undersigned and the Company until this subscription is accepted on behalf of the Company. This Subscription Agreement shall survive the death or disability of the undersigned and shall be binding upon the undersigned's heirs and legal representatives.

The undersigned hereby executes this Subscription Agreement as of the ____ day of _____, 199__, at _____, _____ (city) (state).

SUBSTITUTE FORM W-9
PAYER'S REQUEST FOR TAXPAYER IDENTIFICATION NUMBER

Under the penalties of perjury, I certify that: (1) the Social Security number or Taxpayer Identification Number given below is correct; and (2) I am not subject to backup withholding. INSTRUCTION: YOU MUST CROSS OUT NUMBER 2 ABOVE IF YOU HAVE BEEN NOTIFIED BY THE INTERNAL REVENUE SERVICE THAT YOU ARE SUBJECT TO BACKUP WITHHOLDING BECAUSE OF UNDERREPORTING INTEREST OR DIVIDENDS ON YOUR TAX RETURN.

MAIL TO:
J.J.B. Hilliard, W.L. Lyons, Inc.
P.O. Box 70210

Louisville, KY 40270-0210

Signature:
Print Name:

Federal Employer Identification Number/
Social Security Number
Street Address
City, State and Zip Code

()
Telephone Number

NO PERSON HAS BEEN AUTHORIZED IN CONNECTION WITH THE OFFERING MADE HEREBY TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATION NOT CONTAINED IN THIS PROSPECTUS AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY OR THE SELLING SHAREHOLDERS. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF ANY OFFER TO BUY ANY OF THE SECURITIES OFFERED HEREBY TO ANY PERSON OR BY ANYONE IN ANY JURISDICTION IN WHICH IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION. NEITHER THE DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY DATE SUBSEQUENT TO THE DATE HEREOF.

TABLE OF CONTENTS

	PAGE

Prospectus Summary.....	2
Risk Factors.....	7
Use of Proceeds.....	17
Dividend Policy.....	17
Capitalization.....	18
Dilution.....	19
Selected Financial Data.....	21
Management's Discussion and Analysis of Financial Condition and Results of Operations.....	23
Business.....	38
Management.....	55
Certain Transactions.....	62
Principal and Selling Shareholders.....	64
Description of Capital Stock.....	66
Shares Eligible for Future Sale.....	70
Plan of Distribution.....	72
Legal Matters.....	73
Experts.....	73
Additional Information.....	74
Index to Financial Statements.....	F-1

UNTIL FEBRUARY 23, 1998 (90 DAYS AFTER THE DATE OF THIS PROSPECTUS), ALL DEALERS EFFECTING TRANSACTIONS IN THE COMMON STOCK OFFERED HEREBY, WHETHER OR NOT PARTICIPATING IN THIS DISTRIBUTION, MAY BE REQUIRED TO DELIVER A PROSPECTUS. THIS IS IN ADDITION TO THE OBLIGATION OF DEALERS TO DELIVER A PROSPECTUS WHEN ACTING AS UNDERWRITERS AND WITH RESPECT TO THEIR UNSOLD ALLOTMENTS OR SUBSCRIPTIONS.

A MINIMUM OF
2,500,000 SHARES
AND
A MAXIMUM OF
5,295,015 SHARES

[LOGO]

COMMON STOCK

PROSPECTUS

November 25, 1998

PART II
INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

The estimated expenses in connection with the issuance and distribution of the securities being registered, other than fees paid to the Placement Agent are set forth in the following table. Each amount, except for the SEC fees, is estimated. The Company intends to pay all expenses of registration, issuance and distribution with respect to the shares being sold by the Selling Shareholders.

SEC registration fees.....	\$	15,000
Escrow agent's fees and expenses.....		5,000
Transfer agent's and registrar's fees and expenses.....		12,000
Printing and engraving expenses.....		425,000
Legal fees and expenses.....		475,000
Accounting fees and expenses.....		400,000
Blue sky fees and expenses.....		75,000
Miscellaneous.....		100,000

Total.....	\$	1,507,000(1)

(1) The total includes approximately \$1,000,000 in costs which have been previously incurred and paid by the Company.

ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS

The Company, a Texas corporation, is empowered by Article 2.02-1 of the Texas Business Corporation Act (the "TBCA"), subject to the procedures and limitations stated therein, to indemnify certain persons, including any person who was, is or is threatened to be made a named defendant or respondent in a threatened, pending, or completed action, suit or proceeding because the person is or was a director or officer, against judgments, penalties (including excise and similar taxes), fines, settlements and reasonable expenses (including court costs and attorneys' fees) actually incurred by the person in connection with the threatened, pending, or completed action, suit or proceeding. The Company is required by Article 2.02-1 to indemnify a director or officer against reasonable expenses (including court costs and attorneys' fees) incurred by him in connection with a threatened, pending, or completed action, suit or proceeding in which he is a named defendant or respondent because he is or was a director or officer if he has been wholly successful, on the merits or otherwise, in the defense of the action, suit or proceeding. Article 2.02-1 provides that indemnification pursuant to its provisions is not exclusive of other rights of indemnification to which a person may be entitled under the corporation's articles of incorporation or any bylaw, agreement, vote of shareholders or disinterested directors, or otherwise. The Amended and Restated Bylaws of the Company provide for indemnification by the Company of its directors and officers to the fullest extent permitted by the TBCA. In addition, the Company has, pursuant to Article 1302-7.06 of the Texas Miscellaneous Corporation Laws Act, provided in its Articles that a director of the Company shall not be liable to the Company or its shareholders for monetary damages for an act or omission in a director's capacity as director of the Company.

Furthermore, the Company has entered into individual indemnification agreements with each director of the Company that contractually obligate the Company to provide to the directors indemnification for liabilities they may incur in the performance of their duties and insurance or self-insurance in lieu thereof. The form of such indemnification agreements with a schedule of director signatories is filed as Exhibit 10.8 hereto.

The Underwriting Agreement among the Company and the Underwriters provides for the indemnification by the Underwriters of the Company, certain of its officers and any controlling person against any

liabilities and expenses incurred by any of them in certain stated proceedings and under certain stated conditions.

ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES

The following sets forth information regarding all sales of unregistered securities of the Company during the past three years. All such shares were issued in reliance upon an exemption from registration under the Securities Act by reason of Section 4(2) or 3(b) of the Securities Act and/or the rules and regulations promulgated thereunder. In connection with each of these transactions, the shares were sold to a very limited number of persons and such persons were provided access either through employment or other relationships to all relevant information regarding the Company and/or represented to the Company that they were "sophisticated" investors. No underwriters were involved in the sales of securities set forth below. Appropriate legends are affixed to the certificates evidencing such shares and such persons represented to the Company that the shares were purchased for investment purposes only and with no view toward distribution. All of the securities described below are deemed restricted securities for purposes of the Securities Act.

1. Issuance of an aggregate of 10,000,000 shares of Common Stock on June 1, 1997 in exchange for (i) all the outstanding common stock of each of Eight Point Services, Inc., Triple Gold Business, Inc., Five Small Fry, Inc. and Beta Nutrient Technology, Inc., held by the individuals listed below, and (ii) all of the limited partnership interests in Dynamic Eight Partners, Ltd., Power Three Partners, Ltd., Beta M. Partners, Ltd. and Eleven Point Partners, Ltd. held by the individuals listed below.

NAME	NUMBER OF SHARES
Samuel L. Caster.....	3,094,946
William C. Fioretti.....	3,094,946
Charles E. Fioretti.....	2,867,284
Patrick D. Cobb.....	235,706
Dick R. Hankins.....	235,706
Don W. Herndon.....	235,706
Gary L. Watson.....	235,706

2. Issuance of an aggregate of 2,027,571 shares of Common Stock to the individuals set forth below on June 1, 1997 in exchange for the cancellation of certain incentive compensation agreements.

NAME	NUMBER OF SHARES
Ray Robbins.....	607,333
H. Reginald McDaniel.....	546,600
Bill H. McAnalley, Ph.D.....	303,667
Peter E. Hammer.....	228,206
Charles E. Fioretti.....	227,662
Kim Snyder.....	114,103

3. Issuance of 74,167 shares of Common Stock on March 3, 1998 to Richard Howard in exchange for the cancellation of his incentive compensation agreement.

4. The Company has granted a warrant to purchase 475,015 shares of Common Stock at a price of \$1.35 per share.

5. The Company has granted options to purchase an aggregate of 2,243,000 shares of Common Stock at a weighted average exercise price of \$3.32 per share.

ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(A) EXHIBITS

EXHIBIT NO. EXHIBITS

- 3.1 Amended and Restated Articles of Incorporation of the Company.+
- 3.2 Amended and Restated Bylaws of the Company.+
- 3.3 Amendment to the Bylaws of the Company.+
- 4.1 Specimen Certificate.+
- 4.2 Warrant dated May 1, 1997 issued to Christopher A. Marlett.+
- 5 Opinion and Consent of Akin, Gump, Strauss, Hauer & Feld, L.L.P.+
- 10.1 1997 Stock Option Plan dated May 20, 1997.+
- 10.2 1998 Incentive Stock Option Plan dated April 8, 1998.+
- 10.3 Agreement and Plan of Merger dated as of June 1, 1997 among the Company and Eight Point Services, Inc., Triple Gold Business, Inc., Five Small Fry, Inc., and Beta Nutrient Technology, Inc.+
- 10.4 Exchange Agreement dated June 1, 1997 among the Company and the limited partners of Power Three Partners, Ltd., Eleven Point Partners, Ltd. and Beta M. Partners, Ltd.+
- 10.5 Plan and Agreement of Reorganization dated June 1, 1997 by and among the Company, Dynamic Eight Partners, Ltd., Power Three Partners, Ltd., Eleven Point Partners, Ltd. and Beta M. Partners, Ltd. and the general and limited partners of the partnerships.+
- 10.6 Exchange Agreement by and among Gary Watson, Patrick Cobb, Samuel Caster, Charles Fioretti and William Fioretti and the Company dated August 31, 1997.+
- 10.7 Option Agreement dated July 1, 1997 with Multi-Venture Partners, Ltd.+
- 10.8 Form of Indemnification Agreement with a schedule of director signatures.+
- 10.9 Secured Promissory Note dated December 31, 1997 in the amount of \$162,051.90 made by Bill McAnalley.+
- 10.10 Secured Promissory Note dated December 31, 1997 in the amount of \$121,782.14 made by Peter E. Hammer.+
- 10.11 Master Lease Agreement dated December 23, 1997 by and between Banc One Leasing Corporation and the Company.+
- 10.12 Letter of Understanding Regarding Development of Proprietary Information for the Company effective as of August 1, 1997, as amended, by and between Bill H. McAnalley, Ph.D. and the Company.+
- 10.13 Commercial Lease Agreement dated November 7, 1996 between MEPC Quorum Properties II Inc. and the Company, as amended by the First Amendment thereto dated May 29, 1997 and the Second Amendment thereto dated November 13, 1997.+
- 10.14 Commercial Lease Agreement dated May 29, 1997 between MEPC Quorum Properties II Inc. and the Company, as amended by the First Amendment thereto dated November 6, 1997.+
- 10.15 Assignment of Patent Rights dated October 30, 1997 by and among Bill H. McAnalley, H. Reginald McDaniel, D. Eric Moore, Eileen P. Vennum and William C. Fioretti and the Company.+
- 10.16 Supply Agreement effective as of March 31, 1995 by and between the Company and Caraloe, Inc.+

EXHIBIT NO. EXHIBITS

- 10.17 Supply Agreement effective as of August 14, 1997 by and between the Company and Caraloe, Inc.+
- 10.18 Trademark License Agreement effective as of March 31, 1995 by and between the Company and Caraloe, Inc.+
- 10.19 Trademark License Agreement effective as of August 14, 1997 by and between the Company and Caraloe, Inc.+
- 10.20 Letter of Agreement from the Company to Michael L. Finney of LAREX, Incorporated dated December 23, 1997.+
- 10.21 Product Development and Distribution Agreement effective as of September 15, 1997 between New Era Nutrition Inc. and the Company.+
- 10.22 Severance and Consulting Agreement and Complete Release dated August 1, 1997 between Ronald E. Kozak and the Company.+
- 10.23 Summary of Management Bonus Plan.+
- 10.24 Promissory Note dated August 31, 1997 in the amount of \$45,907.40 made by Patrick D. Cobb.+
- 10.25 Promissory Note dated August 31, 1997 in the amount of \$275,444.42 made by Samuel L. Caster.+
- 10.26 Promissory Note dated August 31, 1997 in the amount of \$275,444.42 made by Charles E. Fioretti.+
- 10.27 Individual Guaranty of Samuel L. Caster dated January 5, 1998.+
- 10.28 Individual Guaranty of Charles E. Fioretti dated January 5, 1998.+
- 10.29 Lease dated September 1, 1998 between Mannatech Australia Pty Limited and Legal & General Properties No. 1 Pty Limited.+
- 10.30 Form of Employment Agreement to be entered into between the Company and each of Charles E. Fioretti, Patrick D. Cobb, Anthony E. Canale, Bill H. McAnalley and Deanne Varner.+
- 10.31 Letter Agreement, dated September 9, 1998, between the Company and J.J.B. Hilliard, W.L. Lyons, Inc.+
- 10.32 Escrow Agreement dated November 19, 1998 by and among the Company, the Selling Shareholders, J.J.B. Hilliard, W.L. Lyons, Inc., and Bank One, Kentucky, NA*
- 10.33 Placement Agent Agreement dated November 18, 1998 by and among the Company, the Selling Shareholders, and J.J.B. Hilliard, W.L. Lyons, Inc.*
- 16 Letter of Belew Averitt LLP, former accountants to the Company.+
- 23.1 Consent of PricewaterhouseCoopers LLP.*
- 23.2 Consent of Belew Averitt LLP.*
- 23.3 Consent of Akin, Gump, Strauss, Hauer & Feld, L.L.P. (included in its opinion filed as Exhibit 5 to this Registration Statement).+
- 24 Power of Attorney (included on signature page of this Registration Statement).+
- 27 Financial Data Schedule+

- -----
+ Previously filed

* Filed herewith

(B) FINANCIAL STATEMENT SCHEDULES

None.

Schedules not listed above have been omitted because they are not required, are not applicable, or the information is included in the Financial Statements or Notes thereto.

ITEM 17. UNDERTAKINGS

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling persons of the registrant pursuant to Item 14 herein, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The undersigned registrant hereby undertakes:

(1) That, for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of the registration statement as of the time it was declared effective.

(2) That, for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the information statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

(4) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial BONA FIDE offering thereof.

(5) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Amendment No. 2 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dallas, State of Texas on November 19, 1998.

MANNATECH, INCORPORATED

By: /s/ CHARLES E. FIORETTI

 Charles E. Fioretti
 CHAIRMAN OF THE BOARD AND
 CHIEF EXECUTIVE OFFICER

Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No. 2 to Registration Statement has been signed below by the following persons in the capacities and as of the dates indicated.

SIGNATURE	TITLE	DATE
----- /s/ CHARLES E. FIORETTI ----- Charles E. Fioretti	Chairman of the Board and Chief Executive Officer (principal executive officer)	November 19, 1998
* ----- Samuel L. Caster	President and Director	November 19, 1998
* ----- Patrick D. Cobb	Vice President, Chief Financial Officer and Director (principal accounting and financial officer)	November 19, 1998
* ----- Chris T. Sullivan	Director	November 19, 1998
* ----- Steven A. Barker	Director	November 19, 1998

*By: /s/ CHARLES E. FIORETTI

 Charles E. Fioretti
 ATTORNEY-IN-FACT

INDEX TO EXHIBITS

EXHIBIT NO. EXHIBITS

- 3.1 Amended and Restated Articles of Incorporation of the Company.+
- 3.2 Amended and Restated Bylaws of the Company.+
- 3.3 Amendment to the Bylaws of the Company.+
- 4.1 Specimen Certificate.+
- 4.2 Warrant dated May 1, 1997 issued to Christopher A. Marlett.+
- 5 Opinion and Consent of Akin, Gump, Strauss, Hauer & Feld, L.L.P.+
- 10.1 1997 Stock Option Plan dated May 20, 1997.+
- 10.2 1998 Incentive Stock Option Plan dated April 8, 1998.+
- 10.3 Agreement and Plan of Merger dated as of June 1, 1997 among the Company and Eight Point Services, Inc., Triple Gold Business, Inc., Five Small Fry, Inc., and Beta Nutrient Technology, Inc.+
- 10.4 Exchange Agreement dated June 1, 1997 among the Company and the limited partners of Power Three Partners, Ltd., Eleven Point Partners, Ltd. and Beta M. Partners, Ltd.+
- 10.5 Plan and Agreement of Reorganization dated June 1, 1997 by and among the Company, Dynamic Eight Partners, Ltd., Power Three Partners, Ltd., Eleven Point Partners, Ltd. and Beta M. Partners, Ltd. and the general and limited partners of the partnerships.+
- 10.6 Exchange Agreement by and among Gary Watson, Patrick Cobb, Samuel Caster, Charles Fioretti and William Fioretti and the Company dated August 31, 1997.+
- 10.7 Option Agreement dated July 1, 1997 with Multi-Venture Partners, Ltd.+
- 10.8 Form of Indemnification Agreement with a schedule of director signatures.+
- 10.9 Secured Promissory Note dated December 31, 1997 in the amount of \$162,051.90 made by Bill McAnalley.+
- 10.10 Secured Promissory Note dated December 31, 1997 in the amount of \$121,782.14 made by Peter E. Hammer.+
- 10.11 Master Lease Agreement dated December 23, 1997 by and between Banc One Leasing Corporation and the Company.+
- 10.12 Letter of Understanding Regarding Development of Proprietary Information for the Company effective as of August 1, 1997, as amended, by and between Bill H. McAnalley, Ph.D. and the Company.+
- 10.13 Commercial Lease Agreement dated November 7, 1996 between MEPC Quorum Properties II Inc. and the Company, as amended by the First Amendment thereto dated May 29, 1997 and the Second Amendment thereto dated November 13, 1997.+
- 10.14 Commercial Lease Agreement dated May 29, 1997 between MEPC Quorum Properties II Inc. and the Company, as amended by the First Amendment thereto dated November 6, 1997.+
- 10.15 Assignment of Patent Rights dated October 30, 1997 by and among Bill H. McAnalley, H. Reginald McDaniel, D. Eric Moore, Eileen P. Vennum and William C. Fioretti and the Company.+
- 10.16 Supply Agreement effective as of March 31, 1995 by and between the Company and Caraloe, Inc.+
- 10.17 Supply Agreement effective as of August 14, 1997 by and between the Company and Caraloe, Inc.+

EXHIBIT NO. EXHIBITS

- 10.18 Trademark License Agreement effective as of March 31, 1995 by and between the Company and Caraloe, Inc.+
- 10.19 Trademark License Agreement effective as of August 14, 1997 by and between the Company and Caraloe, Inc.+
- 10.20 Letter of Agreement from the Company to Michael L. Finney of LAREX, Incorporated dated December 23, 1997.+
- 10.21 Product Development and Distribution Agreement effective as of September 15, 1997 between New Era Nutrition Inc. and the Company.+
- 10.22 Severance and Consulting Agreement and Complete Release dated August 1, 1997 between Ronald E. Kozak and the Company.+
- 10.23 Summary of Management Bonus Plan.+
- 10.24 Promissory Note dated August 31, 1997 in the amount of \$45,907.40 made by Patrick D. Cobb.+
- 10.25 Promissory Note dated August 31, 1997 in the amount of \$275,444.42 made by Samuel L. Caster.+
- 10.26 Promissory Note dated August 31, 1997 in the amount of \$275,444.42 made by Charles E. Fioretti.+
- 10.27 Individual Guaranty of Samuel L. Caster dated January 5, 1998.+
- 10.28 Individual Guaranty of Charles E. Fioretti dated January 5, 1998.+
- 10.29 Lease dated September 1, 1998 between Mannatech Australia Pty Limited and Legal & General Properties No. 1 Pty Limited.+
- 10.30 Form of Employment Agreement to be entered into between the Company and each of Charles E. Fioretti, Patrick D. Cobb, Anthony E. Canale, Bill H. McAnalley and Deanne Varner.+
- 10.31 Letter Agreement, dated September 9, 1998, between the Company and J.J.B. Hilliard, W.L. Lyons, Inc.+
- 10.32 Escrow Agreement dated November 19, 1998 by and among the Company, the Selling Shareholders, J.J.B. Hilliard, W.L. Lyons, Inc., and Bank One, Kentucky, NA*
- 10.33 Placement Agent Agreement dated November 18, 1998 by and among the Company, the Selling Shareholders and J.J.B. Hilliard, W.L. Lyons, Inc.*
- 16 Letter of Belew Averitt LLP, former accountants to the Company.+
- 23.1 Consent of PricewaterhouseCoopers LLP.*
- 23.2 Consent of Belew Averitt LLP.*
- 23.3 Consent of Akin, Gump, Strauss, Hauer & Feld, L.L.P. (included in its opinion filed as Exhibit 5 to this Registration Statement).+
- 24 Power of Attorney (included on signature page of this Registration Statement).+
- 27 Financial Data Schedule.+

- -----
+ Previously filed

* Filed herewith

ESCROW AGREEMENT

THIS ESCROW AGREEMENT (this "Agreement") is entered into as of the 18th day of November, 1998, by and among Mannatech, Incorporated, a Texas corporation ("Issuer"), the selling shareholders set forth on Schedule A hereto (the "Selling Shareholders"), J.J.B. Hilliard, W.L. Lyons, Inc., ("Placement Agent") and Bank One, Kentucky, NA ("Escrow Agent").

R E C I T A L S:

A. Issuer and the Selling Shareholders propose to offer for sale to subscribers an aggregate of 5,295,015 shares of the capital stock of Issuer, having a per share par value of \$0.0001 per share (the "Shares") at a price of \$8.00 per Share, payable at the time of subscribing for a Share. 2,500,000 shares and the proceeds therefrom shall be subject to this Agreement. The payment of \$20,000,000 for at least 2,500,000 Shares will be paid into the escrow created by this Agreement.

B. Issuer and the Selling Shareholders intend to sell the Shares on a best-efforts "minimum or none" basis in a public offering (the "Offering") by delivering to each subscriber a Prospectus (the "Prospectus") describing the Offering.

C. Issuer and the Selling Shareholders desire to establish an escrow account in which funds received from subscribers would be deposited pending completion of the period during which the Escrow Account shall be open (the "Escrow Period"). Bank One, Kentucky, NA, agrees to serve as Escrow Agent in accordance with the terms and conditions set forth herein.

D. The Selling Shareholders have authorized Issuer to take all necessary action on their behalf to sell the Shares.

AGREEMENT:

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:

1. Issuer, for itself and on behalf of the Selling Shareholders, hereby appoints Bank One, Kentucky, NA, as Escrow Agent and Escrow Agent shall establish an escrow account (the "Escrow Account") on its books styled "Mannatech Subscription Account." Commencing upon the execution of this Agreement, Escrow Agent shall act as Escrow Agent and hereby agrees to receive and disburse the proceeds from the offering of the Shares in accordance with the terms here of. Issuer agrees to notify the Escrow Agent promptly of the closing of the offering and sale of the Shares.

2. Issuer or Placement Agent shall cause all checks received from subscribers for Shares to be promptly deposited into the Escrow Account. Issuer or Placement Agent shall deliver to the Escrow Agent checks of the subscribers made payable to the Mannatech Subscription Account or endorsed to the Mannatech Subscription Account. Any checks that are received by Escrow Agent that are not made

payable or endorsed to the Mannatech, Incorporated Escrow Account shall be returned to the Issuer. Issuer shall furnish to the Escrow Agent at the time of each deposit of the above-mentioned funds a list containing the name of each subscriber, the subscriber's address, the number of Shares subscribed for, and the amount of the check being delivered to the Escrow Agent. Prior to the receipt of the Minimum (as described below), the Issuer is aware and understands that it is not entitled to any proceeds from subscriptions deposited into the Escrow Account and no amounts deposited in the Escrow Account during the Escrow Period shall become the property of the Issuer or any other entity, or be subject to the debts of the Issuer or any other entity.

3. The Escrow Period shall commence on the date hereof and shall terminate ten (10) Business Days (as defined below) following the earlier to occur of the following dates:

- (a) The date upon which Escrow Agent confirms upon written request of the Issuer that it has received into the Escrow Account and collected gross subscription proceeds from the sale of 2,500,000 Shares aggregating \$20,000,000 in deposited funds (the "Minimum") assuming that, prior to such date, the S-1 Registration Statement as amended, File Number 333-63133 has been declared effective by the Securities and Exchange Commission, and Issuer has received notice that the Shares have been approved for listing on the NASDAQ NMS subject only to meeting the public float and market maker requirements for such listing; or
- (b) The "Cessation Date," which for the purposes of this Agreement shall be January 15, 1999, except as extended in writing by the agreement of parties.
- (c) The date upon which a determination is made by the Issuer to terminate the Offering prior to the sale of the Minimum, as communicated to Escrow Agent in writing.

Upon the occurrence of any of the events described in (a), (b) or (c) above, the Escrow Period shall continue for such ten (10) Business-Day period solely for the limited purposes of collecting subscribers' checks that have been deposited prior to such event and disbursing funds from the Escrow Account as provided herein. Escrow Agent will not accept deposits of subscribers' checks after notice that any of the events described in subparagraphs (a), (b) and (c) has occurred.

"Business Day" shall mean a day on which commercial banks in Louisville, Kentucky, are open for the general transaction of business. If any action or time for performance pursuant to this Agreement is to occur on any Saturday, Sunday or holiday, such time for action or performance shall be extended to the next Business Day.

4. The Escrow Agent will deposit the subscribers' checks for collection and credit the proceeds to the Escrow Account to be held by it under the terms of this Agreement. Notwithstanding anything to the contrary contained herein, Escrow Agent is under no duty or responsibility to enforce collection of any checks delivered to Escrow Agent hereunder. The Escrow Agent hereby is authorized to forward each check for collection and deposit the proceeds

in the Escrow Account. As an alternative, the Escrow Agent may telephone the bank on which the check is drawn to confirm that the check has been paid. Additionally, to insure that such funds have cleared normal banking channels for collection, Escrow Agent is authorized to hold for ten (10) Business Days funds to be released. Issuer shall immediately reimburse Escrow Agent any monies paid to it if thereafter the subscriber's check is returned unpaid. Any item returned unpaid to the Escrow Agent on its first presentation for payment shall be returned to Issuer and need not be again presented by the Escrow Agent for collection. Issuer agrees to reimburse Escrow Agent for the cost incurred with any returned check. The Escrow Agent shall not be required to invest any funds deposited in the Escrow Account and shall in no event be liable for any investment loss. For purposes of this Agreement, the term "collected funds" or the term "collected" when referring to the proceeds of subscribers' checks shall mean all funds received by Escrow Agent that have cleared normal banking channels and are in the form of cash

5. If prior to the Cessation Date, subscribers' checks in an amount of at least the Minimum have been deposited in the Escrow Account, upon request from Issuer, Escrow Agent will confirm the amounts collected by it from subscribers' checks. If such amount is at least equal to the Minimum, the Issuer may send Escrow Agent a written notice providing a list of all accepted subscribers, specifying the total amount of their subscription to be remitted to Issuer, and containing a request to terminate the Escrow Period and remit such amount, less any fees or other amounts then owing from Issuer to Escrow Agent hereunder, to the Issuer as promptly as possible, but in no event later than ten (10) Business Days after such termination, by issuing its bank check payable to the Issuer or by depositing such amount directly into the account of Issuer maintained with Bank One, Kentucky, NA, as designated in writing by Issuer to Escrow Agent. The Escrow Period shall not terminate upon receipt by Escrow Agent of such notice, but shall continue for such (10) Business-Day period solely for the limited purposes of collecting subscribers' checks that have been deposited prior to Escrow Agent's receipt of such notice and disbursing funds from the Escrow Account as provided herein. Escrow Agent will not accept deposits of subscribers' checks after receipt of such notice.

If, on the Cessation Date, the Minimum Amount has not been deposited with the Escrow Agent and collected, or if Issuer notifies the Escrow Agent in writing that Issuer elects to terminate the Offering as provided in paragraph 3(c) above, the Escrow Agent shall then issue and mail its bank checks to the subscribers in the amount of the subscribers' respective checks, without deduction, penalty or expense to the subscriber, and shall, for this purpose, be authorized to rely upon the names and addresses of subscribers furnished it as contemplated above. No subscriber shall be paid interest with respect to such deposited funds. The purchase money returned to each subscriber shall be free and clear of any and all claims of the Issuer and any of its creditors. For each subscription for which the Escrow Agent has not collected funds but has submitted the subscriber's check for collection, the Escrow Agent shall promptly issue a check to such subscriber in the amount of the collected funds from such subscriber's check after the Escrow Agent has collected such funds. If Escrow Agent has not yet submitted such subscriber's check for collection, the Escrow Agent shall promptly remit the subscriber's check directly to such subscriber.

At such time as Escrow Agent shall have made the payments and remittances provided in the Agreement, the Escrow Agent shall be completely discharged and released of any and all further liabilities and responsibilities hereunder.

6. As consideration for its agreement to act as Escrow Agent as herein described, Issuer agrees to pay the Escrow Agent an acceptance fee/establishment fee of \$250.00 and an administration fee of \$2,500.00 upon execution of this Agreement, plus the fees described on the attached fee schedule. Further, Issuer agrees to pay all disbursements and advances incurred or made by the Escrow Agent in performance of its duties hereunder, including reasonable fees, expenses and disbursements of its counsel, all in accordance with the attached fee schedule or the other provisions of this Agreement. No such fees or reimbursements shall be paid out of or chargeable to the funds on deposit in the Escrow Account until such time as the Minimum has been collected.

If the Issuer rejects any subscription for which Escrow Agent has already collected funds, the Escrow Agent shall promptly issue a refund check to the rejected subscriber in the amount of the subscriber's check. If the Issuer rejects any subscription for which the Escrow Agent has not yet collected funds but has submitted the subscriber's check for collection, the Escrow Agent shall promptly issue a check in the amount of the collected funds from the subscriber's check to the rejected subscriber after the Escrow Agent has cleared such funds. If Escrow Agent has not yet submitted a rejected subscriber's check for collection, the Escrow Agent shall promptly remit the subscriber's check directly to the subscriber.

7. This Agreement shall automatically terminate upon the earlier of (i) twenty (20) days after the Cessation Date or (ii) twenty (20) days after the date upon which the Escrow Agent has delivered the final portion of Escrow Account funds pursuant to the terms of this Agreement.

8. It is understood that the Escrow Agent reserves the right to resign as Escrow Agent at any time by giving written notice of its resignation, specifying the effective date thereof, to each other party hereto. Within thirty (30) days after receiving the aforesaid notice, the other party or parties hereto shall appoint a successor Escrow Agent to which the Escrow Agent may distribute the property then held hereunder, less its fees, costs and expenses (including counsel fees and expenses) which may remain unpaid at that time. If a successor Escrow Agent has not been appointed and has not accepted such appointment by the end of such thirty (30) day period, the Escrow Agent may apply to a court of competent jurisdiction for the appointment of a successor Escrow Agent and the fees, costs and expenses (including reasonable counsel fees and expenses) which it incurs in connection with such a proceeding shall be paid by the Company.

9. The parties hereto agree that the following provisions shall control with respect to the rights, duties, liabilities, privileges and immunities of the Escrow Agent:

- a. Escrow Agent shall have no obligation to invest the Escrow Account.

b. The Escrow Agent shall have no responsibility except for the safekeeping and delivery of the amounts deposited in the Escrow Account in accordance with this Agreement. The Escrow Agent shall not be liable for any act done or omitted to be done under this Agreement or in connection with the amounts deposited in the Escrow Account, except as a result of the Escrow Agent's gross negligence or willful misconduct. The Escrow Agent is not a party to nor is it bound by, nor need it give consideration to the terms of provisions of, even though it may have knowledge of, (i) any agreement or undertaking by, between or among the Issuer and any other party, except this Agreement, (ii) any agreement or undertaking that may be evidenced by this Agreement, (iii) any other agreements that may now or in the future be deposited with the Escrow Agent in connection with this Agreement. The Escrow Agent is not a party to, is not responsible for, and makes no representation with respect to the offer, sale or distribution of the Shares including, but not limited to, matters set forth in any offering documents prepared and distributed in connection with the offer, sale and distribution of the Shares. The Issuer covenants that it will not commence any action against the Escrow Agent at law, in equity, or otherwise as a result of any action taken or thing done by the Escrow Agent pursuant to this Agreement, or for any disbursement made as authorized herein upon failure of the Issuer to give the notice within the times herein prescribed. The Escrow Agent has no duty to determine or inquire into any happening or occurrence of or of any performance or failure of performance of the Issuer or of any other party with respect to agreements or arrangements with any other party. If any question, dispute or disagreement arises among the parties hereto and/or any other party with respect to the funds deposited in the Escrow Account or the proper interpretation of this Agreement, the Escrow Agent shall not be required to act and shall not be held liable for refusal to act until the question or dispute is settled, and the Escrow Agent has the absolute right at its discretion to do either or both of the following:

- (i) withhold and/or stop all further performance under this Agreement until the Escrow Agent is satisfied, by receipt of a written document in form and substance satisfactory to the Escrow Agent and executed and binding upon all interested parties hereto (who may include the subscribers), that the question, dispute, or disagreement had been resolved; or
- (ii) file a suit in interpleader and obtain by final judgment, rendered by a court of competent jurisdiction, an order binding all parties interested in the matter. In any such suit, or should the Escrow Agent become involved in litigation in any manner whatsoever on account of this Agreement or the Escrow Account, the Escrow Agent shall be entitled to recover from the Issuer its attorneys' fees and costs.

The Escrow Agent shall never be required to post a bond in connection with any services hereunder. The Escrow Agent may consult with counsel of its own choice and shall have full and complete authorization and protection for and shall not be liable for any action taken or suffered by it hereunder in good faith and

believed by it to be authorized hereby, nor for action taken or omitted by it in accordance with the advice of such counsel (who shall not be counsel for the Issuer).

- c. The Escrow Agent shall be obligated only for the performance of such duties as are specifically set forth in this Agreement and may rely and shall be protected in acting or refraining from acting upon any written notice, instruction or request furnished to it hereunder and believed by it to be genuine and to have been signed or presented by the proper party or parties and to take statements made therein as authorized and correct without any affirmative duty of investigation.
- d. The Issuer hereby agrees to indemnify the Escrow Agent for, and to hold it harmless against, any loss, liability, or expense (including, without limitation, all legal expenses incurred in enforcing any of the provisions of this Agreement or otherwise in connection herewith) incurred without gross negligence or willful misconduct on the part of the Escrow Agent, arising out of or in connection with its entering into this Agreement and carrying out its duties hereunder, including the costs and expenses of defending itself against any claim of liability hereunder or arising out of or in connection with the sale of the Shares. This covenant shall survive the termination of this Agreement.
- e. The Escrow Agent shall not be bound by any modification, amendment, termination, cancellation, rescission or supersession of this Agreement unless the same shall be in writing and signed by all of the other parties hereto and, if its duties as Escrow Agent hereunder are affected thereby, unless it shall have given prior written consent thereto.
- f. Escrow Agent shall not be liable for any damage, loss, liability, or delay caused by accidents, strikes, fire, flood, war, riot, equipment breakdown, electrical or mechanical failure, acts of God or any cause which is reasonably unavoidable or beyond its reasonable control.

10. Notices required to be sent hereunder shall be delivered by hand, sent by an express mail service or sent via United States mail, postage prepaid, certified, return receipt requested, to the following address:

If to Placement Agent: J.J.B. Hilliard, W.L. Lyons, Inc.
Corporate Finance Division
501 S. 4th Avenue
Louisville, KY 40202-2617

If to Issuer: Mannatech, Incorporated
600 S. Royal Lane, Suite 200
Coppell, Texas 75019
Attention: Patrick D. Cobb

If to Escrow Agent: Bank One, Kentucky, NA
Corporate Trust Department
416 Jefferson Street
Louisville, KY 40202

No notice to the Escrow Agent shall be deemed to be delivered until actually received by the Escrow Agent. From time to time any party hereto may designate an address other than the address listed above by giving the other parties hereto not less than five (5) days advance notice of such change in address in accordance with the provisions hereof.

11. This Agreement shall be construed, enforced and administered in accordance with the laws of the Commonwealth of Kentucky.

12. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature page were an original thereof.

[remainder of page left intentionally blank]

EXECUTED on the date first written above.

SELLING SHAREHOLDERS:
(Named in Schedule A Hereto)

ISSUER:
Mannatech, Incorporated

By: _____
Name: Charles E. Fioretti
Title: Attorney-in-Fact

By: _____
Name: Charles E. Fioretti
Title: Chief Executive Officer
Tax I.D. #75-2508900

By: _____
Name: Samuel L. Caster
Title: Attorney-in-Fact

ESCROW AGENT:
Bank One, Kentucky, NA

By: _____
Name: _____
Title: _____

PLACEMENT AGENT:
J.J.B. Hilliard, W.L. Lyons, Inc.

By: _____
Name: _____
Title: _____
Tax I.D. # _____

SCHEDULE A

SELLING SHAREHOLDERS

Name -----	Number of Shares -----	
	Minimum Offering -----	Maximum Offering -----
Samuel L. Caster	105,980	360,000
William C. Fioretti	300,620	760,000
Charles E. Fioretti	105,980	360,000
Chris T. Sullivan	38,928	105,000
Patrick D. Cobb	48,660	150,000
H. Reginald McDaniel	37,031	55,000
Christopher A. Marlett	17,031	475,015
Dick Hankins, Jr.	97,320	300,000
Don Herndon	29,196	60,000
Gary Watson	48,660	200,000
Bill H. McAnalley	29,196	60,000
Peter E. Hammer	19,500	65,000
Kim Snyder	12,165	25,000
Kathy Schiffer	9,733	20,000
Phillip P. Brous	100,000	100,000

MANNATECH, INCORPORATED

INITIAL PUBLIC OFFERING

A MINIMUM OF 2,500,000 SHARES
AND A MAXIMUM OF 5,295,015 SHARES

COMMON STOCK, \$0.0001 PAR VALUE

PLACEMENT AGENT AGREEMENT

November 18, 1998

J.J.B. Hilliard, W.L. Lyons, Inc.
501 South Fourth Avenue
Louisville, Kentucky 40202

Dear Sirs:

Mannatech, Incorporated, a Texas corporation (the "COMPANY"), and certain selling shareholders named on the attached SCHEDULE A (the "SELLING SHAREHOLDERS") propose to sell, in an initial public offering, a minimum of 2,500,000 shares and a maximum of 5,295,015 shares of the Company's common stock, \$0.0001 par value per share (the "COMMON STOCK"). Of the first 2,500,000 shares, 1,500,000 will be offered by the Company and 1,000,000 by the Selling Shareholders. The next 1,055,000 shares will be offered by the Selling Shareholders. Sales of shares in excess of 3,555,000 up to 4,955,000 shares will be divided equally between the Company and the Selling Shareholders, and sales in excess of 4,955,000 up to the maximum of 5,295,015 shares (the "SHARES") will be made by the Selling Shareholders. That portion of the Shares to be issued and sold by the Company are herein referred to as the "PRIMARY SHARES," and that portion of the Shares to be sold by the Selling Shareholders are herein referred to as the "SELLING SHAREHOLDERS' SHARES." All sales by the Selling Shareholders will be divided ratably among the Selling Shareholders. The Company hereby appoints J.J.B. Hilliard, W.L. Lyons, Inc. as placement agent (the "PLACEMENT AGENT") of the offering (the "OFFERING"), to assist the Company on the following terms and conditions.

Section 1. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to and agrees with you that:

- (a) The Company has filed with the Securities and Exchange Commission (the "COMMISSION") a registration statement on Form S-1 (No. 333-63133) and a related preliminary prospectus for the registration of the Shares under the Securities Act of

1933, as amended (the "1933 ACT"), and the applicable rules and regulations thereunder (the "1933 ACT REGULATIONS"). The Company has prepared and filed such amendments thereto, if any, and such amended preliminary prospectuses, if any, as may have been required to the date hereof, and will file such additional amendments thereto and such amended prospectuses as may hereafter be required. Copies of such registration statement and of each amendment thereto, including the related preliminary prospectus, heretofore filed by the Company with the Commission have been delivered to you. The term "REGISTRATION STATEMENT" as used in this Agreement shall mean such registration statement at the time such registration statement shall become effective (the "EFFECTIVE TIME") including any prospectus included with such Registration Statement, and, in the event any post-effective amendment thereto becomes effective prior to the Initial Closing Time (as hereinafter defined), shall also mean such registration statement as hereafter amended; provided, however, that such term shall also include all Rule 430A Information deemed to be included in such registration statement at the time such registration statement becomes effective as provided by Rule 430A of the 1933 Act Regulations. The term "PRELIMINARY PROSPECTUS" shall mean any preliminary prospectus included in the Registration Statement at the Effective Time. The term "PROSPECTUS" as used in this Agreement shall mean the final prospectus relating to the Shares in the form in which it is filed with the Commission after the date hereof pursuant to Rule 424(b) of the 1933 Act Regulations. The term "RULE 430A INFORMATION" means information with respect to the Shares and the offering thereof permitted pursuant to Rule 430A of the 1933 Act Regulations to be omitted from the Registration Statement when it became effective.

- (b) No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission, and no proceedings for that purpose have been instituted or threatened by the Commission or the state securities or blue sky authority of any jurisdiction, and each Preliminary Prospectus and any amendment or supplement thereto, at the time of filing thereof, conformed in all material respects to the requirements of the 1933 Act and the 1933 Act Regulations, and did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
- (c) When the Prospectus is first filed pursuant to Rule 424(b) of the 1933 Act Regulations, when any amendment to the Registration Statement becomes effective, when any amendment or supplement to the Prospectus is filed with the Commission and at each Closing Time (i) the Registration Statement, the Prospectus and any amendments thereof and supplements thereto will conform in all material respects with the applicable requirements of the 1933 Act and the 1933 Act Regulations, and (ii) neither the Registration Statement, the Prospectus nor any amendment or supplement thereto will contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading.

- (d) The Company has been duly incorporated and is validly existing as a corporation under the laws of the state of Texas with all requisite corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement and the Prospectus.
- (e) The Primary Shares have been duly authorized by the Company and, when issued and delivered in accordance with the terms of this Agreement and the Escrow Agreement (as hereinafter defined), will be validly issued, fully paid and nonassessable and will conform to the description thereof contained in the Prospectus; and the issuance of such Primary Shares will not be subject to any preemptive or similar rights.
- (f) This Agreement has been duly authorized, executed and delivered by the Company and constitutes a valid and binding agreement of the Company, enforceable in accordance with its terms.
- (g) No authorization, approval, consent or order of, or any filing or declaration with, any court or governmental authority or agency is necessary in connection with the issuance and sale of the Common Stock pursuant to the offering or the offering of the Shares or the consummation of the transactions contemplated hereby, except as may have been obtained, or will be obtained prior to completion of the Offering, under the 1933 Act and the 1933 Act Regulations.

Section 2. REPRESENTATIONS AND WARRANTIES OF THE SELLING SHAREHOLDERS.

Each of the Selling Shareholders, severally and not jointly, represents and warrants to, and agrees with, you that:

- (a) All consents, approvals, authorizations and orders necessary for the execution and delivery by such Selling Shareholder of this Agreement, the Power of Attorney and Custody Agreement (the "CUSTODY AGREEMENT") hereinafter referred to, and for the sale and delivery of the Shares to be sold by such Selling Shareholder in the Offering, have been obtained, or will be obtained prior to completion of the Offering; and such Selling Shareholder has the requisite power and authority to enter into this Agreement and the Custody Agreement and to sell, assign, transfer and deliver the Shares to be sold by such Selling Shareholder in the Offering, except as set forth on SCHEDULE B hereto.
- (b) This Agreement and the Custody Agreement have each been duly authorized, executed and delivered by such Selling Shareholder and each such document constitutes a valid and binding obligation of such Selling Shareholder, enforceable against such Selling Shareholder in accordance with its terms.

Each of the Selling Shareholders represents and warrants that a certificate in negotiable form representing all of the Shares to be sold by such Selling Shareholder has been, or prior to the Closing will be, placed in custody under the Custody Agreement, in the form heretofore furnished to you, duly executed and delivered by such Selling Shareholder to the Custodian (as defined in the

Custody Agreement), and that such Selling Shareholder has duly executed and delivered a power of attorney, in the form contained in the Custody Agreement (the "POWER OF ATTORNEY"), appointing Charles E. Fioretti and Deanne Varner and, in certain instances, Samuel L. Caster, and each of them, as such Selling Shareholder's attorney-in-fact (the "ATTORNEY-IN-FACT") with authority to execute and deliver this Agreement on behalf of such Selling Shareholder, to authorize the delivery of the Shares to be sold by such Selling Shareholder hereunder and otherwise to act on behalf of the Selling Shareholder in connection with the transactions contemplated by this Agreement, the Escrow Agreement and the Custody Agreement.

Section 3. DUTIES OF PLACEMENT AGENT.

- (a) The Company and the Selling Shareholders hereby confirm their appointment of you as Placement Agent, to assist the Company and the Selling Shareholders to the extent set forth herein. On the basis of the representations and warranties herein contained, and subject to the terms and conditions herein set forth, you hereby confirm your acceptance of such appointment and agree to use your best efforts to assist the Company and the Selling Shareholders as set forth herein. Among other things, you will assist the Company and the Selling Shareholders with:
- (i) the distribution of materials, as appropriate, to prospective investors, including communicating with such prospective investors regarding the details of the Offering and establishing and maintaining a toll-free telephone line for such prospective investors;
 - (ii) the receipt and processing of subscriptions to purchase Shares, and systematically accounting therefor;
 - (iii) administrative and recording duties related to the Company's solicitation of prospective investors, including, but not limited to, ascertaining and ensuring that each prospective investor has received a Prospectus and that each subscriber has received a Prospectus;
 - (iv) administrative matters related to the closing or closings for the Offering, including without limitation the transmission of subscription and other relevant information concerning subscribers of the Shares to the Escrow Agent and the Company's transfer agent;
 - (v) depositing and accounting for funds received as set forth in paragraph (d) below; and
 - (vi) such other administrative duties as may be requested by the Company and are appropriate to perform in assisting the Company and the Selling Shareholders with the Offering, including conforming to any further guidelines or protocols hereafter developed by the Company for the conduct of the Offering.

The price at which the Shares shall be offered and sold shall be \$8.00 per share, which price has been established by the Board of Directors of the Company after consideration of all factors which it deemed relevant and appropriate. The Placement Agent has not advised the Company in any manner regarding the price at which the Shares shall be sold. All subscriptions shall be subject to the Company's right in its sole discretion to accept or reject any subscription for any reason.

- (b) The agency granted by the Company is restricted to the acts set forth in this Section 3 and such further acts as may be requested of the Placement Agent by the Company and agreed to in writing by the Company and the Placement Agent. No general agency in favor of the Placement Agent is created by this Agreement.
- (c) As compensation for your services hereunder, the Company hereby agrees to pay you an amount equal to four percent (4%) of the aggregate value of the Shares purchased in the Offering (the "MANAGEMENT FEE"), less a \$50,000 retention fee (the "RETENTION FEE") which has been paid to you prior to the execution of this Agreement. The Management Fee shall be paid to you at the Initial Closing Time and at each subsequent Closing, if any, based upon the aggregate value of Shares to be purchased at each applicable Closing Time. The Management Fee shall be payable by wire transfer to the account or accounts designated to the Company in writing by you at the offices of J.J.B. Hilliard, W.L. Lyons, Inc., 501 South Fourth Avenue, Louisville, Kentucky 40202, or at such other place as shall be agreed upon by the Company and you.
- (d) It is hereby agreed between the Company and you that unless 2,500,000 shares of Common Stock are subscribed for and good funds therefore received on or before 5:00 p.m., Louisville, Kentucky time, on the date set forth in the Prospectus as the "TERMINATION DATE" of the Offering, this Agreement shall automatically be terminated and the entire subscription proceeds shall be returned to subscribers without interest or deduction. During the period of the Offering, until the Initial Closing Time, the proceeds from the subscriptions for the Common Stock shall, upon receipt by you, be promptly deposited in an account at Bank One, Kentucky, N.A., Louisville, Kentucky (the "ESCROW AGENT"), subject to the terms of an escrow agreement, the form of which is attached hereto as EXHIBIT A (the "ESCROW AGREEMENT"). Until the Initial Closing Time, you shall promptly upon receipt deliver all cashier's checks received by you from subscribers to the Escrow Agent. Such cashier's checks shall be accompanied by one executed copy of the Subscription Agreement for the purchase of Shares, properly completed and executed and in the form included in the Prospectus (the "SUBSCRIPTION AGREEMENT"). The Placement Agent shall confirm that each person submitting a Subscription Agreement has received a Prospectus. All such cashier's checks and executed copies of the Subscription Agreement shall be deposited by the Escrow Agent, pursuant to the Escrow Agreement, in the Mannatech Subscription Account (the "ESCROW ACCOUNT") established by the Company with the Escrow Agent. All

checks received by you from subscribers to purchase Shares shall be made payable to "Mannatech Subscription Account." After the Initial Closing Time, such funds shall be deposited by you in a segregated account entitled "Mannatech Subscription Account (the "Post-Escrow Account"), bearing interest for the benefit of the Company, pending subsequent closings. You will promptly deliver to the Company one photocopy of each Subscription Agreement received by you which has been deposited in the Escrow Account or the Post-Escrow Account, as the case may be. Promptly after receipt of a Subscription Agreement and the funds therefor and delivery of a copy of the Subscription Agreement, you will mail an interim receipt, in the form annexed hereto as EXHIBIT B, to each such subscriber to purchase Shares for the amount deposited in the Escrow Account or the Post-Escrow Account, as the case may be, on behalf of such subscriber.

Section 4. DELIVERY OF AND PAYMENT FOR THE COMMON STOCK. As soon as practicable after you and the Company have determined that 2,500,000 shares of Common Stock have been subscribed for and good funds therefor have been received by and deposited with the Escrow Agent, you shall so notify the Escrow Agent. Delivery of certificates representing the shares of Common Stock and payment for the Common Stock shall be made at a closing (the "CLOSING") to be held at the Company's office in Dallas, Texas, at 10:00 a.m., Dallas time, on the third full business day after the date on which you so notify the Escrow Agent as provided in the immediately preceding sentence or such other day and time as shall be agreed upon in writing by the Company and you. Such notice shall set forth the number of shares to be delivered by the Company against payment therefor by the Escrow Agent. The date and hour of such delivery and payment are herein called the "INITIAL CLOSING TIME." Payment for the Common Stock purchased from the Company shall be made to the Company or its order by the Escrow Agent, acting upon instructions from you pursuant to the terms of the Escrow Agreement, and delivered to the Company by the Escrow Agent by wire transfer in immediately available funds. Payment for the Common Stock purchased from the Selling Shareholders shall be made to the Attorney-in-Fact or his or her order by the Escrow Agent, for the accounts of the several Selling Shareholders, acting upon instructions from you pursuant to the terms of the Escrow Agreement, and delivered to the Attorney-in-Fact by the Escrow Agent for the accounts of the several Selling Shareholders by wire transfer in immediately available funds. Following the Initial Closing Time, at the discretion of the Company, a Closing or Closings shall occur with respect to Shares subscribed for after the Initial Closing Time.

Section 5. CERTAIN COVENANTS OF THE COMPANY. The Company covenants and agrees with you as follows:

- (a) The Company will deliver to you notice of its intention to prepare or file any amendment to the Registration Statement (including any post-effective amendment) or any amendment or supplement to the Prospectus which the Company proposes for use in connection with the offering of the Shares and which differs from the Prospectus on file with the Commission at the time of this Agreement, whether or not such revised Prospectus is required to be filed pursuant to Rule 424(b) of the

1933 Act Regulations, and will furnish you and your counsel with copies of any such amendment or supplement a reasonable amount of time prior to such use.

- (b) The Company will apply for listing and quotation of the Shares on the Nasdaq National Market System (the "NASDAQ NMS"), and will use its best efforts to obtain such listing. The Company will promptly notify you that the Common Stock has been approved for quotation and trading on the Nasdaq NMS, or of any determination by The Nasdaq Stock Market that the Common Stock fails to so qualify. In the event of a determination by The Nasdaq Stock Market that the Shares fail to qualify for listing and quotation on the Nasdaq NMS, all funds in the Escrow Account shall be returned to the subscribers pursuant to the terms of the Escrow Agreement.
- (c) If any event shall occur as a result of which it is necessary to amend or supplement the Prospectus (as then amended or supplemented) in order to ensure that the Prospectus does not contain an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, or it is necessary to amend or supplement the Prospectus to comply with the 1933 Act or any other law, the Company will forthwith prepare and furnish, at the Company's expense, to you, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances under which they were made, be misleading or so that the Prospectus will comply with the 1933 Act or such other law, as the case may be.

Section 6. CERTAIN COVENANTS OF THE PLACEMENT AGENT. You hereby agree to register with Nasdaq Market Operations as a market maker in the Common Stock no later than five business days after the execution of this Agreement. You hereby agree to comply with all securities laws and all rules of the NASD and of the Nasdaq NMS applicable to market makers on the Nasdaq NMS. In order to avoid the termination of your registration as a market maker, you hereby agree to enter quotations in the Common Stock within five business days after your registration as a market maker in the Common Stock becomes effective. You agree to inform the Company in writing (i) fifteen business days in advance of any voluntary termination of your market maker status with respect to the Common Stock and (ii) two business days after being notified of any violation which could result in termination of your status as a market maker in the Common Stock.

Section 7. REPRESENTATIONS AND WARRANTIES OF THE PLACEMENT AGENT. The Placement Agent represents and warrants to and agrees with the Company that:

- (a) The Placement Agent has been duly incorporated and is validly existing as a corporation under the laws of the Commonwealth of Kentucky with all requisite corporate power and authority to conduct its business as a broker-dealer. The Placement Agent has all licenses, approvals and consents necessary to operate as a broker-dealer under the laws of the each state in which it conducts such activities

and under the federal securities laws. The Placement Agent is a member in good standing of the NASD and meets the capital requirements of the Securities Exchange Act of 1934 for operation as a broker-dealer.

- (b) This Agreement has been duly authorized, executed and delivered by the Placement Agent and constitutes a valid and binding agreement of the Placement Agent, enforceable in accordance with its terms.

Section 8. PAYMENT OF EXPENSES. The Company will bear and pay all costs, fees and expenses incident to the performance of the Company's obligations under this Agreement. The Placement Agent will bear and pay all costs, fees and expenses incident to the performance of the Placement Agent's obligations under this Agreement.

If the sale of the Shares provided for herein is not consummated for any reason, the Placement Agent shall retain the Retention Fee. If the sale of the Shares provided for herein is not consummated because any condition set forth in SECTION 9 hereof is not satisfied, because of any termination pursuant to SECTION 12 hereof or because of any refusal, inability or failure on the part of the Company to perform any agreement herein or comply with any provision hereof other than by reason of default by the Placement Agent, the Company will reimburse the Placement Agent on demand for all reasonable, documented out-of-pocket expenses incurred after September 16, 1998, in connection with the Offering, including fees and disbursements of the Placement Agent's counsel, up to an aggregate amount not to exceed \$50,000 (the "EXPENSE REIMBURSEMENT FEE"). The Expense Reimbursement Fee is separate and distinct from the Retention Fee. All amounts paid pursuant to this paragraph shall be considered liquidated damages in the event that the Company shall abandon the Offering or otherwise terminate this Agreement, but the foregoing notwithstanding, shall not constitute liquidated damages in the instance where the Placement Agent shall have substantially performed the duties, undertakings, obligations and covenants of this Agreement.

Section 9. CONDITIONS OF CLOSING. The obligation of the Escrow Agent to deliver payment for the Shares is subject to the accuracy of the representations and warranties of the Company and each Selling Shareholder contained herein as of the Initial Closing Time and as of each subsequent Closing and to the performance by the Company and each Selling Shareholder of their obligations hereunder, and to the following further conditions:

- (a) Subscriptions for at least 2,500,000 Shares and payment therefor shall have been received by the Escrow Agent.
- (b) The Shares shall have been approved for listing on the Nasdaq NMS, subject only to the closing on sufficient Shares to meet the public float requirements of the Nasdaq NMS.
- (c) Three broker-dealers, including the Placement Agent, shall have registered as Nasdaq NMS market makers in the Shares or shall have executed an agreement with

the Company to so register within the time period prescribed by Rule 4611 of The Nasdaq Stock Market.

- (d) The Registration Statement shall have been declared effective by the Commission and no stop order suspending such effectiveness shall have been issued by the Commission and no proceedings for that purpose shall have been instituted by the Commission.

Section 10. INDEMNIFICATION AND CONTRIBUTION

- (a) The Company will indemnify and hold harmless Placement Agent against any losses, claims, damages or liabilities, joint or several, to which such Placement Agent may become subject under the 1933 Act, or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise (i) from acts outside the scope of the Placement Agent's duties under this Agreement, (ii) out of or are based upon any breach of any warranty or covenant of the Company herein contained, (iii) out of or are based upon any untrue statement or alleged untrue statement of a material fact contained in (A) any Preliminary Prospectus, the Registration Statement, or the Prospectus, or any amendment or supplement thereto, or (B) any application or other document, or any amendment or supplement thereto, executed by the Company or based upon written information furnished by or on behalf of the Company filed in any jurisdiction in order to qualify the Shares under the securities or Blue Sky laws thereof or filed with the Commission or any securities association or securities exchange (each an "APPLICATION"), or (iv) out of or are based upon the omission or alleged omission to state in any Preliminary Prospectus, the Registration Statement, the Prospectus, or any amendment or supplement thereto, or any Application a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse Placement Agent for any legal or other expenses reasonably incurred by Placement Agent in connection with investigating or defending any such loss, claim, damage, liability or action. In addition to its other obligations under this SECTION 10(a), the Company agrees that as an interim measure during the pendency of any such claim, action, investigation, inquiry or other proceeding arising out of or based upon any statement or omission, or any alleged statement or omission, described in this SECTION 10(a), it will reimburse the Placement Agent on a quarterly basis for all reasonable legal and other expenses incurred in connection with investigating or defending any such claim, action, investigation, inquiry or other proceeding, notwithstanding the absence of a judicial determination as to the propriety and enforceability of the Company's obligation to reimburse the Placement Agent for such expenses and the possibility that such payments might later be held to have been improper by a court of competent jurisdiction. The Company will not, without the prior written consent of Placement Agent, settle or compromise or consent to the entry of any judgment in any pending or threatened action or claim or related cause of action or portion of such cause of action in respect of which indemnification may be sought hereunder (whether or not Placement Agent is a party to such action or

claim), unless such settlement, compromise or consent includes an unconditional release of Placement Agent from all liability arising out of such action or claim (or related cause of action or portion thereof).

The indemnity agreement in this SECTION 10(a) shall extend upon the same terms and conditions to, and shall inure to the benefit of, each person, if any, who controls Placement Agent within the meaning of the 1933 Act to the same extent as such agreement applies to the Placement Agent.

(b) Placement Agent will indemnify and hold harmless the Company and each Selling Shareholder against any losses, claims, damages or liabilities to which the Company may become subject, under the 1933 Act, or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any breach of any warranty or covenant by Placement Agent herein contained; and will reimburse the Company and each Selling Shareholder for any legal or other expenses reasonably incurred by the Company and each Selling Shareholder in connection with investigating or defending any such loss, claim damage, liability or action. In addition to its other obligations under this SECTION 10(b), Placement Agent agrees that, as an interim measure during the pendency of any such claim, action, investigation, inquiry or other proceeding, it will reimburse the Company and each Selling Shareholder on a monthly basis for all reasonable legal and other expenses incurred in connection with investigating or defending any such claim, action, investigation, inquiry or other proceeding, notwithstanding the absence of a judicial determination as to the propriety and enforceability of its obligation to reimburse the Company and each Selling Shareholder for such expenses and the possibility that such payments might later be held to have been improper by a court of competent jurisdiction. Placement Agent will not, without the prior written consent of the Company and each Selling Shareholder, settle or compromise or consent to the entry of judgment in any pending or threatened action or claim or related cause of action or portion of such cause of action in respect of which indemnification may be sought hereunder (whether or not the Company and each Selling Shareholder is a party to such action or claim), unless such settlement, compromise or consent includes an unconditional release of the Company and each Selling Shareholder from all liability arising out of such action or claim (or related cause of action or portion thereof).

The indemnity agreement in this SECTION 10(b) shall extend upon the same terms and conditions to, and shall inure to the benefit of, each officer and director of the Company and each person, if any, who controls the Company within the meaning of the 1933 Act to the same extent as such agreement applies to the Company.

(c) Promptly after receipt by an indemnified party under subsection (a) or (b) above of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof;

no indemnification provided for in subsection (a) or (b) shall be available to any party who shall fail to give notice as provided in this subsection (c) if the party to whom notice was not given was unaware of the proceeding to which such notice would have related and was prejudiced by the failure to give such notice, but the omission so to notify the indemnifying party will not relieve the indemnifying party from any liability that it may have to any indemnified party otherwise than under SECTION 10. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof with counsel satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified of its election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation, except that if the indemnified party has been advised by counsel in writing that there are one or more defenses available to the indemnified party which are different from or additional to those available to the indemnifying party, then the indemnified party shall have the right to employ separate counsel and in that event the reasonable fees and expenses of such separate counsel for the indemnified party shall be paid by the indemnifying party; provided, however, that if the indemnifying party is the Company, the Company shall only be obligated to pay the reasonable fees and expenses of a single law firm (and any reasonably necessary local counsel) employed by the indemnified party. The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment.

- (d) In order to provide for just and equitable contribution in circumstances under which the indemnity provided for in this SECTION 10 is for any reason judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the right of appeal) to be unenforceable by the indemnified parties although applicable in accordance with its terms, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by the Company and the Selling Shareholders on the one hand and the Placement Agent on the other from the offering of the Shares; provided, however, that no person guilty of fraudulent misrepresentations (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation; provided, further, that if the allocation provided above is not permitted by applicable law, then

each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company and the Selling Shareholders on the one hand and the Placement Agent on the other in connection with the statements or omissions or actions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company and the Selling Shareholders on the one hand and the Placement Agent on the other shall be deemed to be in the same proportion as the total net proceeds from the Offering (before deducting expenses) received by the Company and the Selling Shareholders, respectively, bear to the Placement Agent Fee received by the Placement Agent. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or the Selling Shareholders and such parties' relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company, the Selling Shareholders and Placement Agent agree that it would not be just and equitable if contributions pursuant to this SECTION 10(d) were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to above in this SECTION 10(d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities referred to above shall be deemed to include any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending such action or claim. Notwithstanding the provisions of this SECTION 10(d), the Placement Agent shall not be required to contribute any amount in excess of the amount by which the total price at which the Shares sold to the purchasers exceeds the amount of any damages which such Placement Agent has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. For purposes of this SECTION 10(d), each person, if any, who controls Placement Agent within the meaning of Section 15 of the 1933 Act shall have the same rights to contribution as Placement Agent, and each director and officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act shall have the same rights to contribution as the Company.

Section 11. REPRESENTATIONS, WARRANTIES AND AGREEMENTS TO SURVIVE DELIVERY. The respective representations, warranties, indemnities, agreements and other statements of the Company, each Selling Shareholder and the Placement Agent, as set forth in or made pursuant to this Agreement, will remain operative and in full force and effect regardless of any investigation made by or on behalf of the Placement Agent or any controlling person of the Placement Agent, or the Company or any Selling Shareholder, or any officer or director or controlling person of the Company or any Selling Shareholder, and shall survive delivery of and payment for the Shares or termination of this Agreement.

Section 12. EFFECTIVE DATE OF AGREEMENT AND TERMINATION

- (a) This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.
- (b) The Placement Agent may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing Time if any of the conditions specified in SECTION 9 shall not have been fulfilled when and as required by the terms of this Agreement to be fulfilled.
- (c) If this Agreement is terminated pursuant to this SECTION 12, such termination shall be without liability of any party to any other party, except to the extent provided in SECTION 8. Notwithstanding any such termination, the provisions of SECTION 10 shall remain in effect.

Section 13. NOTICES. All notices and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if delivered, mailed or transmitted by any standard form of telecommunication. Notices to the Placement Agent shall be directed to J.J.B. Hilliard, W.L. Lyons, Inc., 501 South Fourth Avenue, Louisville, Kentucky 40202, Attention: Robert C. Oliver (with a copy sent in the same manner to Stites & Harbison, 400 West Market Street, Suite 1800, Louisville, Kentucky 40202, Attention: C. Craig Bradley, Jr.); and notices to the Company and the Selling Shareholders shall be directed to them at 600 S. Royal Lane, Suite 200, Coppell, Texas 75019, Attention: Charles E. Fioretti, Chief Executive Officer (with a copy sent in the same manner to Akin, Gump, Strauss, Hauer & Feld, L.L.P., 1700 Pacific, Suite 4100, Dallas, Texas 75201, Attention: J. Kenneth Menges, Jr., P.C.).

Section 14. PARTIES. This Agreement is made solely for the benefit of and is binding upon the Placement Agent, the Company and the Selling Shareholders and, to the extent provided in SECTIONS 10 AND 11 hereof, the officers and directors of the Company and each person who controls the Company, any Selling Shareholder or the Placement Agent, and their respective executors, administrators, successors and assigns and subject to the provisions of SECTION 10, no other person shall acquire or have any right under or by virtue of this Agreement. The term "SUCCESSORS AND ASSIGNS" shall not include any purchaser of any of the Shares merely by reason of such purchase.

Section 15. GOVERNING LAW; VENUE. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Texas without regard to the principles of conflicts of law thereof.

Section 16. COUNTERPARTS. This Agreement may be executed in one or more counterparts and when a counterpart has been executed by each party, all such counterparts taken together shall constitute one and the same agreement.

[THIS SPACE INTENTIONALLY LEFT BLANK.]

If the foregoing is in accordance with your understanding, please sign and return to us a counterpart hereof, and upon the acceptance hereof by you, this letter and such acceptance will constitute a binding agreement among each of the Company, the Selling Shareholders and the Placement Agent in accordance with its terms.

Any person executing and delivering this Agreement as Attorney-in-Fact for the Selling Shareholders represents by so doing that he or she has been duly appointed as Attorney-in-Fact by each Selling Shareholder pursuant to a validly existing and binding Power of Attorney which authorizes such Attorney-in-Fact to take such action.

Very truly yours,
MANNATECH, INCORPORATED

By: /s/ Charles E. Fioretti

Name: Charles E. Fioretti

Title: Chief Executive Officer

SELLING SHAREHOLDERS
(Named in Schedule A attached hereto)

By: /s/ Charles E. Fioretti

Name: Charles E. Fioretti

Title: Attorney-in-Fact

By: /s/ Samuel L. Caster

Name: Samuel L. Caster
Title: Attorney-in-Fact

The foregoing Agreement is hereby confirmed and accepted as of the date first written above:

J.J.B. HILLIARD, W.L. LYONS, INC.

By: /s/ Robert C. Oliver

Name: Robert C. Oliver

Title: Senior Vice President

SCHEDULE A
SELLING SHAREHOLDERS

Name	Number of Shares	
	Minimum Offering	Maximum Offering
Samuel L. Caster.....	105,980	360,000
William C. Fioretti.....	300,620	760,000
Charles E. Fioretti.....	105,980	360,000
Chris T. Sullivan.....	38,928	105,000
Patrick D. Cobb.....	48,660	150,000
H. Reginald McDaniel.....	37,031	55,000
Christopher A. Marlett.....	17,031	475,015
Dick Hankins, Jr.....	97,320	300,000
Don Herndon.....	29,196	60,000
Gary Watson.....	48,660	200,000
Bill H. McAnalley.....	29,196	60,000
Peter E. Hammer.....	19,500	65,000
Kim Snyder.....	12,165	25,000
Kathy Schiffer.....	9,733	20,000
Phillip P. Brous.....	100,000	100,000

SCHEDULE B

PLEDGED SHARES

Shares held by the Selling Shareholders set forth below are pledged to the party set forth in the right hand column below. Such shares will be sold in the Offering to repay the debt owed.

Debtor

Peter E. Hammer
Peter E. Hammer
Bill H. McAnalley
Kim Snyder
H. Reginald McDaniel

Secured Party

Mannatech, Incorporated
Charles E. Fioretti
Mannatech, Incorporated
Mannatech, Incorporated
Mannatech, Incorporated

EXHIBIT A
FORM OF ESCROW AGREEMENT

[Attached]

EXHIBIT B

Form of Interim Receipt

[Mannatech Letterhead]

(Subscriber Name)
(Subscriber Address)

Dear Subscriber:

We have received your subscription for _____ shares at a price of \$8.00 per share and have deposited your cashier's check in the amount of \$_____ in the Mannatech Subscription Account pending such time as [THE MINIMUM OF 2,500,000 SHARES ARE SUBSCRIBED FOR] [THERE ARE SUFFICIENT SHARES SUBSCRIBED FOR TO WARRANT A CLOSING ON SUCH SHARES] at which time your shares will be delivered to you. If this does not occur, your money will be returned to you, without interest or deduction. Thank you for your interest in Mannatech, Incorporated. If you have any questions, please call the placement agent for this offering, J.J.B. Hilliard, W.L. Lyons, Inc. at (800) ____-____.

Charles E. Fioretti
Chairman of the Board and Chief Executive
Officer

CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the use in the Prospectus constituting part of this Registration Statement on Form S-1 of our report dated March 26, 1998, relating to the financial statements of Mannatech, Incorporated, which appears in such Prospectus. We also consent to the references to us under the headings "Experts" and "Selected Financial Data" in such Prospectus. However, it should be noted that PricewaterhouseCoopers LLP has not prepared or certified such "Selected Financial Data."

/s/ PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP

Dallas, Texas
November 19, 1998

CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the use in the Prospectus constituting part of this Registration Statement on Form S-1 of our report dated August 21, 1997, relating to the financial statements of Mannatech, Incorporated (formerly Emprise International, Inc. in 1995). We also consent to the references to us under the headings "Experts" and "Selected Financial Data" in such Prospectus. However, it should be noted that Belew Averitt LLP has not prepared or certified such "Selected Financial Data."

/s/ Belew Averitt LLP

- -----

Belew Averitt LLP

Dallas, Texas

November 19, 1998